

Approved



Uganda
Country Operational Plan
FY 2018



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		0		0	1,557,627	1,557,627
USAID		122,406,760	7,282,500	129,689,260	22,416,013	152,105,273
DOD		12,734,893		12,734,893	2,373,746	15,108,639
PC		2,003,124		2,003,124	276,562	2,279,686
HHS/CDC	3,212,500	175,135,709		178,348,209	6,066,552	184,414,761
HHS/HRSA		350,000		350,000	0	350,000
State/AF		685,000		685,000	250,000	935,000
State/PRM		647,566		647,566	0	647,566
State/SGAC		50,650,198		50,650,198	0	50,650,198
Total	3,212,500	364,613,250	7,282,500	375,108,250	32,940,500	408,048,750

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency							Total
	DOD	HHS/CDC	PC	State/AF	State/SGAC	State/PRM	USAID	
CIRC	1,406,734	17,231,765	0	0	0	32,796	17,249,789	35,921,084
HBHC	1,159,586	13,116,029	0	0	0	150,000	8,349,070	22,774,685
HKID	1,601,460	8,484,205	94,880	62,500	0	139,770	17,813,124	28,195,939
HLAB	237,391	3,156,346	0	500,000	0	0	833,033	5,076,770
HMBL	0	5,214	0	0	0	0	4,428	9,642
HMIN	0	2,604	0	0	0	0	4,428	7,032
HTXD	2,393	36,457,450	0	0	50,650,198	0	13,589,562	100,699,603
HTXS	2,711,671	40,790,389	0	0	0	247,000	30,469,573	74,218,633
HVAB	0	0	0	0	0	0	1,484,954	1,484,954

Approved



HVCT	545,892	8,247,876	0	0	0	0	5,666,227	14,459,995
HVMS	34,705	11,533,559	1,840,890				5,170,345	18,579,499
HVOP	2,302,509	11,924,929	67,354	122,500	0	0	7,840,420	22,257,712
HVSI	1,050,127	5,317,753	0	0	0	0	2,978,159	9,346,039
HVTB	650,397	4,415,841	0	0	0	31,000	4,455,957	9,553,195
IDUP	0	233,553	0	0	0	0	0	233,553
MTCT	421,729	4,952,836	0	0	0	31,000	2,949,382	8,354,947
OHSS	70,000	3,160,432	0	0	0	0	4,676,128	7,906,560
PDCS	417,013	6,946,235	0	0	0	9,000	4,648,694	12,020,942
PDTX	123,286	2,371,193	0	0	0	7,000	1,505,987	4,007,466
	12,734,893	178,348,209	2,003,124	685,000	50,650,198	647,566	129,689,260	375,108,250



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount
HBHC	22,501,836
HKID	27,843,066
HVTB	9,385,248
PDCS	11,828,221
Total Technical Area Planned Funding:	71,558,371

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount
HLAB	4,626,007
HVSI	7,630,036
OHSS	6,759,197
Total Technical Area Planned Funding:	19,015,240

Technical Area: Prevention

Budget Code	Budget Code Planned Amount
CIRC	35,690,053
HMBL	0
HMIN	0
HVAB	1,478,929
HVCT	14,291,979
HVOP	22,028,211
IDUP	233,553
MTCT	8,080,487
Total Technical Area Planned Funding:	81,803,212

Approved



Technical Area: Treatment

Budget Code	Budget Code Planned Amount
HTXD	100,612,194
HTXS	73,937,519
PDTX	3,875,291
Total Technical Area Planned Funding:	178,425,004

Technical Area Summary Indicators and Targets

Indicator Number	Label	2019
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	100 %
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	920,991
	Number of new ANC and L&D clients	920,991
	By Age (Denominator): <15-19	174,980
	By Age (Denominator): 20-24	303,917
	By Number of known positives: 15-19	206
	By Number of known positives: 20-24	1,135
	By Number of new positives: 15-19	3,813
	By Number of new positives: 20-24	6,605
	By Number of new negative: 15-19	170,961
	By Number of new negative: 20-24	296,177
	By Age (Numerator): 15-19	174,980
	By Age (Numerator): 20-24	303,917
	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	202,638
	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	156,569
PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	64,470	



PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	18,417
PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Known at Entry Positive	16,920
PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Newly Identified Negative	181,302
PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Newly Identified Positive	4,416
PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Known at Entry Positive	13,088
PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Newly Identified Negative	140,076
PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Newly Identified Positive	3,405
PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 35-39, Female, Known at Entry Positive	5,430
PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 35-39, Female, Newly Identified Negative	57,612
PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 35-39, Female, Newly Identified Positive	1,428
PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 40-49, Female, Known at Entry Positive	1,610
PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 40-49, Female, Newly Identified Negative	16,379



	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	428
	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	202,638
	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	156,569
	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	64,470
	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	18,417
PMTCT_STAT_TA	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA)	100 %
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	376,287
	Number of new ANC and L&D clients	376,287
	By Age (Denominator): 15-19	71,503
	By Age (Denominator): 20-24	124,185
	By known positives: 15-19	59
	By known positives: 20-24	405
	By new positives: 15-19	1,382
	By new positives: 20-24	2,419
	By new negatives: 15-19	70,062
	By new negatives: 20-24	121,361
	By Age (Numerator): : 15-19	71,503
	By Age (Numerator): 20-24	124,185
	PMTCT_STAT_D_TA_Age_Sex 25-29, Female	82,763



PMTCT_STAT_D_TA_Age_Sex 30-34, Female	63,968
PMTCT_STAT_D_TA_Age_Sex 35-39, Female	26,339
PMTCT_STAT_D_TA_Age_Sex 40-49, Female	7,529
PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 25-29, Female, Known at Entry Positive	6,519
PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 25-29, Female, Newly Identified Negative	74,644
PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 25-29, Female, Newly Identified Positive	1,600
PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 30-34, Female, Known at Entry Positive	5,042
PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 30-34, Female, Newly Identified Negative	57,683
PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 30-34, Female, Newly Identified Positive	1,243
PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 35-39, Female, Known at Entry Positive	2,082
PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 35-39, Female, Newly Identified Negative	23,771
PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 35-39, Female, Newly Identified Positive	486
PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 40-49, Female,	593



	Known at Entry Positive	
	PMTCT_STAT_N_TA_Age_Sex_K knownNewResult 40-49, Female, Newly Identified Negative	6,817
	PMTCT_STAT_N_TA_Age_Sex_K knownNewResult 40-49, Female, Newly Identified Positive	119
	PMTCT_STAT_N_TA_Age_Sex 25-29, Female	82,763
	PMTCT_STAT_N_TA_Age_Sex 30-34, Female	63,968
	PMTCT_STAT_N_TA_Age_Sex 35-39, Female	26,339
	PMTCT_STAT_N_TA_Age_Sex 40-49, Female	7,529
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	6 %
	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	55,381
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	920,991
	New on ART	18,532
	Already on ART at beginning of current pregnancy	36,849
PMTCT_ART_TA	PMTCT_ART_TA Percentage of HIV-positive pregnant women who received ART to reduce risk of	6 %



	mother-to-child-transmission (MTCT) during pregnancy	
	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	21,030
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	376,287
	New on ART	6,721
	Already on ART at beginning of current pregnancy	14,309
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	756,456
	By Age: 10-14	36,946
	By Age: 15-19	189,151
	By Age: 20-24	189,151
	By Age: 25-29	226,951
	By Age: 50+	22,581
	By circumcision technique: Surgical VMMC	755,456
	By circumcision technique: Device-based VMMC	1,000
	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	30,618
	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	30,618
VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	30,440	



PrEP_NEW_DSD	PrEP_NEW_DSD Number of individuals who have received antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection in the reporting period.	n/a
	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	13,047
	Male 15-19	127
	Male 20-24	911
	Male 50+	264
	Female 15-19	783
	Female 20-24	3,003
	Female 50+	127
	FSW	8,977
	MSM	511
	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	1,309
	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	649
	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	1,309
	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	649
	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	1,309
	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	649
	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	1,309
	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	649



	PrEP_NEW_N_DSD_KeyPopAbr Other Key Populations	82
PrEP_NEW_TA	PrEP_NEW_TA Number of individuals who have received antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection in the reporting period.	n/a
	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	3,794
	Male 15-19	38
	Male 20-24	268
	Male 50+	72
	Female 15-19	225
	Female 20-24	873
	Female 50+	38
	FSW	2,659
	MSM	151
	PrEP_NEW_N_TA_Age_Sex_v2 25-29, Female	379
	PrEP_NEW_N_TA_Age_Sex_v2 25-29, Male	191
	PrEP_NEW_N_TA_Age_Sex_v2 30-34, Female	379
	PrEP_NEW_N_TA_Age_Sex_v2 30-34, Male	191
	PrEP_NEW_N_TA_Age_Sex_v2 35-39, Female	379
	PrEP_NEW_N_TA_Age_Sex_v2 35-39, Male	191
PrEP_NEW_N_TA_Age_Sex_v2 40-49, Female	379	



	PrEP_NEW_N_TA_Age_Sex_v2 40-49, Male	191
	PrEP_NEW_N_TA_KeyPopAbr Other Key Populations	22
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	474,052
	Age/sex: 15-19 Male	8,757
	Age/sex: 20-24 Male	21,481
	Age/sex: 50+ Male	15,899
	Age/sex: 10-14 Female	34,725
	Age/sex: 15-19 Female	103,725
	Age/sex: 20-24 Female	73,309
	Age/sex: 50+ Female	8,708
	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	20,258
	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	36,143
	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	19,984
	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	35,780
	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	15,390
	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	27,508



	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	18,807
	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	33,578
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	261,863
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	836
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	7,461
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual	107



	and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	573
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	92,266
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	522
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	98



	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	160,000
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	945,748
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	3,499
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	106
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	742
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	12
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	982
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	48
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	317
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	16
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	1,823
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	93
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	808
	Service Delivery Point (Facility)	39



	Inpatient: 20-24, Male, Positive	
	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	19
	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	1
	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	614
	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	30
	Service Delivery Point (Facility) Inpatient: 1-9, Negative	3,206
	Service Delivery Point (Facility) Inpatient: 1-9, Positive	104
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	18,885
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	339
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	3,980
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	62
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	11,619
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	326
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	5,801
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	146
	Service Delivery Point (Facility)	17,456



	Other PITC: 20-24, Female, Negative	
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	509
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	18,737
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	546
	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	172
	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	3
	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	8,050
	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	215
	Service Delivery Point (Facility) Other PITC: 1-9, Negative	17,296
	Service Delivery Point (Facility) Other PITC: 1-9, Positive	339
	Service Delivery Point (Facility) Pediatric : <5 Negative	26,779
	Service Delivery Point (Facility) Pediatric : <5 Positive	514
	Service Delivery Point (Facility) TB: 10-14, Female, Negative	130
	Service Delivery Point (Facility) TB: 10-14, Female, Positive	40
	Service Delivery Point (Facility) TB: 10-14, Male, Negative	55
	Service Delivery Point (Facility) TB: 10-14, Male, Positive	22
	Service Delivery Point (Facility) TB:	533



	15-19, Female, Negative	
	Service Delivery Point (Facility) TB: 15-19, Female, Positive	177
	Service Delivery Point (Facility) TB: 15-19, Male, Negative	802
	Service Delivery Point (Facility) TB: 15-19, Male, Positive	266
	Service Delivery Point (Facility) TB: 20-24, Female, Negative	930
	Service Delivery Point (Facility) TB: 20-24, Female, Positive	307
	Service Delivery Point (Facility) TB: 20-24, Male, Negative	371
	Service Delivery Point (Facility) TB: 20-24, Male, Positive	121
	Service Delivery Point (Facility) TB: 50+, Female, Negative	210
	Service Delivery Point (Facility) TB: 50+, Female, Positive	62
	Service Delivery Point (Facility) TB: 50+, Male, Negative	533
	Service Delivery Point (Facility) TB: 50+, Male, Positive	177
	Service Delivery Point (Facility) TB: 1-9, Negative	371
	Service Delivery Point (Facility) TB: 1-9, Positive	121
	Service Delivery Point (Facility) VMC: 10-14, Negative	5,943
	Service Delivery Point (Facility) VMC: 10-14, Positive	27
	Service Delivery Point (Facility) VMC: 15-19, Negative	34,095
	Service Delivery Point (Facility)	179



	VMMC: 15-19, Positive	
	Service Delivery Point (Facility) VMMC: 20-24, Negative	34,095
	Service Delivery Point (Facility) VMMC: 20-24, Positive	179
	Service Delivery Point (Facility) VMMC: 50+, Negative	4,091
	Service Delivery Point (Facility) VMMC: 50+, Positive	18
	Service Delivery Point (Facility) Index: 10-14, Female, Negative	2,392
	Service Delivery Point (Facility) Index: 10-14, Female, Positive	103
	Service Delivery Point (Facility) Index: 10-14, Male, Negative	492
	Service Delivery Point (Facility) Index: 10-14, Male, Positive	12
	Service Delivery Point (Facility) Index: 15-19, Female, Negative	620
	Service Delivery Point (Facility) Index: 15-19, Female, Positive	90
	Service Delivery Point (Facility) Index: 15-19, Male, Negative	291
	Service Delivery Point (Facility) Index: 15-19, Male, Positive	36
	Service Delivery Point (Facility) Index: 20-24, Female, Negative	1,058
	Service Delivery Point (Facility) Index: 20-24, Female, Positive	157
	Service Delivery Point (Facility) Index: 20-24, Male, Negative	1,188
	Service Delivery Point (Facility) Index: 20-24, Male, Positive	180
	Service Delivery Point (Facility)	4



	Index: 50+, Female, Negative	
	Service Delivery Point (Facility) Index: 50+, Female, Positive	1
	Service Delivery Point (Facility) Index: 50+, Male, Negative	906
	Service Delivery Point (Facility) Index: 50+, Male, Positive	136
	Service Delivery Point (Facility) Index: 1-9, Negative	2,206
	Service Delivery Point (Facility) Index: 1-9, Positive	94
	By Key Population: FSW, Negative	6,527
	By Key Population: FSW, Positive	3,155
	By Key Population: MSM, Negative	497
	By Key Population: MSM, Positive	174
	By Key Population: People in prisons and other enclosed settings, Negative	19,464
	By Key Population: People in prisons and other enclosed settings, Positive	3,784
	By Key Population: PWID, Negative	286
	By Key Population: PWID, Positive	64
	By Key Population: TG, Negative	127
	By Key Population: TG, Positive	29
	Service Delivery Point (Facility) ANC: 15-19, Negative	83,412
	Service Delivery Point (Facility) ANC: 15-19, Positive	1,694
	Service Delivery Point (Facility) ANC: 20-24, Negative	144,893
	Service Delivery Point (Facility) ANC: 20-24, Positive	2,958



HTS_TST_N_TA_Index_Age_Sex_ Result 25-29, Female, Negative	3,355
HTS_TST_N_TA_Index_Age_Sex_ Result 25-29, Female, Positive	561
HTS_TST_N_TA_Index_Age_Sex_ Result 25-29, Male, Negative	2,754
HTS_TST_N_TA_Index_Age_Sex_ Result 25-29, Male, Positive	455
HTS_TST_N_TA_Index_Age_Sex_ Result 30-34, Female, Negative	772
HTS_TST_N_TA_Index_Age_Sex_ Result 30-34, Female, Positive	114
HTS_TST_N_TA_Index_Age_Sex_ Result 30-34, Male, Negative	2,119
HTS_TST_N_TA_Index_Age_Sex_ Result 30-34, Male, Positive	345
HTS_TST_N_TA_Index_Age_Sex_ Result 35-39, Female, Negative	1,493
HTS_TST_N_TA_Index_Age_Sex_ Result 35-39, Female, Positive	233
HTS_TST_N_TA_Index_Age_Sex_ Result 35-39, Male, Negative	2,527
HTS_TST_N_TA_Index_Age_Sex_ Result 35-39, Male, Positive	409
HTS_TST_N_TA_Index_Age_Sex_ Result 40-49, Female, Negative	1,152
HTS_TST_N_TA_Index_Age_Sex_ Result 40-49, Female, Positive	172
HTS_TST_N_TA_Index_Age_Sex_ Result 40-49, Male, Negative	3,190
HTS_TST_N_TA_Index_Age_Sex_ Result 40-49, Male, Positive	534
HTS_TST_N_TA_Inpat_Age_Sex_ Result 25-29, Female, Negative	2,275



HTS_TST_N_TA_Inpat_Age_Sex_	117
Result 25-29, Female, Positive	
HTS_TST_N_TA_Inpat_Age_Sex_	1,505
Result 25-29, Male, Negative	
HTS_TST_N_TA_Inpat_Age_Sex_	77
Result 25-29, Male, Positive	
HTS_TST_N_TA_Inpat_Age_Sex_	985
Result 30-34, Female, Negative	
HTS_TST_N_TA_Inpat_Age_Sex_	48
Result 30-34, Female, Positive	
HTS_TST_N_TA_Inpat_Age_Sex_	998
Result 30-34, Male, Negative	
HTS_TST_N_TA_Inpat_Age_Sex_	48
Result 30-34, Male, Positive	
HTS_TST_N_TA_Inpat_Age_Sex_	1,021
Result 35-39, Female, Negative	
HTS_TST_N_TA_Inpat_Age_Sex_	49
Result 35-39, Female, Positive	
HTS_TST_N_TA_Inpat_Age_Sex_	1,347
Result 35-39, Male, Negative	
HTS_TST_N_TA_Inpat_Age_Sex_	67
Result 35-39, Male, Positive	
HTS_TST_N_TA_Inpat_Age_Sex_	693
Result 40-49, Female, Negative	
HTS_TST_N_TA_Inpat_Age_Sex_	31
Result 40-49, Female, Positive	
HTS_TST_N_TA_Inpat_Age_Sex_	1,250
Result 40-49, Male, Negative	
HTS_TST_N_TA_Inpat_Age_Sex_	62
Result 40-49, Male, Positive	
HTS_TST_N_TA_MN_Age_Sex_R	3,280
esult <5, Unknown Sex, Negative	
HTS_TST_N_TA_MN_Age_Sex_R	114
esult <5, Unknown Sex, Positive	



HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Negative	28,425
HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Positive	857
HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Negative	29,247
HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Positive	876
HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Negative	10,174
HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Positive	283
HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Negative	18,750
HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Positive	546
HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Negative	11,230
HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Positive	314
HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Negative	21,225
HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Positive	628
HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Negative	9,107
HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Positive	248
HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Negative	17,202
HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Positive	502
HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Negative	96,467



HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Positive	1,921
HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Negative	41,742
HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Positive	1,510
HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Negative	43,332
HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Positive	622
HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Negative	29,210
HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Positive	181
HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Negative	808
HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Positive	42
HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Negative	241
HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Positive	9
HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Negative	1,541
HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Positive	91
HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Negative	666
HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Positive	29
HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Negative	1,934
HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Positive	116



HTS_TST_N_TA_STI_Age_Sex_R esult 25-29, Male, Negative	1,251
HTS_TST_N_TA_STI_Age_Sex_R esult 25-29, Male, Positive	75
HTS_TST_N_TA_STI_Age_Sex_R esult 30-34, Female, Negative	809
HTS_TST_N_TA_STI_Age_Sex_R esult 30-34, Female, Positive	42
HTS_TST_N_TA_STI_Age_Sex_R esult 30-34, Male, Negative	814
HTS_TST_N_TA_STI_Age_Sex_R esult 30-34, Male, Positive	43
HTS_TST_N_TA_STI_Age_Sex_R esult 35-39, Female, Negative	836
HTS_TST_N_TA_STI_Age_Sex_R esult 35-39, Female, Positive	46
HTS_TST_N_TA_STI_Age_Sex_R esult 35-39, Male, Negative	1,127
HTS_TST_N_TA_STI_Age_Sex_R esult 35-39, Male, Positive	68
HTS_TST_N_TA_STI_Age_Sex_R esult 40-49, Female, Negative	553
HTS_TST_N_TA_STI_Age_Sex_R esult 40-49, Female, Positive	26
HTS_TST_N_TA_STI_Age_Sex_R esult 40-49, Male, Negative	1,041
HTS_TST_N_TA_STI_Age_Sex_R esult 40-49, Male, Positive	63
HTS_TST_N_TA_STI_Age_Sex_R esult 50+, Female, Negative	13
HTS_TST_N_TA_STI_Age_Sex_R esult 50+, Female, Positive	2
HTS_TST_N_TA_STI_Age_Sex_R esult 50+, Male, Negative	480



HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Positive	23
HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Negative	371
HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Positive	121
HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	210
HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Positive	62
HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Negative	450
HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Positive	152
HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	294
HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Positive	91
HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Negative	575
HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Positive	188
HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	930
HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Positive	307
HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Negative	371
HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Positive	121
HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative	371
HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Positive	121



	HTS_TST_N_TA_VMMC_Age_Sex _Result 25-29, Male, Negative	40,907
	HTS_TST_N_TA_VMMC_Age_Sex _Result 25-29, Male, Positive	218
	HTS_TST_N_TA_VMMC_Age_Sex _Result 30-34, Male, Negative	5,811
	HTS_TST_N_TA_VMMC_Age_Sex _Result 30-34, Male, Positive	27
	HTS_TST_N_TA_VMMC_Age_Sex _Result 35-39, Male, Negative	5,811
	HTS_TST_N_TA_VMMC_Age_Sex _Result 35-39, Male, Positive	27
	HTS_TST_N_TA_VMMC_Age_Sex _Result 40-49, Male, Negative	5,636
	HTS_TST_N_TA_VMMC_Age_Sex _Result 40-49, Male, Positive	25
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 15-19, Female, Directly-Assisted	515
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 15-19, Female, Unassisted	1,364
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 20-24, Female, Directly-Assisted	1,368
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 20-24, Female, Unassisted	4,097
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 20-24, Male, Directly-Assisted	65
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 20-24, Male, Unassisted	65
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 25-29, Female, Directly-Assisted	820



	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	2,735
	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	65
	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	65
	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	463
	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	1,092
	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	191
	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	548
	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	56
	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	135
	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Sex Partner	13,668
	HTS_SELF_N_TA_KeyPop_HIVSelfTest FSW, Directly-Assisted	687
	HTS_SELF_N_TA_KeyPop_HIVSelfTest FSW, Unassisted	2,052
	HTS_SELF_N_TA_KeyPop_HIVSelfTest MSM, Directly-Assisted	135
	HTS_SELF_N_TA_KeyPop_HIVSelfTest MSM, Unassisted	135
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB	100 %



	cases with documented HIV status.	
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	43,724
	Total number of registered new and relapsed TB cases, during the reporting period.	43,724
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,379
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	26,181
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,201
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	12,963
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,379
	Aggregated Age/Sex: Male 15+	26,181



	(Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,201
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	12,963
TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	100 %
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	13,259
	Total number of registered new and relapsed TB cases, during the reporting period.	13,259
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	662
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	708
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	3,931



	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	7,958
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	708
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	7,958
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	662
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,931
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Female, Directly-Assisted	3,609
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Female, Unassisted	9,488
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Female, Directly-Assisted	9,481
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Female,	28,459



	Unassisted	
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Male, Directly-Assisted	478
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Male, Unassisted	478
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Female, Directly-Assisted	5,691
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Female, Unassisted	18,969
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Male, Directly-Assisted	478
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Male, Unassisted	478
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Female, Directly-Assisted	3,227
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Female, Unassisted	7,590
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Female, Directly-Assisted	1,328
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Female, Unassisted	3,793
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Female, Directly-Assisted	378
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Female, Unassisted	950



	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	94,851
	HTS_SELF_N_DSD_KeyPop_HIV SelfTest FSW, Directly-Assisted	4,739
	HTS_SELF_N_DSD_KeyPop_HIV SelfTest FSW, Unassisted	14,226
	HTS_SELF_N_DSD_KeyPop_HIV SelfTest MSM, Directly-Assisted	950
	HTS_SELF_N_DSD_KeyPop_HIV SelfTest MSM, Unassisted	950
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	3,220,122
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	40,867
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	1,267
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	8,698
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	192
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	9,387
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	498
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	3,061
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	162
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	17,416
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	920



	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	7,785
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	413
	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	200
	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	11
	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	5,873
	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	311
	Service Delivery Point (Facility) Inpatient: 1-9, Negative	37,498
	Service Delivery Point (Facility) Inpatient: 1-9, Positive	1,239
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	8,589
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	358
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	4,294
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	179
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	5,726
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	239



	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	15,928
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	664
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	119
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	5
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	18,037
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	752
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	61,934
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	1,239
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	13,080
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	289
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	40,373
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	1,282
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	20,166



Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	657
Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	60,679
Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	1,908
Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	65,125
Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	2,048
Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	756
Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	26
Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	27,975
Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	899
Service Delivery Point (Facility) Other PITC: 1-9, Negative	56,699
Service Delivery Point (Facility) Other PITC: 1-9, Positive	1,239
Service Delivery Point (Facility) Pediatric : <5 Negative	87,802
Service Delivery Point (Facility) Pediatric : <5 Positive	1,822
Service Delivery Point (Facility) TB: 10-14, Female, Negative	532
Service Delivery Point (Facility) TB: 10-14, Female, Positive	176
Service Delivery Point (Facility) TB: 10-14, Male, Negative	276



	Service Delivery Point (Facility) TB: 10-14, Male, Positive	86
	Service Delivery Point (Facility) TB: 15-19, Female, Negative	1,785
	Service Delivery Point (Facility) TB: 15-19, Female, Positive	581
	Service Delivery Point (Facility) TB: 15-19, Male, Negative	2,676
	Service Delivery Point (Facility) TB: 15-19, Male, Positive	870
	Service Delivery Point (Facility) TB: 20-24, Female, Negative	3,043
	Service Delivery Point (Facility) TB: 20-24, Female, Positive	992
	Service Delivery Point (Facility) TB: 20-24, Male, Negative	1,284
	Service Delivery Point (Facility) TB: 20-24, Male, Positive	420
	Service Delivery Point (Facility) TB: 50+, Female, Negative	783
	Service Delivery Point (Facility) TB: 50+, Female, Positive	263
	Service Delivery Point (Facility) TB: 50+, Male, Negative	1,785
	Service Delivery Point (Facility) TB: 50+, Male, Positive	581
	Service Delivery Point (Facility) TB: 1-9, Negative	1,284
	Service Delivery Point (Facility) TB: 1-9, Positive	420
	Service Delivery Point (Facility) VMC: 10-14, Negative	30,806
	Service Delivery Point (Facility) VMC: 10-14, Positive	162



	Service Delivery Point (Facility) VMMC: 15-19, Negative	154,031
	Service Delivery Point (Facility) VMMC: 15-19, Positive	809
	Service Delivery Point (Facility) VMMC: 20-24, Negative	154,031
	Service Delivery Point (Facility) VMMC: 20-24, Positive	809
	Service Delivery Point (Facility) VMMC: 50+, Negative	18,484
	Service Delivery Point (Facility) VMMC: 50+, Positive	101
	Service Delivery Point (Facility) Index: 10-14, Female, Negative	8,049
	Service Delivery Point (Facility) Index: 10-14, Female, Positive	447
	Service Delivery Point (Facility) Index: 10-14, Male, Negative	1,730
	Service Delivery Point (Facility) Index: 10-14, Male, Positive	105
	Service Delivery Point (Facility) Index: 15-19, Female, Negative	2,203
	Service Delivery Point (Facility) Index: 15-19, Female, Positive	408
	Service Delivery Point (Facility) Index: 15-19, Male, Negative	1,120
	Service Delivery Point (Facility) Index: 15-19, Male, Positive	213
	Service Delivery Point (Facility) Index: 20-24, Female, Negative	3,647
	Service Delivery Point (Facility) Index: 20-24, Female, Positive	673
	Service Delivery Point (Facility) Index: 20-24, Male, Negative	4,047



Service Delivery Point (Facility) Index: 20-24, Male, Positive	744
Service Delivery Point (Facility) Index: 50+, Female, Negative	35
Service Delivery Point (Facility) Index: 50+, Female, Positive	6
Service Delivery Point (Facility) Index: 50+, Male, Negative	3,140
Service Delivery Point (Facility) Index: 50+, Male, Positive	578
Service Delivery Point (Facility) Index: 1-9, Negative	7,346
Service Delivery Point (Facility) Index: 1-9, Positive	409
By Key Population: FSW, Negative	37,843
By Key Population: FSW, Positive	18,121
By Key Population: MSM, Negative	3,316
By Key Population: MSM, Positive	1,095
By Key Population: People in prisons and other enclosed settings, Negative	100,434
By Key Population: People in prisons and other enclosed settings, Positive	19,059
By Key Population: PWID, Negative	2,325
By Key Population: PWID, Positive	586
By Key Population: TG, Negative	748
By Key Population: TG, Positive	239
Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	10,441
Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	550



	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	2,222
	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	117
	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	2,138
	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	377
	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	1,069
	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	189
	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	1,425
	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	252
	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	3,965
	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	700
	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	30
	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	5
	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	4,490
	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	792
	Service Delivery Point (Community) Index Mod: 1-9, Negative	9,552
	Service Delivery Point (Community) Index Mod: 1-9, Positive	503



	Service Delivery Point (Facility) ANC: 15-19, Negative	147,789
	Service Delivery Point (Facility) ANC: 15-19, Positive	3,501
	Service Delivery Point (Facility) ANC: 20-24, Negative	256,663
	Service Delivery Point (Facility) ANC: 20-24, Positive	6,066
	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	11,258
	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	2,017
	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	9,229
	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	1,660
	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	2,709
	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	500
	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	7,126
	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	1,287
	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	5,070
	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	925
	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	8,457
	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	1,530
	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	3,930



HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	725
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	10,696
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	1,917
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	21,704
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	1,145
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	14,326
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	756
HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	9,392
HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	498
HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	9,515
HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	505
HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	9,752
HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	518
HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	12,844
HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	680
HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	6,587
HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	352



HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Male, Negative	11,968
HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Male, Positive	634
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Female, Negative	44,449
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Female, Positive	1,852
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Male, Negative	36,462
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Male, Positive	1,519
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Female, Negative	10,593
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Female, Positive	441
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Male, Negative	28,129
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Male, Positive	1,172
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 35-39, Female, Negative	19,970
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 35-39, Female, Positive	832
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 35-39, Male, Negative	33,421
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 35-39, Male, Positive	1,393



HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	18,326
HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	764
HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	42,253
HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	1,760
HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	10,754
HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	472
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	11,065
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	1,953
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	9,077
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	1,602
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	2,637
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	465
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	7,003
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	1,236



HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	4,972
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	877
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	8,320
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	1,468
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	4,562
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	805
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	10,519
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	1,856
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	98,793
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	3,078
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	101,671
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	3,173
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	35,356
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female,	1,125



	Positive	
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	65,171
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	2,050
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	39,029
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	1,240
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	73,770
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	2,310
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	31,693
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	1,014
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	59,787
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	1,879
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	170,881
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	3,985
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	73,949



HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	3,084
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	76,783
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	1,347
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	51,722
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	475
HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	2,850
HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	233
HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	951
HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	81
HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	5,247
HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	420
HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	2,366
HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	199
HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	6,531
HTS_TST_N_DSD_STI_Age_Sex_	521



	Result 25-29, Female, Positive	
	HTS_TST_N_DSD_STI_Age_Sex_ Result 25-29, Male, Negative	4,334
	HTS_TST_N_DSD_STI_Age_Sex_ Result 25-29, Male, Positive	345
	HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Female, Negative	2,852
	HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Female, Positive	234
	HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Male, Negative	2,895
	HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Male, Positive	236
	HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Female, Negative	2,965
	HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Female, Positive	240
	HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Male, Negative	3,880
	HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Male, Positive	309
	HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Female, Negative	2,016
	HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Female, Positive	167
	HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Male, Negative	3,623
	HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Male, Positive	288
	HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Female, Negative	121
	HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Female, Positive	8
	HTS_TST_N_DSD_STI_Age_Sex_	1,751



	Result 50+, Male, Negative	
	HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Male, Positive	145
	HTS_TST_N_DSD_TBC_Age_Sex_ Result 25-29, Female, Negative	1,284
	HTS_TST_N_DSD_TBC_Age_Sex_ Result 25-29, Female, Positive	420
	HTS_TST_N_DSD_TBC_Age_Sex_ Result 25-29, Male, Negative	783
	HTS_TST_N_DSD_TBC_Age_Sex_ Result 25-29, Male, Positive	263
	HTS_TST_N_DSD_TBC_Age_Sex_ Result 30-34, Female, Negative	1,536
	HTS_TST_N_DSD_TBC_Age_Sex_ Result 30-34, Female, Positive	497
	HTS_TST_N_DSD_TBC_Age_Sex_ Result 30-34, Male, Negative	1,030
	HTS_TST_N_DSD_TBC_Age_Sex_ Result 30-34, Male, Positive	342
	HTS_TST_N_DSD_TBC_Age_Sex_ Result 35-39, Female, Negative	1,908
	HTS_TST_N_DSD_TBC_Age_Sex_ Result 35-39, Female, Positive	624
	HTS_TST_N_DSD_TBC_Age_Sex_ Result 35-39, Male, Negative	3,043
	HTS_TST_N_DSD_TBC_Age_Sex_ Result 35-39, Male, Positive	992
	HTS_TST_N_DSD_TBC_Age_Sex_ Result 40-49, Female, Negative	1,284
	HTS_TST_N_DSD_TBC_Age_Sex_ Result 40-49, Female, Positive	420
	HTS_TST_N_DSD_TBC_Age_Sex_ Result 40-49, Male, Negative	1,284
	HTS_TST_N_DSD_TBC_Age_Sex	420



	_Result 40-49, Male, Positive	
	HTS_TST_N_DSD_VMMC_Age_S ex_Result 25-29, Male, Negative	184,846
	HTS_TST_N_DSD_VMMC_Age_S ex_Result 25-29, Male, Positive	967
	HTS_TST_N_DSD_VMMC_Age_S ex_Result 30-34, Male, Negative	24,640
	HTS_TST_N_DSD_VMMC_Age_S ex_Result 30-34, Male, Positive	134
	HTS_TST_N_DSD_VMMC_Age_S ex_Result 35-39, Male, Negative	24,640
	HTS_TST_N_DSD_VMMC_Age_S ex_Result 35-39, Male, Positive	134
	HTS_TST_N_DSD_VMMC_Age_S ex_Result 40-49, Male, Negative	24,640
	HTS_TST_N_DSD_VMMC_Age_S ex_Result 40-49, Male, Positive	135
GEND_GBV_DSD	Number of people receiving post-GBV care	87,279
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	61,113
	By type of service: Sexual Violence (Post-Rape Care)	26,166
	By PEP service provision (related to sexual violence services provided)	7,853
	<10, Female, Physical and/or Emotional Violence	803
	<10, Female, Sexual Violence (Post-Rape Care)	526
	<10, Male, Physical and/or Emotional Violence	447
	<10, Male, Sexual Violence	48



	(Post-Rape Care)	
	10-14, Female, Physical and/or Emotional Violence	2,147
	10-14, Female, Sexual Violence (Post-Rape Care)	1,644
	10-14, Male, Physical and/or Emotional Violence	773
	10-14, Male, Sexual Violence (Post-Rape Care)	95
	15-19, Female, Physical and/or Emotional Violence	18,675
	15-19, Female, Sexual Violence (Post-Rape Care)	15,042
	15-19, Male, Physical and/or Emotional Violence	1,900
	15-19, Male, Sexual Violence (Post-Rape Care)	556
	20-24, Female, Physical and/or Emotional Violence	9,086
	20-24, Female, Sexual Violence (Post-Rape Care)	4,562
	20-24, Male, Physical and/or Emotional Violence	4,525
	20-24, Male, Sexual Violence (Post-Rape Care)	1,938
	50+, Female, Physical and/or Emotional Violence	2,371
	50+, Female, Sexual Violence (Post-Rape Care)	185
	50+, Male, Physical and/or Emotional Violence	1,470
	50+, Male, Sexual Violence (Post-Rape Care)	94
	GEND_GBV_N_DSD_Age_Sex_Vi	3,355



	olenceType_v3 25-29, Female, Physical and/or Emotional Violence	
	GEND_GBV_N_DSD_Age_Sex_Vi olenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	324
	GEND_GBV_N_DSD_Age_Sex_Vi olenceType_v3 25-29, Male, Physical and/or Emotional Violence	2,322
	GEND_GBV_N_DSD_Age_Sex_Vi olenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	117
	GEND_GBV_N_DSD_Age_Sex_Vi olenceType_v3 30-34, Female, Physical and/or Emotional Violence	3,357
	GEND_GBV_N_DSD_Age_Sex_Vi olenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	324
	GEND_GBV_N_DSD_Age_Sex_Vi olenceType_v3 30-34, Male, Physical and/or Emotional Violence	2,322
	GEND_GBV_N_DSD_Age_Sex_Vi olenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	117
	GEND_GBV_N_DSD_Age_Sex_Vi olenceType_v3 35-39, Female, Physical and/or Emotional Violence	3,357
	GEND_GBV_N_DSD_Age_Sex_Vi olenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	324
	GEND_GBV_N_DSD_Age_Sex_Vi olenceType_v3 35-39, Male, Physical and/or Emotional Violence	2,322
	GEND_GBV_N_DSD_Age_Sex_Vi olenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	117



	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	1,117
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	107
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	775
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	35
GEND_GBV_TA	Number of people receiving post-GBV care	6,248
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	4,593
	By type of service: Sexual Violence (Post-Rape Care)	1,655
	By PEP service provision (related to sexual violence services provided)	500
	<10, Female, Physical and/or Emotional Violence	58
	<10, Female, Sexual Violence (Post-Rape Care)	35
	<10, Male, Physical and/or Emotional Violence	30
	<10, Male, Sexual Violence (Post-Rape Care)	3
	10-14, Female, Physical and/or Emotional Violence	162
	10-14, Female, Sexual Violence (Post-Rape Care)	102



	10-14, Male, Physical and/or Emotional Violence	57
	10-14, Male, Sexual Violence (Post-Rape Care)	4
	15-19, Female, Physical and/or Emotional Violence	1,450
	15-19, Female, Sexual Violence (Post-Rape Care)	955
	15-19, Male, Physical and/or Emotional Violence	142
	15-19, Male, Sexual Violence (Post-Rape Care)	36
	20-24, Female, Physical and/or Emotional Violence	681
	20-24, Female, Sexual Violence (Post-Rape Care)	291
	20-24, Male, Physical and/or Emotional Violence	340
	20-24, Male, Sexual Violence (Post-Rape Care)	118
	50+, Female, Physical and/or Emotional Violence	177
	50+, Female, Sexual Violence (Post-Rape Care)	14
	50+, Male, Physical and/or Emotional Violence	108
	50+, Male, Sexual Violence (Post-Rape Care)	4
	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	247
	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	19



GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	176
GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	5
GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	246
GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	19
GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	175
GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	5
GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	245
GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	19
GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	174
GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	5
GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	82
GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 40-49, Female,	5



	Sexual Violence (Post-Rape Care)	
	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	58
	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	1
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	418,619
	Age/Sex: 10-14 Male	46,052
	Age/Sex: 15-17 Male	37,667
	By: Age/sex: Male 18-24	37,660
	By: Age/sex: Male 25+	8,365
	Age/Sex: 10-14 Female	50,228
	Age/Sex: 15-17 Female	46,048
	By: Age/sex: 18-24 Female	46,089
	By: Age/sex: 25+ Female	12,537
	Sum of Age/Sex disaggregates	179,995
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	25,168
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	6,288
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	21,880
Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	5,476	



	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	15,102
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	3,786
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	13,140
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	3,288
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	4,929
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	758
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	4,522
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	618
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	3,425
	Required only for DREAMS	6,840



	countries - By service, age and sex: Economic Strengthening Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	23,941
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	2,738
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	5,473
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	19,151
	Age/Sex: <1	16,746
	Age/Sex: 1-9	117,227
	Program Completion: Active	397,696
	Program Completion: Graduation	20,923
	OVC_SERV_N_DSD_Age_Sex_Service_v4 <1, Unknown Sex, Social Protection	1,645
	OVC_SERV_N_DSD_Age_Sex_Service_v4 1-9, Unknown Sex, Social Protection	11,498
OVC_HIVSTAT_DSD	OVC_HIVSTAT_DSD Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	75 %
	Number of orphans and vulnerable	313,968



	children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	
	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	418,619
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	18,677
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	971
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	10,470
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during	1,052



	the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6,184
TB_ART_TA	TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	5,198
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	240
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2,979
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on	267



	ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,712
TB_PREV_DSD	TB_PREV_DSD TB_PREV_DSD	85 %
	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	156,643
	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	184,288
	By Age/Sex (Denominator): <15, Female	11,070
	By Age/Sex (Denominator): <15, Male	7,385
	By Age/Sex (Denominator): 15+, Female	112,391
	By Age/Sex (Denominator): 15+, Male	53,442
	By Age/Sex (Numerator): <15,	9,404



	Female	
	By Age/Sex (Numerator): <15, Male	6,274
	By Age/Sex (Numerator): 15+, Female	95,529
	By Age/Sex (Numerator): 15+, Male	45,436
	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	160,277
	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	18,435
	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	4,809
	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	767
	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	136,219
	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	15,677
	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	4,088
	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	659



TB_PREV_TA	TB_PREV_TA TB_PREV_TA	85 %
	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	35,462
	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	41,713
	By Age/Sex (Denominator): <15, Female	2,488
	By Age/Sex (Denominator): <15, Male	1,661
	By Age/Sex (Denominator): 15+, Female	25,466
	By Age/Sex (Denominator): 15+, Male	12,098
	By Age/Sex (Numerator): <15, Female	2,120
	By Age/Sex (Numerator): <15, Male	1,409
	By Age/Sex (Numerator): 15+, Female	21,658
	By Age/Sex (Numerator): 15+, Male	10,275
	TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT	36,340



	Regimen, Life-long ART, Already, Positive	
	TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	4,169
	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	1,068
	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	136
	TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	30,903
	TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	3,538
	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	906
	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	115
TX_TB_DSD	TX_TB_DSD The proportion of ART patients who were screened who are receiving TB treatment	0 %
	Number of ART patients who were screened for TB at least once during the reporting period	1,034,190
	Denominator: By Aggregated Age/Sex: <15, Female	62,060
	Denominator: By Aggregated	41,384



	Age/Sex: <15, Male	
	Denominator: By Aggregated Age/Sex:15+, Female	630,814
	Denominator: By Aggregated Age/Sex:15+, Male	299,932
	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	41,384
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	2,100
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	8,293
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	30,991
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	899,703
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	26,898
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	103,427
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	4,162
TX_TB_TA	TX_TB_TA The proportion of ART patients who were screened who are receiving TB treatment	0 %



	Number of ART patients who were screened for TB at least once during the reporting period	234,133
	Denominator: By Aggregated Age/Sex: <15, Female	14,042
	Denominator: By Aggregated Age/Sex: <15, Male	9,353
	Denominator: By Aggregated Age/Sex: 15+, Female	142,847
	Denominator: By Aggregated Age/Sex: 15+, Male	67,891
	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	9,353
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	435
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	1,858
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	7,060
	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	203,724
	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	6,081
	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	23,407



	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	921
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	55,381
	By infants who received a virologic test within 2 months of birth	46,758
	By infants who received their first virologic HIV test between 2 and 12 months of age	8,623
	Sum of Infant Age disaggregates	55,381
PMTCT_EID_TA	PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	21,030
	By infants who received a virologic test within 2 months of birth	17,556
	By infants who received their first virologic HIV test between 2 and 12 months of age	3,474
	Sum of Infant Age disaggregates	21,030
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,034,190
	Age/Sex: 15-19 Male	4,263
	Age/Sex: 15-19 Female	21,212



	Age/Sex: <1	5,619
	Age/Sex: <1-9	29,867
	Age/Sex: 10-14 Male	11,093
	Age/Sex: 10-14 Female	24,615
	Age/Sex: 20-24 Male	5,727
	Age/Sex: 50+ Male	72,873
	Age/Sex: 20-24 Female	61,271
	Age/Sex: 50+ Female	107,480
	TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Female, Positive	86,727
	TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Male, Positive	16,075
	TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Female, Positive	123,439
	TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Male, Positive	37,550
	TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Female, Positive	101,220
	TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Male, Positive	48,898
	TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Female, Positive	148,464
	TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Male, Positive	127,797
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	234,133
	Age/Sex: 15-19 Male	785
	Age/Sex: 15-19 Female	4,613
	Sum of Age/Sex disaggregations	5,398
	Age/Sex: <1	1,056
	Age/Sex: 1-9	6,577
	Age/Sex: 10-14 Male	2,286



	Age/Sex: 10-14 Female	5,341
	Age/Sex: 20-24 Male	1,185
	Age/Sex: 50+ Male	16,617
	Age/Sex: 20-24 Female	13,847
	Age/Sex: 50+ Female	24,514
	TX_CURR_N_TA_Age_Sex_HIVSt atus 25-29, Female, Positive	19,667
	TX_CURR_N_TA_Age_Sex_HIVSt atus 25-29, Male, Positive	3,622
	TX_CURR_N_TA_Age_Sex_HIVSt atus 30-34, Female, Positive	28,100
	TX_CURR_N_TA_Age_Sex_HIVSt atus 30-34, Male, Positive	8,563
	TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Female, Positive	23,040
	TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Male, Positive	11,164
	TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Female, Positive	33,953
	TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Male, Positive	29,203
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	104,225
	By Age/Sex: <1	703
	By Age/Sex: 1-9	3,822
	By Age/Sex: 10-14 Male	967
	By Age/Sex: 15-19 Male	2,154
	By Age/Sex: 20-24 Male	5,307
	By Age/Sex: 50+ Male	3,906
	By Age/Sex: 10-14 Female	3,566
	By Age/Sex: 15-19 Female	6,449
	By Age/Sex: 20-24 Female	11,876



	By Age/Sex: 50+ Female	255
	Pregnancy status	9,560
	Breastfeeding status	9,560
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 25-29, Female, Positive	14,570
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 25-29, Male, Positive	9,744
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 30-34, Female, Positive	6,411
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 30-34, Male, Positive	6,470
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 35-39, Female, Positive	6,655
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 35-39, Male, Positive	8,725
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 40-49, Female, Positive	4,515
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 40-49, Male, Positive	8,130
	Number of adults and children newly enrolled on antiretroviral therapy (ART)	22,165
TX_NEW_TA	By Age/Sex: <1	110
	By Age/Sex: 1-9	764
	By Age/Sex: 10-14 Male	165
	By Age/Sex: 15-19 Male	413
	By Age/Sex: 20-24 Male	1,105
	By Age/Sex: 50+ Male	815
	By Age/Sex: 10-14 Female	708
	By Age/Sex: 15-19 Female	1,352
	By Age/Sex: 20-24 Female	2,503
	By Age/Sex: 50+ Female	35
	Sum of Age/Sex disaggregates	7,096



	Pregnancy status	2,028
	Breastfeeding status	2,028
	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	3,469
	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	2,069
	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	1,353
	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	1,369
	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	1,404
	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	1,863
	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	934
	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	1,734
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	0 %
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	930,782
	Denominator: Indication: Routine	809,782
	Denominator: Indication: Targeted	121,000
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	2,542



	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	36,213
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	5,143
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	77,102
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	18,626
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	241,999
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	37,240
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	511,917
TX_PVLS_TA	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	0 %
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	210,712
	Denominator: Indication: Routine	183,319
	Denominator: Indication: Targeted	27,393
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	8,425
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	1,137
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	4,207



	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	548
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	115,896
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	17,518
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	54,791
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	8,190
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	90 %
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	229,684
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	255,193
	Numerator by Status: Pregnant	22,324
	Numerator by Status: Breastfeeding	22,324
	Denominator by Status: Pregnant	24,802
	Denominator by Status: Breastfeeding	24,802
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,331



	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	104,851
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,298
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	118,204
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,580
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	116,518
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	4,773



	including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	131,322
TX_RET_TA	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	90 %
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	58,378
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	64,872
	Numerator by Status: Pregnant	5,692
	Numerator by Status: Breastfeeding	5,692
	Denominator by Status: Pregnant	6,327
	Denominator by Status: Breastfeeding	6,327
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after	458



	initiating ART)	
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	26,793
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	882
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	30,245
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	516
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	29,749
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	982



	<p>beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	<p>33,625</p>



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
9043	Henry Jackson Foundation	Private Contractor	U.S. Department of Defense	GHP-State	9,277,376
9167	Kalangala District Health Office	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
9183	The AIDS Support Organization	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
9303	U.S. Department of Defense (Defense)	Other USG Agency	U.S. Department of Defense	GHP-State	70,000
10326	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development		
11479	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	185,000
11480	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	162,234



12981	Uganda Virus Research Institute	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
13002	United Nations High Commissioner for Refugees	Multi-lateral Agency	U.S. Department of State/Bureau of Population, Refugees, and Migration	GHP-State	647,566
13029	Regional Procurement Support Office/Frankfurt	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	500,000
13170	Makerere University School of Public Health	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
13317	Joint Clinical Research Center, Uganda	NGO	U.S. Agency for International Development		
13466	Uganda Protestant Medical Board	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
13717	Registered Trustees for the Uganda Episcopal	Implementing Agency	U.S. Department of Health and Human		



	Conference		Services/Centers for Disease Control and Prevention		
13835	Baylor College of Medicine Children's Foundation	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
13837	QED Group, LLC	Private Contractor	U.S. Agency for International Development		
13841	World Health Organization	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
13864	Ministry of Health, Uganda	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
13874	Program for Appropriate Technology in Health	NGO	U.S. Agency for International Development	GHP-State	441,449
13877	Children's AIDS Fund	NGO	U.S. Department of Health and Human Services/Centers		



			for Disease Control and Prevention		
13880	Makerere University School of Public Health	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
13892	Research Triangle International	Private Contractor	U.S. Agency for International Development	GHP-State	1,000,000
13901	FHI 360	NGO	U.S. Agency for International Development	GHP-State	1,591,714
16594	University of North Carolina at Chapel Hill, Carolina Population Center	University	U.S. Agency for International Development	GHP-State	720,000
16626	Cardno Emerging Markets	NGO	U.S. Agency for International Development		
17063	Uganda Health Marketing Group	NGO	U.S. Agency for International Development	GHP-State	1,000,000
17065	Catholic Relief Services	FBO	U.S. Agency for International Development	GHP-State	7,941,947
17066	World Vision	NGO	U.S. Agency for International Development	GHP-State	279,189
17078	University Research Council	NGO	U.S. Agency for International		



			Development		
17094	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-State	1,255,966
17649	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development	GHP-State	9,863,633
17651	IntraHealth International, Inc	NGO	U.S. Agency for International Development	GHP-State	6,711,431
17654	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Agency for International Development	GHP-State	16,056,066
17688	Social and Scientific Systems	Private Contractor	U.S. Agency for International Development	GHP-State	3,119,600
17690	IntraHealth International, Inc	NGO	U.S. Agency for International Development	GHP-State	1,322,148
17696	World Education	NGO	U.S. Agency for International Development	GHP-State	8,487,431
17698	Uganda Prisons Services	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,802,308
17703	Makerere University School of Public Health	University	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	7,150,684



			Prevention		
17704	African Society for Laboratory Medicine	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
17705	Makerere University John Hopkins University Collaboration	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	400,000
17706	Infectious Disease Institute	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	12,250,971
17855	Research Triangle International	Private Contractor	U.S. Department of Defense		
17874	National Medical Research Unit	NGO	U.S. Department of Defense		
17976	Association of Public Health Laboratories	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
17977	American International Health Alliance	NGO	U.S. Department of Health and Human	GHP-State	350,000



	Twinning Center		Services/Health Resources and Services Administration		
17978	Infectious Disease Institute	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	21,287,615
17979	Medical Access Uganda Limited (MAUL)	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	64,424,150
18003	Global Healthcare Public Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,030,000
18017	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
18032	Rakai Health Sciences Program	NGO	U.S. Department of Health and Human Services/Centers	GHP-State	15,680,468



			for Disease Control and Prevention		
18033	Mildmay Uganda	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	12,807,245
18034	The AIDS Support Organization	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,322,557
18041	African Field Epidemiology Network	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,070,093
18042	Makerere University School of Public Health	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,230,005
18273	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development	GHP-State	5,721,347
18274	John Snow Inc (JSI)	Implementing Agency	U.S. Agency for International	GHP-State	10,373,301



			Development		
18276	DevTech Systems Inc	Private Contractor	U.S. Agency for International Development		
18361	Catholic Relief Services	FBO	U.S. Agency for International Development		
18369	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	33,166,805
18502	Population Services International	NGO	U.S. Department of Defense	GHP-State	502,554
18553	John Snow Inc (JSI)	Implementing Agency	U.S. Agency for International Development	GHP-State, GHP-USAID	1,300,000
18554	Right to Care	NGO	U.S. Agency for International Development	GHP-State	300,000
18557	University Research Council	NGO	U.S. Agency for International Development	GHP-State	800,000
18559	TBD	TBD	Redacted	Redacted	Redacted
18560	TBD	TBD	Redacted	Redacted	Redacted
18561	TBD	TBD	Redacted	Redacted	Redacted
18562	TBD	TBD	Redacted	Redacted	Redacted
18563	TBD	TBD	Redacted	Redacted	Redacted
18565	Population Council	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	600,000



18566	Uganda Virus Research Institute	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,542,693
18567	Baylor University, College of Medicine	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	12,034,765
18568	Population Council	NGO	U.S. Agency for International Development	GHP-State	275,000
18569	UNICEF	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	300,000
18583	STOP TB Partnership Trust Fund	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	1,485,124
18668	TBD	TBD	Redacted	Redacted	Redacted
18671	Infectious Disease Institute	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
18672	TBD	TBD	Redacted	Redacted	Redacted
70363	TBD	TBD	Redacted	Redacted	Redacted
70364	TBD	TBD	Redacted	Redacted	Redacted
70365	[Placeholder]	TBD	U.S. Department		



			of Defense		
70366	[Placeholder]	TBD	U.S. Department of Defense		
70367	TBD	TBD	Redacted	Redacted	Redacted
70368	TBD	TBD	Redacted	Redacted	Redacted
70369	TBD	TBD	Redacted	Redacted	Redacted
70370	[Placeholder]	TBD	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
70371	[Placeholder]	TBD	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
70372	[Placeholder]	TBD	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
70373	[Placeholder]	TBD	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
70374	[Placeholder]	TBD	U.S. Department		



			of Health and Human Services/Centers for Disease Control and Prevention		
70375	[Placeholder]	TBD	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
70376	[Placeholder]	TBD	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
70377	[Placeholder]	TBD	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
70378	[Placeholder]	TBD	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
70379	[Placeholder]	TBD	U.S. Department of Health and		



			Human Services/Health Resources and Services Administration		
70380	[Placeholder]	TBD	U.S. Department of Health and Human Services/Health Resources and Services Administration		
70381	[Placeholder]	TBD	U.S. Department of Health and Human Services/Health Resources and Services Administration		
70382	[Placeholder]	TBD	U.S. Peace Corps		
70383	[Placeholder]	TBD	U.S. Peace Corps		
70384	Price Waterhouse Coopers	Private Contractor	U.S. Agency for International Development	GHP-State	600,000
70385	TBD	TBD	Redacted	Redacted	Redacted
70386	TBD	TBD	Redacted	Redacted	Redacted
70387	Research Triangle International	Private Contractor	U.S. Agency for International Development	GHP-State	478,929
70388	TBD	TBD	Redacted	Redacted	Redacted
70389	Beyond Logistics	Unknown	U.S. Agency for International Development		
70390	Remote Medical International	Private Contractor	U.S. Agency for International Development	GHP-State	1,870,228



			Development		
70391	TBD	TBD	Redacted	Redacted	Redacted
70392	TBD	TBD	Redacted	Redacted	Redacted
70393	[Placeholder]	TBD	U.S. Agency for International Development		
70394	[Placeholder]	TBD	U.S. Agency for International Development		
70395	[Placeholder]	TBD	U.S. Agency for International Development		
70396	[Placeholder]	TBD	U.S. Agency for International Development		
70397	[Placeholder]	TBD	U.S. Agency for International Development		
70518	[Placeholder]	TBD	U.S. Department of State/Office of the Global AIDS Coordinator		



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 9043	Mechanism Name: Makerere University Walter Reed Project (MUWRP)
Funding Agency: DOD	Procurement Type: Cooperative Agreement
Prime Partner Name: Henry Jackson Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 9,277,376	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 1,781,283	
Total All Funding Sources and Applied Pipeline Amount: 11,058,659	
Funding Source	Funding Amount
GHP-State	9,277,376

Cross-Cutting Budget Attribution(s)

Gender: GBV	301,879
Focus Area:	GBV Prevention
Sub Area:	Implementation
Key Populations: FSW	40,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and



	operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Key Populations: MSM and TG	10,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Adolescent Girls and Young Women (AGYW)	1,373,195
Economic Strengthening	10,000
Human Resources for Health	110,000
Condom programming	12,000
Water	100,000
Food and Nutrition: Policy, Tools, and Service Delivery	2,000
Construction	1,400,000
Motor Vehicles: Purchased	250,000
Food and Nutrition: Commodities	10,000

Budget Code Information

Mechanism ID: 9043		
Mechanism Name: Makerere University Walter Reed Project (MUWRP)		
Prime Partner Name: Henry Jackson Foundation		
Strategic Area	Budget Code	Planned Amount



Care	HBHC	777,463
Strategic Area	Budget Code	Planned Amount
Care	HKID	1,349,878
Strategic Area	Budget Code	Planned Amount
Care	HVTB	550,628
Strategic Area	Budget Code	Planned Amount
Care	PDCS	322,331
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	183,816
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	561,285
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	848,461
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	433,030



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	1,796,365
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	393,314
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,965,787
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	95,018

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	2,798
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	42,008
PMTCT_ART_DSD	New on ART	1,185
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,613
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	1,913



PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	28,937
PMTCT_ART_TA	New on ART	773
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	1,140
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	42,008
PMTCT_STAT_DSD	Number of new ANC and L&D clients	42,008
PMTCT_STAT_DSD	By Age (Denominator): <15-19	7,981
PMTCT_STAT_DSD	By Age (Denominator): 20-24	13,862
PMTCT_STAT_DSD	By Number of known positives: 15-19	10
PMTCT_STAT_DSD	By Number of known positives: 20-24	50
PMTCT_STAT_DSD	By Number of new positives: 15-19	242
PMTCT_STAT_DSD	By Number of new positives: 20-24	418
PMTCT_STAT_DSD	By Number of new negative: 15-19	7,729
PMTCT_STAT_DSD	By Number of new negative: 20-24	13,394
PMTCT_STAT_DSD	By Age (Numerator): 15-19	7,981
PMTCT_STAT_DSD	By Age (Numerator): 20-24	13,862
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	9,245
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	7,141
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	2,938
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	841
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	742
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	8,224
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	279
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	572
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	6,351



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	218
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	239
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	2,608
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	91
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	72
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	740
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	29
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	9,245
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	7,141
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	2,938
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	841
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	28,937
PMTCT_STAT_TA	Number of new ANC and L&D clients	28,937
PMTCT_STAT_TA	By Age (Denominator): 15-19	5,498
PMTCT_STAT_TA	By Age (Denominator): 20-24	9,550
PMTCT_STAT_TA	By known positives: 15-19	5
PMTCT_STAT_TA	By known positives: 20-24	33
PMTCT_STAT_TA	By new positives: 15-19	159
PMTCT_STAT_TA	By new positives: 20-24	279
PMTCT_STAT_TA	By new negatives: 15-19	5,334
PMTCT_STAT_TA	By new negatives: 20-24	9,238
PMTCT_STAT_TA	By Age (Numerator): : 15-19	5,498
PMTCT_STAT_TA	By Age (Numerator): 20-24	9,550
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 25-29, Female	6,363



PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 30-34, Female	4,920
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 35-39, Female	2,029
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 40-49, Female	577
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	516
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	5,662
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	185
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	402
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	4,377
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	141
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	165
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	1,807
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	57
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	46
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	518
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	13
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 25-29, Female	6,363
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 30-34, Female	4,920
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 35-39, Female	2,029
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 40-49, Female	577
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	53,126



VMMC_CIRC_DSD	By Age: 10-14	2,658
VMMC_CIRC_DSD	By Age: 15-19	13,289
VMMC_CIRC_DSD	By Age: 20-24	13,289
VMMC_CIRC_DSD	By Age: 25-29	15,937
VMMC_CIRC_DSD	By Age: 50+	1,575
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	30,811
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	46,748
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	52,776
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	350
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	2,126
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	2,126
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	2,126
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	1,715
PrEP_NEW_DSD	Male 15-19	17
PrEP_NEW_DSD	Male 20-24	120
PrEP_NEW_DSD	Male 50+	36
PrEP_NEW_DSD	Female 15-19	103
PrEP_NEW_DSD	Female 20-24	394
PrEP_NEW_DSD	Female 50+	17
PrEP_NEW_DSD	FSW	1,204
PrEP_NEW_DSD	MSM	67
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	173
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	84
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	173
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	84
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	173
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	84
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	173
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	84
PrEP_NEW_DSD	PrEP_NEW_N_DSD_KeyPopAbr Other Key	11



	Populations	
PrEP_NEW_TA	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	231
PrEP_NEW_TA	Male 15-19	3
PrEP_NEW_TA	Male 20-24	16
PrEP_NEW_TA	Male 50+	5
PrEP_NEW_TA	Female 15-19	14
PrEP_NEW_TA	Female 20-24	46
PrEP_NEW_TA	Female 50+	3
PrEP_NEW_TA	FSW	163
PrEP_NEW_TA	MSM	9
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 25-29, Female	24
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 25-29, Male	12
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 30-34, Female	24
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 30-34, Male	12
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 35-39, Female	24
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 35-39, Male	12
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 40-49, Female	24
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 40-49, Male	12
PrEP_NEW_TA	PrEP_NEW_N_TA_KeyPopAbr Other Key Populations	1
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	27,378
PP_PREV_DSD	Age/sex: 15-19 Male	883
PP_PREV_DSD	Age/sex: 20-24 Male	1,674
PP_PREV_DSD	Age/sex: 50+ Male	525
PP_PREV_DSD	Age/sex: 15-19 Female	3,159
PP_PREV_DSD	Age/sex: 20-24 Female	2,301
PP_PREV_DSD	Age/sex: 50+ Female	299
PP_PREV_DSD	Sum of Age/Sex disaggregates	8,841
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	1,936



PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	3,451
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	1,931
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	3,446
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	1,135
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	2,029
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	1,657
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	2,952
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	21,797
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	488
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	40
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	13,173
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	8,096
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	164,655
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14,	2,616



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	82
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	557
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	472
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	26
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	154
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	876
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	47
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	390
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	11
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	295
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	2,388
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	79
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	417



	15-19, Female, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	17
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	208
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	278
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	772
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	32
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	6
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	874
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	37
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	3,660
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	74
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	773
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	1,797
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	57
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	898



	Male, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	2,706
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	85
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	2,899
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	91
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	35
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	1,246
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	41
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	3,345
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	74
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	5,180
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	105
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female,	65



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	41
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	97
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	60
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	107
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	69
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	45
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	28
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	65
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	41
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	45
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	1,790
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	8,954
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	43
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	8,954
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	43
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	1,075



HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	473
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	26
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	100
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	97
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	49
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	160
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	182
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	140
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	432
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	25
HTC_TST_DSD	By Key Population: FSW, Negative	3,134



HTC_TST_DSD	By Key Population: FSW, Positive	1,521
HTC_TST_DSD	By Key Population: MSM, Negative	206
HTC_TST_DSD	By Key Population: MSM, Positive	91
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	7,218
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	1,522
HTC_TST_DSD	By Key Population: PWID, Negative	10
HTC_TST_DSD	By Key Population: PWID, Positive	2
HTC_TST_DSD	By Key Population: TG, Negative	74
HTC_TST_DSD	By Key Population: TG, Positive	14
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	621
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	33
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	133
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	98
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	17
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	50
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	66
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	182
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	32



	Male, Positive	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	207
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	37
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	570
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	7,421
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	242
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	12,891
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	418
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	494
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	90
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	408
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	75
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	122
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	318
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	57
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	226
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39,	42



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	375
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	70
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	174
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	473
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	86
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	1,091
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	56
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	718
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	472
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	478
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	490
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39,	644



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	330
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	601
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	2,155
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	90
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	1,767
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	73
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	514
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	1,363
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	57
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	969
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	1,620
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	68



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	889
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	37
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	2,047
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	85
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	634
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	508
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	90
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	418
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	73
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	121
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	322
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	57
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	228
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	383

	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	68
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	209
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	37
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	482
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	85
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	4,403
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	138
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	4,527
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	143
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	1,577
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	2,901
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	92
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	1,740
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	53
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	3,288
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	104



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	1,409
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	2,667
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	84
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	8,581
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	275
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	3,716
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	216
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	3,858
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	94
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	2,595
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	130
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	43
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24,	237



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	106
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	294
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	194
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	130
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	132
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	135
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	174
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	91
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	7



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	160
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	79
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	45
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	28
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	57
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	37
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	37
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	69
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39,	107



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	69
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	45
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	45
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	10,746
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	52
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	1,433
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	1,433
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	1,433
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	7
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	64,606
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	34
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	1



HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	7
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	20
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	6
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	38
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	18
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	13
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	31
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	1,170
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	20
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	246
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	660
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	19
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	330
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	988



HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	29
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	1,066
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	32
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	8
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	457
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	12
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Negative	1,076
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Positive	20
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	1,666
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	35
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Negative	4
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	17
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Positive	12
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	32
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Positive	20



HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	34
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	22
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	13
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	7
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	17
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	12
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Negative	13
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 10-14, Negative	855
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 10-14, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Negative	4,272
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Positive	13
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Negative	4,272
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Positive	13
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Negative	511
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	149
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Negative	33



HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	35
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	17
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	60
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	63
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	49
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	139
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Positive	6
HTC_TST_TA	By Key Population: FSW, Negative	1,130
HTC_TST_TA	By Key Population: FSW, Positive	547
HTC_TST_TA	By Key Population: MSM, Negative	77
HTC_TST_TA	By Key Population: MSM, Positive	35
HTC_TST_TA	By Key Population: People in prisons and other enclosed settings, Negative	2,602
HTC_TST_TA	By Key Population: People in prisons and other enclosed settings, Positive	546
HTC_TST_TA	By Key Population: TG, Negative	28
HTC_TST_TA	By Key Population: TG, Positive	5



HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	5,115
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	159
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	8,887
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	279
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Negative	183
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Positive	31
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative	152
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Positive	24
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Negative	41
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Positive	6
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Negative	112
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Positive	19
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Negative	80
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Positive	12
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative	137
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Positive	21
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Negative	62
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Positive	8
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Negative	175



HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Positive	29
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Negative	47
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Positive	3
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Negative	33
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Negative	20
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Negative	20
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Negative	21
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Negative	29
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Negative	15
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Negative	27
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Negative	205
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Positive	7
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Negative	1,611
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Positive	48
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Negative	1,656
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Positive	49

HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Negative	576
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Positive	17
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Negative	1,067
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Positive	32
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Negative	636
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Positive	19
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Negative	1,202
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Positive	36
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Negative	520
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Positive	14
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Negative	973
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Positive	29
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Negative	5,916
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Positive	180
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Negative	2,557
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Positive	138
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Negative	2,654



HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Positive	58
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Negative	1,794
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Positive	14
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Negative	43
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Negative	13
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Negative	84
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Positive	5
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Negative	36
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Negative	106
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Positive	6
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Negative	69
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Positive	3
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Negative	43
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Negative	43



HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Negative	44
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Negative	62
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Positive	3
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Negative	31
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Negative	60
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Negative	27
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Negative	13
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Positive	7
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	7
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Positive	3
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Negative	13
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Positive	9



HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	10
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Positive	5
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Negative	19
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Positive	14
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	34
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Positive	22
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Negative	13
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Positive	7
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative	13
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Positive	7
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 25-29, Male, Negative	5,124
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 25-29, Male, Positive	15
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 30-34, Male, Negative	683
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 35-39, Male, Negative	683
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 40-49, Male, Negative	683



HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 40-49, Male, Positive	2
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	91
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	240
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	241
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	721
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	11
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	11
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	144
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	481
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	11
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	11
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	81
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	192
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	34
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	97
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	10
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	24



HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Sex Partner	2,406
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest FSW, Directly-Assisted	120
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest FSW, Unassisted	360
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest MSM, Directly-Assisted	24
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest MSM, Unassisted	24
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,843
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,843
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	99
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,107
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	91
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	546
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	99
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,107
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	91



TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	546
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	577
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	577
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	30
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	31
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	172
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	344
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	31
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	344
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	30
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	172
GEND_GBV_DSD	Number of people receiving post-GBV care	5,278
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	3,777
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,501



GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	450
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	49
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	29
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	27
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	3
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	132
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	94
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	48
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	5
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	1,168
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	855
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	119
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	32
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	559
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	262
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	279
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	111
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	145
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	11
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	89
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	4
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	208
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	19
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	143
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	7
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	208
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3	19



	30-34, Female, Sexual Violence (Post-Rape Care)	
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	143
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	7
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	208
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	19
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	143
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	7
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	69
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	7
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	47
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	3
GEND_GBV_TA	Number of people receiving post-GBV care	10
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	7
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	3
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	1
GEND_GBV_TA	15-19, Female, Physical and/or Emotional Violence	6
GEND_GBV_TA	15-19, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_TA	20-24, Female, Physical and/or Emotional Violence	1
GEND_GBV_TA	20-24, Male, Physical and/or Emotional Violence	1
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	20,744



OVC_SERV_DSD	Age/Sex: 10-14 Male	2,281
OVC_SERV_DSD	Age/Sex: 15-17 Male	1,865
OVC_SERV_DSD	By: Age/sex: Male 18-24	1,864
OVC_SERV_DSD	By: Age/sex: Male 25+	417
OVC_SERV_DSD	Age/Sex: 10-14 Female	2,492
OVC_SERV_DSD	Age/Sex: 15-17 Female	2,281
OVC_SERV_DSD	By: Age/sex: 18-24 Female	2,285
OVC_SERV_DSD	By: Age/sex: 25+ Female	619
OVC_SERV_DSD	Sum of Age/Sex disaggregates	8,919
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	2,064
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	515
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	1,793
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	448
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	1,240
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	308
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	1,074
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	270
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	405
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	64
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	371
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	51



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	282
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	561
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	1,963
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	225
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	450
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	1,570
OVC_SERV_DSD	Age/Sex: <1	830
OVC_SERV_DSD	Age/Sex: 1-9	5,810
OVC_SERV_DSD	Program Completion: Active	19,709
OVC_SERV_DSD	Program Completion: Graduation	1,035
OVC_SERV_DSD	OVC_SERV_N_DSD_Age_Sex_Service_v4 <1, Unknown Sex, Social Protection	135
OVC_SERV_DSD	OVC_SERV_N_DSD_Age_Sex_Service_v4 1-9, Unknown Sex, Social Protection	942
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	15,558
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	20,744
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	955
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	50
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The	536

	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	54
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	315
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	291
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	13
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	167
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	14
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	97
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,798
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	2,365
PMTCT_EID_DSD	By infants who received their first virologic HIV test	433



	between 2 and 12 months of age	
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,798
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,913
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	1,599
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	314
PMTCT_EID_TA	Sum of Infant Age disaggregates	1,913
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	46,909
TX_CURR_DSD	Age/Sex: 15-19 Male	164
TX_CURR_DSD	Age/Sex: 15-19 Female	962
TX_CURR_DSD	Sum of age/sex disaggregates	1,126
TX_CURR_DSD	Age/Sex: <1	155
TX_CURR_DSD	Age/Sex: <1-9	947
TX_CURR_DSD	Age/Sex: 10-14 Male	330
TX_CURR_DSD	Age/Sex: 10-14 Female	773
TX_CURR_DSD	Age/Sex: 20-24 Male	250
TX_CURR_DSD	Age/Sex: 50+ Male	3,403
TX_CURR_DSD	Age/Sex: 20-24 Female	2,840
TX_CURR_DSD	Age/Sex: 50+ Female	5,107
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	4,054
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	714
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	5,800
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,702
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	4,738
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male,	2,221



	Positive	
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	6,971
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	5,778
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	17,530
TX_CURR_TA	Age/Sex: 15-19 Male	59
TX_CURR_TA	Age/Sex: 15-19 Female	357
TX_CURR_TA	Sum of Age/Sex disaggregations	416
TX_CURR_TA	Age/Sex: <1	55
TX_CURR_TA	Age/Sex: 1-9	347
TX_CURR_TA	Age/Sex: 10-14 Male	121
TX_CURR_TA	Age/Sex: 10-14 Female	281
TX_CURR_TA	Age/Sex: 20-24 Male	89
TX_CURR_TA	Age/Sex: 50+ Male	1,273
TX_CURR_TA	Age/Sex: 20-24 Female	1,066
TX_CURR_TA	Age/Sex: 50+ Female	1,910
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	1,519
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	267
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	2,168
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	635
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	1,773
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	832
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	2,620
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	2,158



	Positive	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	5,239
TX_NEW_DSD	By Age/Sex: <1	34
TX_NEW_DSD	By Age/Sex: 1-9	200
TX_NEW_DSD	By Age/Sex: 10-14 Male	49
TX_NEW_DSD	By Age/Sex: 15-19 Male	104
TX_NEW_DSD	By Age/Sex: 20-24 Male	267
TX_NEW_DSD	By Age/Sex: 50+ Male	197
TX_NEW_DSD	By Age/Sex: 10-14 Female	187
TX_NEW_DSD	By Age/Sex: 15-19 Female	319
TX_NEW_DSD	By Age/Sex: 20-24 Female	595
TX_NEW_DSD	By Age/Sex: 50+ Female	15
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,733
TX_NEW_DSD	Pregnancy status	477
TX_NEW_DSD	Breastfeeding status	477
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	738
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	486
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	319
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	325
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	333
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	437
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	227
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	407
TX_NEW_TA	Number of adults and children newly enrolled on	1,944



	antiretroviral therapy (ART)	
TX_NEW_TA	By Age/Sex: <1	10
TX_NEW_TA	By Age/Sex: 1-9	69
TX_NEW_TA	By Age/Sex: 10-14 Male	15
TX_NEW_TA	By Age/Sex: 15-19 Male	37
TX_NEW_TA	By Age/Sex: 20-24 Male	94
TX_NEW_TA	By Age/Sex: 50+ Male	72
TX_NEW_TA	By Age/Sex: 10-14 Female	63
TX_NEW_TA	By Age/Sex: 15-19 Female	120
TX_NEW_TA	By Age/Sex: 20-24 Female	218
TX_NEW_TA	By Age/Sex: 50+ Female	2
TX_NEW_TA	Sum of Age/Sex disaggregates	621
TX_NEW_TA	Pregnancy status	179
TX_NEW_TA	Breastfeeding status	179
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	294
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	184
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	121
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	121
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	124
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	165
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	81
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	154
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	42,219



TX_PVLS_DSD	Denominator: Indication: Routine	36,728
TX_PVLS_DSD	Denominator: Indication: Targeted	5,491
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	114
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	1,643
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	235
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	3,499
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	846
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	10,976
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,688
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	23,218
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	15,775
TX_PVLS_TA	Denominator: Indication: Routine	13,726
TX_PVLS_TA	Denominator: Indication: Targeted	2,049
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	631
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	84
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	314
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	43
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	8,678
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+	1,310



	Female Targeted	
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	4,103
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	612
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	14,709
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	16,344
TX_RET_DSD	Numerator by Status: Pregnant	1,457
TX_RET_DSD	Numerator by Status: Breastfeeding	1,457
TX_RET_DSD	Denominator by Status: Pregnant	1,621
TX_RET_DSD	Denominator by Status: Breastfeeding	1,621
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	49
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,849
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	87
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7,724
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	55
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the	7,615



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	97
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,577
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	5,224
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	5,805
TX_RET_TA	Numerator by Status: Pregnant	518
TX_RET_TA	Numerator by Status: Breastfeeding	518
TX_RET_TA	Denominator by Status: Pregnant	574
TX_RET_TA	Denominator by Status: Breastfeeding	574
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	14
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,435
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	30
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,745



TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	15
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,702
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	32
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,056
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	345
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	904
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	910
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	2,715
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	45
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	45
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	544
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	1,811



	Female, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	45
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	45
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	307
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	724
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	126
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	362
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	34
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	91
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	9,047
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	452
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted	1,359
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	91
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Unassisted	91
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	7,107
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period	8,361

	and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	501
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	333
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	5,103
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	2,424
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	425
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	284
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	4,337
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	2,061
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	7,271
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	837
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	218
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	35
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	6,178
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	710
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	188
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	31
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	2,654

TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	3,122
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	187
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	126
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	1,902
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	907
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	160
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	106
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	1,619
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	769
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	2,719
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	312
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	80
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	11
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	2,315
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	265
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	66
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	8
TX_TB_DSD	Number of ART patients who were screened for TB at	46,909



	least once during the reporting period	
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	2,814
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	1,876
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	28,615
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	13,604
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	1,876
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	95
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	373
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	1,408
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	40,806
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	1,220
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	4,691
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	192
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	17,530
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	1,053
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	701
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	10,692
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	5,084
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	701
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	34
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of	142



	Specimen Sent]: Smear Only	
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	525
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	15,256
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	455
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	1,753
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	66

Implementing Mechanism Details

Mechanism ID: 9167	Mechanism Name: Provision of Comprehensive Public Health services for the fishing communities in Kalangala District in the Republic of Uganda under the President's Emergency Plan for AIDS Relief
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Kalangala District Health Office	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 9167 Mechanism Name: Provision of Comprehensive Public Health services for the fishing communities in Kalangala District in the Republic of Uganda under the President's Emergency Plan for AIDS Relief Prime Partner Name: Kalangala District Health Office		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details



Mechanism ID: 9183	Mechanism Name: Accelerating Delivery of Comprehensive HIV/AIDS/TB services including Prevention, Care, Support and Treatment of people living with HIV/AIDS in the Republic of Uganda under the President's Emergency Plan for AIDS Relief
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: The AIDS Support Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	9183	
Mechanism Name:	Accelerating Delivery of Comprehensive HIV/AIDS/TB services including Prevention, Care, Support and Treatment of people living with HIV/AIDS in the Republic of Uganda under the President's Emergency Plan for AIDS Relief	
Prime Partner Name:	The AIDS Support Organization	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0



Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 9303	Mechanism Name: DOD Mechanism
Funding Agency: DOD	Procurement Type: Cooperative Agreement
Prime Partner Name: U.S. Department of Defense (Defense)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 70,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 70,000	
Funding Source	Funding Amount



GHP-State	70,000
-----------	--------

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 9303		
Mechanism Name: DOD Mechanism		
Prime Partner Name: U.S. Department of Defense (Defense)		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	70,000
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10326	Mechanism Name: Strengthening Uganda's Systems for Treating AIDS Nationally (SUSTAIN)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	10326	
Mechanism Name:	Strengthening Uganda's Systems for Treating AIDS Nationally (SUSTAIN)	
Prime Partner Name:	University Research Corporation, LLC	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 11479	Mechanism Name: State Department
Funding Agency: State/AF	Procurement Type: USG Core
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 185,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 250,000	
Total All Funding Sources and Applied Pipeline Amount: 435,000	
Funding Source	Funding Amount
GHP-State	185,000



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 11479 Mechanism Name: State Department Prime Partner Name: U.S. Department of State		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	62,500
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	122,500
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Approved



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 11480	Mechanism Name: US Peace Corps
Funding Agency: PC	Procurement Type: USG Core
Prime Partner Name: U.S. Peace Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 162,234	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 162,234	
Funding Source	Funding Amount
GHP-State	162,234

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 11480		
Mechanism Name: US Peace Corps		
Prime Partner Name: U.S. Peace Corps		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	94,880



Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	67,354
Strategic Area	Budget Code	Planned Amount



Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	3,785
PP_PREV_DSD	Age/sex: 15-19 Male	117
PP_PREV_DSD	Age/sex: 20-24 Male	227
PP_PREV_DSD	Age/sex: 50+ Male	172
PP_PREV_DSD	Age/sex: 10-14 Female	112
PP_PREV_DSD	Age/sex: 15-19 Female	659
PP_PREV_DSD	Age/sex: 20-24 Female	455
PP_PREV_DSD	Age/sex: 50+ Female	96
PP_PREV_DSD	Sum of Age/Sex disaggregates	1,838
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	160
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	293
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	159
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	293



PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	173
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	315
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	198
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	356
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	1,600
OVC_SERV_DSD	Age/Sex: 10-14 Male	177
OVC_SERV_DSD	Age/Sex: 15-17 Male	147
OVC_SERV_DSD	By: Age/sex: Male 18-24	143
OVC_SERV_DSD	By: Age/sex: Male 25+	31
OVC_SERV_DSD	Age/Sex: 10-14 Female	199
OVC_SERV_DSD	Age/Sex: 15-17 Female	178
OVC_SERV_DSD	By: Age/sex: 18-24 Female	177
OVC_SERV_DSD	By: Age/sex: 25+ Female	42
OVC_SERV_DSD	Sum of Age/Sex disaggregates	701
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	78
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	21
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	68
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	16
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	46
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	14
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	42
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	12
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	15



	and sex: Social Protection Female 10-14	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	2
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	15
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	9
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	22
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	75
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	8
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	16
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	60
OVC_SERV_DSD	Age/Sex: <1	61
OVC_SERV_DSD	Age/Sex: 1-9	445
OVC_SERV_DSD	Program Completion: Active	1,514
OVC_SERV_DSD	Program Completion: Graduation	86
OVC_SERV_DSD	OVC_SERV_N_DSD_Age_Sex_Service_v4 <1, Unknown Sex, Social Protection	6
OVC_SERV_DSD	OVC_SERV_N_DSD_Age_Sex_Service_v4 1-9, Unknown Sex, Social Protection	37
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	1,207
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	1,600



Implementing Mechanism Details

Mechanism ID: 12981	Mechanism Name: Strengthening capacity through improved management and coordination of laboratory, surveillance, and epidemiology activities, public health evaluations and training in Uganda – Lab Quality Assurance	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Uganda Virus Research Institute		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: Yes	Managing Agency: HHS/CDC	
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	12981	
Mechanism Name:	Strengthening capacity through improved management and coordination of laboratory, surveillance, and epidemiology activities, public health evaluations and training in Uganda – Lab Quality Assurance	
Prime Partner Name:	Uganda Virus Research Institute	
Strategic Area	Budget Code	Planned Amount



Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13002	Mechanism Name: Supporting the Continuity of HIV/AIDS prevention and care programs for refugees in Uganda
Funding Agency: State/PRM	Procurement Type: Cooperative Agreement
Prime Partner Name: United Nations High Commissioner for Refugees	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 647,566	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 647,566	
Funding Source	Funding Amount
GHP-State	647,566

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13002	
Mechanism Name:	Supporting the Continuity of HIV/AIDS prevention and care programs for refugees in Uganda	
Prime Partner Name:	United Nations High Commissioner for Refugees	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	150,000
Strategic Area	Budget Code	Planned Amount
Care	HKID	139,770
Strategic Area	Budget Code	Planned Amount
Care	HVTB	31,000
Strategic Area	Budget Code	Planned Amount
Care	PDCS	9,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	32,796
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	31,000
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	247,000



Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	7,000

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	614
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	11,343
PMTCT_ART_DSD	New on ART	230
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	384
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	11,343
PMTCT_STAT_DSD	Number of new ANC and L&D clients	11,343
PMTCT_STAT_DSD	By Age (Denominator): <15-19	2,154
PMTCT_STAT_DSD	By Age (Denominator): 20-24	3,744
PMTCT_STAT_DSD	By Number of known positives: 15-19	3
PMTCT_STAT_DSD	By Number of known positives: 20-24	13
PMTCT_STAT_DSD	By Number of new positives: 15-19	46
PMTCT_STAT_DSD	By Number of new positives: 20-24	81
PMTCT_STAT_DSD	By Number of new negative: 15-19	2,105
PMTCT_STAT_DSD	By Number of new negative: 20-24	3,650
PMTCT_STAT_DSD	By Age (Numerator): 15-19	2,154
PMTCT_STAT_DSD	By Age (Numerator): 20-24	3,744
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	2,495
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	1,928
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	794



PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	228
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	178
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	2,264
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	53
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	138
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	1,749
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	41
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	58
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	718
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	18
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	17
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	205
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	6
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	2,495
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	1,928
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	794
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	228
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	29,352
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	19



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	17
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	1,520
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	322
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	544
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	271
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	816



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	877
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	378
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	1,392
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	2,157
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	45
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	16
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	23
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	6



HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	26
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	16
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	201
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	44
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	30
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	15
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female,	49



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	54
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	43
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	180
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	10
HTC_TST_DSD	By Key Population: FSW, Negative	117
HTC_TST_DSD	By Key Population: FSW, Positive	58
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	270
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	61
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	2,030
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	46
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	3,530
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	81
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	150
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	123
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	24



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	38
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	96
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	68
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	115
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	54
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	144
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	8
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	3



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	262
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	1,330
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	1,369
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	476
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	878
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	527
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	994
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	31



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	426
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	806
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	2,350
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	51
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	1,017
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	1,057
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	709
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	39
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	70



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	33
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	89
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	61
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	39
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	40
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	42
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	53
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	27
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	3



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	49
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	25
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	7
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	11
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	18
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	26



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	2
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	312
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	312
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	19
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	182
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	17
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	94
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	19
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	182
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	17



TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	94
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	2,357
OVC_SERV_DSD	Age/Sex: 10-14 Male	260
OVC_SERV_DSD	Age/Sex: 15-17 Male	212
OVC_SERV_DSD	By: Age/sex: Male 18-24	212
OVC_SERV_DSD	By: Age/sex: Male 25+	48
OVC_SERV_DSD	Age/Sex: 10-14 Female	283
OVC_SERV_DSD	Age/Sex: 15-17 Female	258
OVC_SERV_DSD	By: Age/sex: 18-24 Female	260
OVC_SERV_DSD	By: Age/sex: 25+ Female	68
OVC_SERV_DSD	Sum of Age/Sex disaggregates	1,013
OVC_SERV_DSD	Age/Sex: <1	96
OVC_SERV_DSD	Age/Sex: 1-9	660
OVC_SERV_DSD	Program Completion: Active	2,241
OVC_SERV_DSD	Program Completion: Graduation	116
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	1,769
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	2,357
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	102
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with	56

	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	34
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	614
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	522
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	92
PMTCT_EID_DSD	Sum of Infant Age disaggregates	614
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	8,149
TX_CURR_DSD	Age/Sex: 15-19 Male	29
TX_CURR_DSD	Age/Sex: 15-19 Female	163
TX_CURR_DSD	Sum of age/sex disaggregates	192
TX_CURR_DSD	Age/Sex: <1	41
TX_CURR_DSD	Age/Sex: <1-9	254
TX_CURR_DSD	Age/Sex: 10-14 Male	89
TX_CURR_DSD	Age/Sex: 10-14 Female	207
TX_CURR_DSD	Age/Sex: 20-24 Male	43
TX_CURR_DSD	Age/Sex: 50+ Male	575
TX_CURR_DSD	Age/Sex: 20-24 Female	481
TX_CURR_DSD	Age/Sex: 50+ Female	863
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	687
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	120



TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	979
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	286
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	802
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	376
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	1,176
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	978
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,259
TX_NEW_DSD	By Age/Sex: <1	14
TX_NEW_DSD	By Age/Sex: 1-9	85
TX_NEW_DSD	By Age/Sex: 10-14 Male	20
TX_NEW_DSD	By Age/Sex: 15-19 Male	26
TX_NEW_DSD	By Age/Sex: 20-24 Male	59
TX_NEW_DSD	By Age/Sex: 50+ Male	44
TX_NEW_DSD	By Age/Sex: 10-14 Female	81
TX_NEW_DSD	By Age/Sex: 15-19 Female	71
TX_NEW_DSD	By Age/Sex: 20-24 Female	133
TX_NEW_DSD	By Age/Sex: 50+ Female	3
TX_NEW_DSD	Sum of Age/Sex disaggregates	437
TX_NEW_DSD	Pregnancy status	106
TX_NEW_DSD	Breastfeeding status	106
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	158
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	109
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	71



TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	72
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	74
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	96
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	52
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	91
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	7,334
TX_PVLS_DSD	Denominator: Indication: Routine	6,380
TX_PVLS_DSD	Denominator: Indication: Targeted	954
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	20
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	285
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	42
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	607
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	148
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	1,908
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	292
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	4,032
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,676
TX_RET_DSD	Total number of adults and children who initiated ART	1,861



	in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	
TX_RET_DSD	Numerator by Status: Pregnant	168
TX_RET_DSD	Numerator by Status: Breastfeeding	168
TX_RET_DSD	Denominator by Status: Pregnant	185
TX_RET_DSD	Denominator by Status: Breastfeeding	185
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	780
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	880
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	867
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total	975



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	14
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	37
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	37
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	111
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	22
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	74
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	13
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	30
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	15
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	1



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	373
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted	56
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Unassisted	4
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	1,234
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	1,452
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	87
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	59
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	885
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	421
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	76
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	50
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	752
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	356
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	1,261



TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	146
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	39
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	6
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	1,072
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	124
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	32
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	6
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	8,149
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	488
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	326
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	4,971
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	2,364
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	326
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	18
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	66
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	242
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	7,090
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	212



TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	815
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	32

Implementing Mechanism Details

Mechanism ID: 13029	Mechanism Name: National Lab Infrastructure Initiative
Funding Agency: State/AF	Procurement Type: Cooperative Agreement
Prime Partner Name: Regional Procurement Support Office/Frankfurt	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 500,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 500,000	
Funding Source	Funding Amount
GHP-State	500,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13029	
Mechanism Name:	National Lab Infrastructure Initiative	
Prime Partner Name:	Regional Procurement Support Office/Frankfurt	
Strategic Area	Budget Code	Planned Amount



Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	500,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13170	Mechanism Name: Surveillance - Epi
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Makerere University School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	



Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13170		
Mechanism Name: Surveillance - Epi		
Prime Partner Name: Makerere University School of Public Health		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0



Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13317	Mechanism Name: Targeted HIV/AIDS and Laboratory Services (THALAS)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Joint Clinical Research Center, Uganda	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13317		
Mechanism Name: Targeted HIV/AIDS and Laboratory Services (THALAS)		
Prime Partner Name: Joint Clinical Research Center, Uganda		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13466	Mechanism Name: Provision of Comprehensive HIV/AIDS Care, Treatment and Prevention services in Track 1.0 Health Facilities in Uganda
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Uganda Protestant Medical Board	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	



Funding Source	Funding Amount
-----------------------	-----------------------

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13466	
Mechanism Name:	Provision of Comprehensive HIV/AIDS Care, Treatment and Prevention services in Track 1.0 Health Facilities in Uganda	
Prime Partner Name:	Uganda Protestant Medical Board	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0



Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13717	Mechanism Name: Provision of Comprehensive CARE, Treatment and Prevention Services in Indigenous Health Facilities - AIDS Care and Treatment
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Registered Trustees for the Uganda Episcopal Conference	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13717	
Mechanism Name:	Provision of Comprehensive CARE, Treatment and Prevention Services in Indigenous Health Facilities - AIDS Care and Treatment	
Prime Partner Name:	Registered Trustees for the Uganda Episcopal Conference	
Strategic Area	Budget Code	Planned Amount



Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13835	Mechanism Name: Strengthening National Pediatric HIV/AIDS and Scaling up Comprehensive HIV/AIDS Services in the Republic of Uganda under The President's Emergency Plan For AIDS Relief
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Baylor College of Medicine Children's Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13835	
Mechanism Name:	Strengthening National Pediatric HIV/AIDS and Scaling up Comprehensive HIV/AIDS Services in the Republic of Uganda	
Prime Partner Name:	under The President's Emergency Plan For AIDS Relief Baylor College of Medicine Children's Foundation	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13837	Mechanism Name: Monitoring, Evaluation and Learning Program	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: QED Group, LLC		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13837



Mechanism Name: Monitoring, Evaluation and Learning Program		
Prime Partner Name: QED Group, LLC		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13841	Mechanism Name: CDC-WHO collaboration
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: World Health Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13841		
Mechanism Name: CDC-WHO collaboration		
Prime Partner Name: World Health Organization		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount

Approved



Treatment	PDTX	0
-----------	------	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13864	Mechanism Name: Ministry of Health, Uganda
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health, Uganda	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13864		
Mechanism Name: Ministry of Health, Uganda		
Prime Partner Name: Ministry of Health, Uganda		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0



Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13874	Mechanism Name: Advocacy for Better Health
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Program for Appropriate Technology in Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 441,449	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 441,449	
Funding Source	Funding Amount



GHP-State	441,449
-----------	---------

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	60,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Capacity building
Sub Area:	Implementation
Sub Area:	Collection and Use of Gender-related Strategic Information
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Human Resources for Health	156,000



Budget Code Information

Mechanism ID: 13874		
Mechanism Name: Advocacy for Better Health		
Prime Partner Name: Program for Appropriate Technology in Health		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	237,449
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	104,000
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	100,000
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13877	Mechanism Name: New Hope Project – Provision of Comprehensive HIV/AIDS Care, Treatment and Prevention services in Track 1.0 Health Facilities in Uganda
----------------------------	--



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Children's AIDS Fund	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13877	
Mechanism Name:	New Hope Project – Provision of Comprehensive HIV/AIDS Care, Treatment and Prevention services in Track 1.0 Health	
Prime Partner Name:	Facilities in Uganda Children's AIDS Fund	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0



Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount



Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13880	Mechanism Name: Provision of Comprehensive HIV/AIDS Services and Health Work Force Development for Managing Health Programs in the Republic of Uganda under the President's Plan for AIDS Relief	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Makerere University School of Public Health		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: Yes	Managing Agency: HHS/CDC	
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13880 Mechanism Name: Provision of Comprehensive HIV/AIDS Services and Health Prime Partner Name: Work Force Development for Managing Health Programs in the Republic of Uganda under the President's Plan for AIDS Relief Makerere University School of Public Health		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13892	Mechanism Name: School Health and Reading Program (SHRP)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Research Triangle International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,000,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,000,000	
Funding Source	Funding Amount
GHP-State	1,000,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	187,520
Focus Area:	Post GBV Care
Sub Area:	Monitoring and Evaluation
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation



Sub Area:	Capacity building
Gender: Gender Equality	187,520
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Education	249,920
Human Resources for Health	375,040

Budget Code Information

Mechanism ID: 13892		
Mechanism Name: School Health and Reading Program (SHRP)		
Prime Partner Name: Research Triangle International		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	1,000,000
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	148,664
PP_PREV_DSD	Age/sex: 15-19 Male	661
PP_PREV_DSD	Age/sex: 20-24 Male	1,382
PP_PREV_DSD	Age/sex: 50+ Male	850
PP_PREV_DSD	Age/sex: 10-14 Female	28,822
PP_PREV_DSD	Age/sex: 15-19 Female	62,473
PP_PREV_DSD	Age/sex: 20-24 Female	38,242
PP_PREV_DSD	Age/sex: 50+ Female	462
PP_PREV_DSD	Sum of Age/Sex disaggregates	132,892
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	1,499
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	2,673
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	1,484
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	2,645
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	1,169
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	2,087
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	1,513
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	2,702

Implementing Mechanism Details

Mechanism ID: 13901	Mechanism Name: Communication for Healthy Communities (CHC)
Funding Agency: USAID	Procurement Type: Cooperative Agreement



Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,591,714	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,591,714	
Funding Source	Funding Amount
GHP-State	1,591,714

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	50,000
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	100,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach



	workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Gender: GBV	180,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	30,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic



	Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Condom programming	190,000
Adolescent Girls and Young Women (AGYW)	600,000

Budget Code Information

Mechanism ID:	13901	
Mechanism Name:	Communication for Healthy Communities (CHC)	
Prime Partner Name:	FHI 360	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	60,000
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	40,000
Strategic Area	Budget Code	Planned Amount
Care	PDCS	60,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	175,857
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	400,000
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	615,857



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	40,000
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	140,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	60,000

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16594	Mechanism Name: MEASURE Evaluation Phase IV
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University of North Carolina at Chapel Hill, Carolina Population Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 720,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 181,441	
Total All Funding Sources and Applied Pipeline Amount: 901,441	
Funding Source	Funding Amount



GHP-State	720,000
-----------	---------

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	16594	
Mechanism Name:	MEASURE Evaluation Phase IV	
Prime Partner Name:	University of North Carolina at Chapel Hill, Carolina Population Center	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	150,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0



Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	120,000
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	300,000
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	150,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16626	Mechanism Name: Uganda Private Health Support Program (PHS)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Cardno Emerging Markets	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 16626		
Mechanism Name: Uganda Private Health Support Program (PHS)		
Prime Partner Name: Cardno Emerging Markets		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17063	Mechanism Name: Social Marketing Program
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Uganda Health Marketing Group	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,000,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,000,000	
Funding Source	Funding Amount
GHP-State	1,000,000



Cross-Cutting Budget Attribution(s)

Gender: GBV	50,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Sub Area:	Capacity building
Sub Area:	Collection and Use of Gender-related Strategic Information
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Condom procurement	950,000

Budget Code Information

Mechanism ID: 17063		
Mechanism Name: Social Marketing Program		
Prime Partner Name: Uganda Health Marketing Group		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount



Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	1,000,000
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17065	Mechanism Name: Sustainable Outcomes for Children and Youth Central and Western Uganda (SOCY)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 7,941,947	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 951	
Total All Funding Sources and Applied Pipeline Amount: 7,942,898	
Funding Source	Funding Amount
GHP-State	7,941,947

Cross-Cutting Budget Attribution(s)

Gender: GBV	433,751
-------------	---------



Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	550,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building



Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Food and Nutrition: Policy, Tools, and Service Delivery	1,756,817
Water	94,091
Economic Strengthening	1,500,000
Adolescent Girls and Young Women (AGYW)	481,057
Education	1,015,000

Budget Code Information

Mechanism ID:	17065	
Mechanism Name:	Sustainable Outcomes for Children and Youth Central and Western Uganda (SOCY)	
Prime Partner Name:	Catholic Relief Services	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	7,941,947
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount



Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	129,601
OVC_SERV_DSD	Age/Sex: 10-14 Male	14,257
OVC_SERV_DSD	Age/Sex: 15-17 Male	11,658
OVC_SERV_DSD	By: Age/sex: Male 18-24	11,661
OVC_SERV_DSD	By: Age/sex: Male 25+	2,591
OVC_SERV_DSD	Age/Sex: 10-14 Female	15,550
OVC_SERV_DSD	Age/Sex: 15-17 Female	14,258
OVC_SERV_DSD	By: Age/sex: 18-24 Female	14,265
OVC_SERV_DSD	By: Age/sex: 25+ Female	3,887
OVC_SERV_DSD	Sum of Age/Sex disaggregates	55,723
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	5,831
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	1,459
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	5,072
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	1,269



	and sex: Education Support Male 15-17	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	3,500
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	882
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	3,048
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	758
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	1,143
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	174
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	1,046
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	144
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	793
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	1,585
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	5,547
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	635
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	1,269
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	4,439
OVC_SERV_DSD	Age/Sex: <1	5,182
OVC_SERV_DSD	Age/Sex: 1-9	36,292
OVC_SERV_DSD	Program Completion: Active	123,120
OVC_SERV_DSD	Program Completion: Graduation	6,481
OVC_SERV_DSD	OVC_SERV_N_DSD_Age_Sex_Service_v4 <1,	379



	Unknown Sex, Social Protection	
OVC_SERV_DSD	OVC_SERV_N_DSD_Age_Sex_Service_v4 1-9, Unknown Sex, Social Protection	2,664
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	97,197
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	129,601

Implementing Mechanism Details

Mechanism ID: 17066	Mechanism Name: HIV/Health Initiatives in Workplaces Activity (HIWA)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: World Vision	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 279,189	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 710,034	
Total All Funding Sources and Applied Pipeline Amount: 989,223	
Funding Source	Funding Amount
GHP-State	279,189

Cross-Cutting Budget Attribution(s)

Key Populations: FSW	50,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers



Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Gender: GBV	50,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	50,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information



Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Condom procurement	30,000
Water	25,000

Budget Code Information

Mechanism ID: 17066		
Mechanism Name: HIV/Health Initiatives in Workplaces Activity (HIWA)		
Prime Partner Name: World Vision		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	24,577
Strategic Area	Budget Code	Planned Amount
Care	HKID	0



Strategic Area	Budget Code	Planned Amount
Care	HVTB	9,342
Strategic Area	Budget Code	Planned Amount
Care	PDCS	19,420
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	74,943
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	30,795
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	22,383
Strategic Area	Budget Code	Planned Amount



Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	38,590
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	53,612
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	5,527

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	322
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	4,096
PMTCT_ART_DSD	New on ART	97
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	225
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	4,096
PMTCT_STAT_DSD	Number of new ANC and L&D clients	4,096
PMTCT_STAT_DSD	By Age (Denominator): <15-19	778
PMTCT_STAT_DSD	By Age (Denominator): 20-24	1,351
PMTCT_STAT_DSD	By Number of known positives: 20-24	6
PMTCT_STAT_DSD	By Number of new positives: 15-19	21



PMTCT_STAT_DSD	By Number of new positives: 20-24	34
PMTCT_STAT_DSD	By Number of new negative: 15-19	757
PMTCT_STAT_DSD	By Number of new negative: 20-24	1,311
PMTCT_STAT_DSD	By Age (Numerator): 15-19	778
PMTCT_STAT_DSD	By Age (Numerator): 20-24	1,351
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	901
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	697
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	288
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	81
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	103
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	772
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	26
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	81
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	599
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	17
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	34
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	248
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	6
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	9
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	71
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	1



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	901
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	697
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	288
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	81
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	18
PMTCT_STAT_TA	Number of new ANC and L&D clients	18
PMTCT_STAT_TA	By Age (Denominator): 15-19	3
PMTCT_STAT_TA	By Age (Denominator): 20-24	7
PMTCT_STAT_TA	By new negatives: 15-19	3
PMTCT_STAT_TA	By new negatives: 20-24	7
PMTCT_STAT_TA	By Age (Numerator): : 15-19	3
PMTCT_STAT_TA	By Age (Numerator): 20-24	7
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 25-29, Female	4
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 30-34, Female	3
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 35-39, Female	1
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	4
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	3
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	1
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 25-29, Female	4
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 30-34, Female	3
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 35-39, Female	1
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	13,550
VMMC_CIRC_DSD	By Age: 10-14	677
VMMC_CIRC_DSD	By Age: 15-19	3,388
VMMC_CIRC_DSD	By Age: 20-24	3,388
VMMC_CIRC_DSD	By Age: 25-29	4,065



VMMC_CIRC_DSD	By Age: 50+	406
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	7,859
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	11,924
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	13,550
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	542
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	542
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	542
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	17,119
PP_PREV_DSD	Age/sex: 15-19 Male	366
PP_PREV_DSD	Age/sex: 20-24 Male	943
PP_PREV_DSD	Age/sex: 50+ Male	905
PP_PREV_DSD	Age/sex: 10-14 Female	377
PP_PREV_DSD	Age/sex: 15-19 Female	2,139
PP_PREV_DSD	Age/sex: 20-24 Female	1,781
PP_PREV_DSD	Age/sex: 50+ Female	490
PP_PREV_DSD	Sum of Age/Sex disaggregates	7,001
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	831
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	1,485
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	812
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	1,481
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	923
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	1,644
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	1,055
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	1,887
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	14,315
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	1



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	52
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	11
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	79
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	41
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	121
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	129
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	55
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	48
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	73
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female,	5



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	420
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	2,101
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	2,101
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	252



HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	5
HTC_TST_DSD	By Key Population: FSW, Negative	194
HTC_TST_DSD	By Key Population: FSW, Positive	94
HTC_TST_DSD	By Key Population: MSM, Negative	16
HTC_TST_DSD	By Key Population: MSM, Positive	4
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	442
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	83
HTC_TST_DSD	By Key Population: PWID, Negative	18
HTC_TST_DSD	By Key Population: PWID, Positive	3
HTC_TST_DSD	By Key Population: TG, Negative	2
HTC_TST_DSD	By Key Population: TG, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	716
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	1,242
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	23



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	20
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	15
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	8
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	17
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	22
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	1

HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	9
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	194
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	202
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	70
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	129
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	77
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	146
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	63



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	119
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	828
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	359
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	372
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	249
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	9
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	7



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	1



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	9
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	2,523
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	336
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	336
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	336
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	5,203
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19,	1



	Female, Negative	
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	9
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	4
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	5
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Negative	8
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	12
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 10-14, Negative	254
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 10-14, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Negative	1,269
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Negative	1,269
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Negative	153
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	1



HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	1
HTC_TST_TA	By Key Population: People in prisons and other enclosed settings, Negative	4
HTC_TST_TA	By Key Population: People in prisons and other enclosed settings, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	2
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Negative	1
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Negative	1
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Negative	1
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Negative	1
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Negative	1
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Negative	1
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Negative	1
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Negative	1
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Negative	8
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Negative	8
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Negative	2
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Negative	5
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Negative	3
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Negative	6

	Male, Negative	
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Negative	2
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Negative	4
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Negative	1
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Negative	1
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Negative	1
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 25-29, Male, Negative	1,523
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 25-29, Male, Positive	6
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 30-34, Male, Negative	203
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 35-39, Male, Negative	203
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 40-49, Male, Negative	203
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 40-49, Male, Positive	1
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	151
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	151
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	6



TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	94
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	6
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	45
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	6
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	94
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	6
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	45
GEND_GBV_DSD	Number of people receiving post-GBV care	2,081
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1,422
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	659
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	199
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	18
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	14
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	8
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	49
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	41
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	18



GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	444
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	378
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	45
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	14
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	210
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	115
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	108
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	47
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	54
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	4
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	36
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	77
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	9
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	53
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	3
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	77
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	9
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	53
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	3
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	77
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	9

GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	53
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	3
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	26
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	18
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	1
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	67
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	39
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	22
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	322
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	269



PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	53
PMTCT_EID_DSD	Sum of Infant Age disaggregates	322
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,890
TX_CURR_DSD	Age/Sex: 15-19 Male	9
TX_CURR_DSD	Age/Sex: 15-19 Female	16
TX_CURR_DSD	Sum of age/sex disaggregates	25
TX_CURR_DSD	Age/Sex: <1	9
TX_CURR_DSD	Age/Sex: <1-9	57
TX_CURR_DSD	Age/Sex: 10-14 Male	19
TX_CURR_DSD	Age/Sex: 10-14 Female	49
TX_CURR_DSD	Age/Sex: 20-24 Male	10
TX_CURR_DSD	Age/Sex: 50+ Male	124
TX_CURR_DSD	Age/Sex: 20-24 Female	88
TX_CURR_DSD	Age/Sex: 50+ Female	53
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	105
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	70
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	140
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	140
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	140
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	176
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	175
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	510
TX_CURR_TA	Number of adults and children receiving antiretroviral	89



	therapy (ART)	
TX_CURR_TA	Age/Sex: 1-9	2
TX_CURR_TA	Age/Sex: 10-14 Female	2
TX_CURR_TA	Age/Sex: 50+ Male	6
TX_CURR_TA	Age/Sex: 20-24 Female	4
TX_CURR_TA	Age/Sex: 50+ Female	2
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	5
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	3
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	7
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	7
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	7
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	8
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	11
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	25
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	179
TX_NEW_DSD	By Age/Sex: 1-9	2
TX_NEW_DSD	By Age/Sex: 15-19 Male	2
TX_NEW_DSD	By Age/Sex: 20-24 Male	7
TX_NEW_DSD	By Age/Sex: 50+ Male	7
TX_NEW_DSD	By Age/Sex: 10-14 Female	2
TX_NEW_DSD	By Age/Sex: 15-19 Female	10
TX_NEW_DSD	By Age/Sex: 20-24 Female	23
TX_NEW_DSD	Sum of Age/Sex disaggregates	51
TX_NEW_DSD	Pregnancy status	18



TX_NEW_DSD	Breastfeeding status	18
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	38
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	18
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	10
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	11
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	11
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	17
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	7
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	14
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	8
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	8
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,698
TX_PVLS_DSD	Denominator: Indication: Routine	1,476
TX_PVLS_DSD	Denominator: Indication: Targeted	222
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	3
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	67
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	10
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	142



TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	33
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	441
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	68
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	934
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	80
TX_PVLS_TA	Denominator: Indication: Routine	70
TX_PVLS_TA	Denominator: Indication: Targeted	10
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	3
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	2
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	44
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	7
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	21
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	3
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	381
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	424
TX_RET_DSD	Numerator by Status: Pregnant	37
TX_RET_DSD	Numerator by Status: Breastfeeding	37
TX_RET_DSD	Denominator by Status: Pregnant	42



TX_RET_DSD	Denominator by Status: Breastfeeding	42
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	173
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	196
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	192
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	218
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	17



TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	19
TX_RET_TA	Numerator by Status: Pregnant	2
TX_RET_TA	Numerator by Status: Breastfeeding	2
TX_RET_TA	Denominator by Status: Pregnant	2
TX_RET_TA	Denominator by Status: Breastfeeding	2
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	11
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	57
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	1



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	11
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	38
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	15
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	3
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	191
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted	29
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Unassisted	2
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of	284



	Isoniazid Preventive Therapy (IPT) during the reporting period	
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	336
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	21
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	13
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	203
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	99
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	18
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	11
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	171
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	84
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	293
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	33
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	9
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	1
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	249
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	29
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	6
TB_PREV_TA	The number of ART patients who completed a course	14



	of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	16
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	12
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	4
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	10
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	4
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	14
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	2
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	12
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	2
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	1,890
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	114
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	77
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	1,152
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	547
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	77
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of	3



	Specimen Sent]: Other (No Xpert)	
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	16
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	58
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	1,646
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	49
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	189
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	6
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	89
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	5
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	4
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	55
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	25
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	4
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	4
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	78
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	2
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	9

Implementing Mechanism Details

Mechanism ID: 17078	Mechanism Name: Applying Science to Strengthen and Improve Systems (ASSIST)
----------------------------	--



Project	
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Council	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17078	
Mechanism Name:	Applying Science to Strengthen and Improve Systems (ASSIST)	
Prime Partner Name:	Project University Research Council	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0



Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount



Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17094	Mechanism Name: Uganda Health Supply Chain
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,255,966	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 770,145	
Total All Funding Sources and Applied Pipeline Amount: 2,026,111	
Funding Source	Funding Amount
GHP-State	1,255,966

Cross-Cutting Budget Attribution(s)

Human Resources for Health	382,961
----------------------------	---------



Budget Code Information

Mechanism ID: 17094		
Mechanism Name: Uganda Health Supply Chain		
Prime Partner Name: Management Sciences for Health		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	35,411
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	23,607
Strategic Area	Budget Code	Planned Amount
Care	PDCS	35,411
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	53,003
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	955,497
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	35,000
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	82,626
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	35,411

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17649	Mechanism Name: Regional Health Integration to Enhance Services in East Central Region
----------------------------	---



	(RHITES EC)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 9,863,633	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 9,863,633	
Funding Source	Funding Amount
GHP-State	9,863,633

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	118,165
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Key Populations: FSW	177,246
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on



	sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Gender: GBV	252,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	212,509
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that



	increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Capacity building
Sub Area:	Implementation
Sub Area:	Collection and Use of Gender-related Strategic Information
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Monitoring and Evaluation
Sub Area:	Capacity building
Sub Area:	Implementation
Sub Area:	Collection and Use of Gender-related Strategic Information
Food and Nutrition: Policy, Tools, and Service Delivery	354,499
Condom programming	472,665
Water	117,000

Budget Code Information

Mechanism ID: Mechanism Name: Prime Partner Name:	17649 Regional Health Integration to Enhance Services in East Central Region (RHITES EC) University Research Corporation, LLC	
Strategic Area	Budget Code	Planned Amount



Care	HBHC	1,625,742
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	429,656
Strategic Area	Budget Code	Planned Amount
Care	PDCS	595,065
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	150,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	1,323,050
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	759,356



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	480,325
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	612,799
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	3,686,533
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	201,107

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	4,235
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	118,638
PMTCT_ART_DSD	New on ART	1,530
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,705
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	1,127



PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	25,849
PMTCT_ART_TA	New on ART	407
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	720
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	118,638
PMTCT_STAT_DSD	Number of new ANC and L&D clients	118,638
PMTCT_STAT_DSD	By Age (Denominator): <15-19	22,544
PMTCT_STAT_DSD	By Age (Denominator): 20-24	39,144
PMTCT_STAT_DSD	By Number of known positives: 15-19	16
PMTCT_STAT_DSD	By Number of known positives: 20-24	89
PMTCT_STAT_DSD	By Number of new positives: 15-19	312
PMTCT_STAT_DSD	By Number of new positives: 20-24	543
PMTCT_STAT_DSD	By Number of new negative: 15-19	22,216
PMTCT_STAT_DSD	By Number of new negative: 20-24	38,512
PMTCT_STAT_DSD	By Age (Numerator): 15-19	22,544
PMTCT_STAT_DSD	By Age (Numerator): 20-24	39,144
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	26,103
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	20,169
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	8,305
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	2,373
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	1,243
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	24,497
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	363
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	963
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	18,925



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	281
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	399
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	7,786
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	120
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	120
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	2,215
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	38
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	26,103
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	20,169
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	8,305
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	2,373
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	25,849
PMTCT_STAT_TA	Number of new ANC and L&D clients	25,849
PMTCT_STAT_TA	By Age (Denominator): 15-19	4,909
PMTCT_STAT_TA	By Age (Denominator): 20-24	8,535
PMTCT_STAT_TA	By known positives: 15-19	1
PMTCT_STAT_TA	By known positives: 20-24	16
PMTCT_STAT_TA	By new positives: 15-19	81
PMTCT_STAT_TA	By new positives: 20-24	140
PMTCT_STAT_TA	By new negatives: 15-19	4,827
PMTCT_STAT_TA	By new negatives: 20-24	8,379
PMTCT_STAT_TA	By Age (Numerator): : 15-19	4,909
PMTCT_STAT_TA	By Age (Numerator): 20-24	8,535
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 25-29, Female	5,686



PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 30-34, Female	4,394
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 35-39, Female	1,809
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 40-49, Female	516
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	335
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	5,259
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	92
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	257
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	4,065
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	72
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	106
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	1,676
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	27
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	29
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	485
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	2
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 25-29, Female	5,686
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 30-34, Female	4,394
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 35-39, Female	1,809
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 40-49, Female	516
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	56,299



VMMC_CIRC_DSD	By Age: 10-14	2,816
VMMC_CIRC_DSD	By Age: 15-19	14,079
VMMC_CIRC_DSD	By Age: 20-24	14,079
VMMC_CIRC_DSD	By Age: 25-29	16,893
VMMC_CIRC_DSD	By Age: 50+	1,676
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	32,650
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	49,543
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	56,299
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	2,252
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	2,252
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	2,252
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	51,551
PP_PREV_DSD	Age/sex: 15-19 Male	1,023
PP_PREV_DSD	Age/sex: 20-24 Male	2,068
PP_PREV_DSD	Age/sex: 50+ Male	825
PP_PREV_DSD	Age/sex: 10-14 Female	4,006
PP_PREV_DSD	Age/sex: 15-19 Female	11,991
PP_PREV_DSD	Age/sex: 20-24 Female	7,912
PP_PREV_DSD	Age/sex: 50+ Female	452
PP_PREV_DSD	Sum of Age/Sex disaggregates	28,277
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	2,368
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	4,216
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	2,360
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	4,241
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	1,501
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	2,684
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	2,123
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	3,781
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions	7,279

	that are based on evidence and/or meet the minimum standards required	
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	401
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	33
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,935
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,910
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	259,965
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	6,522
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	203
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	1,387
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	517



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	169
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	962
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	50
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	430
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	325
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	5,961
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	196
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	539
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	270
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	361



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	1,000
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	41
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	6
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	1,132
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	48
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	8,776
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	171
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	1,852
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	45
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	1,976
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	64
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	987
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	2,971
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	95
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	3,190



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	104
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	39
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	1,369
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	44
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	8,036
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	171
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	12,447
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	257
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	42
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	22
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	144
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	56
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	222
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	85
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	246
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	99



HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	102
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	44
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	63
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	144
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	56
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	102
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	44
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	2,484
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	12,417
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	12,417
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	1,490
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	1,135
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	65
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	242
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	108



HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	56
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	183
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	199
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	157
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	29
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	1,040
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	59
HTC_TST_DSD	By Key Population: FSW, Negative	1,409
HTC_TST_DSD	By Key Population: FSW, Positive	678
HTC_TST_DSD	By Key Population: MSM, Negative	105
HTC_TST_DSD	By Key Population: MSM, Positive	48
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	4,239
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	853
HTC_TST_DSD	By Key Population: TG, Negative	37
HTC_TST_DSD	By Key Population: TG, Positive	7
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	1,618



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	85
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	345
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	22
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	128
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	64
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	85
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	237
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	41
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	266
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	48
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	1,482
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	78
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	14,732
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	211
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	25,595
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	365



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	549
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	102
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	452
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	82
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	133
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	347
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	64
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	248
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	413
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	76
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	195
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	37
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	522
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	95
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	1,195



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	64
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	790
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	518
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	526
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	539
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	706
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	364
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	658
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	35
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	2,790
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	116



HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	2,287
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	95
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	665
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	1,766
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	73
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	1,252
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	52
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	2,098
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	88
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	1,151
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	48
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	2,649
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	111
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	1,524
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	68
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	657

HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	116
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	539
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	95
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	156
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	418
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	73
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	296
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	52
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	495
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	88
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	272
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	48
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	623
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	111
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	4,837
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	152



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	4,986
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	158
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	1,729
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	57
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	3,192
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	104
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	1,911
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	3,617
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	115
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	1,554
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	52
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	2,925
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	94
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	17,038
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	243
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	7,372



HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	185
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	7,656
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	83
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	5,158
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	141
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	47
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	257
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	117
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	329
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	214
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	21



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	141
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	146
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	149
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	194
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	103
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	183
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	88
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	102
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	44



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	63
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	123
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	49
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	82
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	156
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	63
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	246
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	99
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	102
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	44
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	102
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	44
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	14,895
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	1,986



HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	1,986
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	1,986
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	6
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	113,576
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	364
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	12
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	78
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	118
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	38
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	220
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	12
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male,	98



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	73
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	332
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Positive	12
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	3,745
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	72
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	792
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	10
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	1,183
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	33
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	590
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	16
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	1,776
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	52
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	1,904
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	53



	Male, Positive	
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	18
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	820
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	23
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Negative	3,429
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Positive	72
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	5,309
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	104
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Negative	17
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Positive	11
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Negative	9
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Positive	9
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	68
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Positive	42
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	104
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Positive	63
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	117
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	71
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male,	47



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	28
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	28
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	16
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	68
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	42
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Negative	47
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Positive	28
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 10-14, Negative	324
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Negative	1,623
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Negative	1,623
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Negative	194
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	482
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Positive	20
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Negative	103
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	62
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male,	29



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	101
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	16
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	115
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	18
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	87
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	14
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	441
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Positive	19
HTC_TST_TA	By Key Population: FSW, Negative	1,427
HTC_TST_TA	By Key Population: FSW, Positive	651
HTC_TST_TA	By Key Population: MSM, Negative	190
HTC_TST_TA	By Key Population: MSM, Positive	83
HTC_TST_TA	By Key Population: People in prisons and other enclosed settings, Negative	3,298
HTC_TST_TA	By Key Population: People in prisons and other enclosed settings, Positive	633
HTC_TST_TA	By Key Population: TG, Negative	70
HTC_TST_TA	By Key Population: TG, Positive	12
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	11,647
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	182
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	20,229
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	318
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Negative	320



HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Positive	52
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative	266
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Positive	46
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Negative	76
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Positive	11
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Negative	207
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Positive	33
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Negative	146
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Positive	24
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative	245
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Positive	40
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Negative	110
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Positive	17
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Negative	310
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Positive	52
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Negative	277
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Positive	15



HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Negative	182
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Positive	9
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Negative	118
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Positive	7
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Negative	121
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Positive	7
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Negative	123
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Positive	7
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Negative	165
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Positive	8
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Negative	83
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Positive	6
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Negative	152
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Positive	7
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Negative	651
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Positive	23
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Negative	2,891



HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Positive	86
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Negative	2,972
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Positive	88
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Negative	1,036
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Positive	29
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Negative	1,906
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Positive	53
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Negative	1,142
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Positive	32
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Negative	2,156
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Positive	65
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Negative	924
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Positive	26
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Negative	1,751
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Positive	51
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Negative	13,465
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Positive	203



HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Negative	5,828
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Positive	164
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Negative	6,049
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Positive	67
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Negative	4,077
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Positive	18
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Negative	79
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Positive	4
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Negative	25
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Negative	155
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Positive	8
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Negative	66
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Negative	192
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Positive	12
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Negative	124
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Positive	6



HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Negative	79
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Positive	4
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Negative	80
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Positive	4
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Negative	82
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Positive	4
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Negative	110
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Positive	6
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Negative	52
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Negative	101
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Positive	6
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Negative	48
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Negative	47
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Positive	28
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	28



HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Positive	16
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Negative	59
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Positive	37
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	38
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Positive	24
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Negative	73
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Positive	44
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	117
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Positive	71
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Negative	47
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Positive	28
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative	47
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Positive	28
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 25-29, Male, Negative	1,946
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 25-29, Male, Positive	5
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 30-34, Male, Negative	261
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 35-39, Male, Negative	261



HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 40-49, Male, Negative	261
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	51
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	139
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	142
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	419
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	7
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	7
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	85
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	279
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	7
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	7
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	48
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	111
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	19
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	56
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	6
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	13



HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Sex Partner	1,400
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest FSW, Directly-Assisted	71
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest FSW, Unassisted	210
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest MSM, Directly-Assisted	13
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest MSM, Unassisted	13
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	3,809
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	3,809
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	208
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,282
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	192
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,127
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	208
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,282
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	192



TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,127
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,049
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	1,049
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	52
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	56
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	314
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	627
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	56
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	627
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	52
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	314
GEND_GBV_DSD	Number of people receiving post-GBV care	10,198
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	6,867
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	3,331



GEND_GBVDSD	By PEP service provision (related to sexual violence services provided)	1,000
GEND_GBVDSD	<10, Female, Physical and/or Emotional Violence	90
GEND_GBVDSD	<10, Female, Sexual Violence (Post-Rape Care)	67
GEND_GBVDSD	<10, Male, Physical and/or Emotional Violence	51
GEND_GBVDSD	<10, Male, Sexual Violence (Post-Rape Care)	6
GEND_GBVDSD	10-14, Female, Physical and/or Emotional Violence	240
GEND_GBVDSD	10-14, Female, Sexual Violence (Post-Rape Care)	209
GEND_GBVDSD	10-14, Male, Physical and/or Emotional Violence	86
GEND_GBVDSD	10-14, Male, Sexual Violence (Post-Rape Care)	14
GEND_GBVDSD	15-19, Female, Physical and/or Emotional Violence	2,096
GEND_GBVDSD	15-19, Female, Sexual Violence (Post-Rape Care)	1,912
GEND_GBVDSD	15-19, Male, Physical and/or Emotional Violence	214
GEND_GBVDSD	15-19, Male, Sexual Violence (Post-Rape Care)	71
GEND_GBVDSD	20-24, Female, Physical and/or Emotional Violence	1,024
GEND_GBVDSD	20-24, Female, Sexual Violence (Post-Rape Care)	581
GEND_GBVDSD	20-24, Male, Physical and/or Emotional Violence	509
GEND_GBVDSD	20-24, Male, Sexual Violence (Post-Rape Care)	245
GEND_GBVDSD	50+, Female, Physical and/or Emotional Violence	267
GEND_GBVDSD	50+, Female, Sexual Violence (Post-Rape Care)	22
GEND_GBVDSD	50+, Male, Physical and/or Emotional Violence	164
GEND_GBVDSD	50+, Male, Sexual Violence (Post-Rape Care)	14
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	378
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	42
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	260
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	15
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	378
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3	42

	30-34, Female, Sexual Violence (Post-Rape Care)	
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	260
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	15
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	378
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	42
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	260
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	15
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	126
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	14
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	86
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	5
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,329
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	69
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	745
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with	75

	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	440
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	496
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	23
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	284
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	26
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	163
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	4,235
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	3,590
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	645
PMTCT_EID_DSD	Sum of Infant Age disaggregates	4,235
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,127
PMTCT_EID_TA	By infants who received a virologic test within 2 months	930



	of birth	
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	197
PMTCT_EID_TA	Sum of Infant Age disaggregates	1,127
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	83,175
TX_CURR_DSD	Age/Sex: 15-19 Male	278
TX_CURR_DSD	Age/Sex: 15-19 Female	1,642
TX_CURR_DSD	Sum of age/sex disaggregates	1,920
TX_CURR_DSD	Age/Sex: <1	468
TX_CURR_DSD	Age/Sex: <1-9	2,869
TX_CURR_DSD	Age/Sex: 10-14 Male	1,000
TX_CURR_DSD	Age/Sex: 10-14 Female	2,337
TX_CURR_DSD	Age/Sex: 20-24 Male	423
TX_CURR_DSD	Age/Sex: 50+ Male	5,824
TX_CURR_DSD	Age/Sex: 20-24 Female	4,864
TX_CURR_DSD	Age/Sex: 50+ Female	8,737
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	6,940
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,225
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	9,920
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	2,912
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	8,109
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	3,803
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	11,940
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	9,884



TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	13,105
TX_CURR_TA	Age/Sex: 15-19 Male	45
TX_CURR_TA	Age/Sex: 15-19 Female	267
TX_CURR_TA	Sum of Age/Sex disaggregations	312
TX_CURR_TA	Age/Sex: <1	47
TX_CURR_TA	Age/Sex: 1-9	292
TX_CURR_TA	Age/Sex: 10-14 Male	103
TX_CURR_TA	Age/Sex: 10-14 Female	236
TX_CURR_TA	Age/Sex: 20-24 Male	69
TX_CURR_TA	Age/Sex: 50+ Male	946
TX_CURR_TA	Age/Sex: 20-24 Female	792
TX_CURR_TA	Age/Sex: 50+ Female	1,421
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	1,128
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	198
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	1,613
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	472
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	1,317
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	616
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	1,937
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	1,606
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	8,536
TX_NEW_DSD	By Age/Sex: <1	113
TX_NEW_DSD	By Age/Sex: 1-9	666



TX_NEW_DSD	By Age/Sex: 10-14 Male	153
TX_NEW_DSD	By Age/Sex: 15-19 Male	153
TX_NEW_DSD	By Age/Sex: 20-24 Male	386
TX_NEW_DSD	By Age/Sex: 50+ Male	289
TX_NEW_DSD	By Age/Sex: 10-14 Female	617
TX_NEW_DSD	By Age/Sex: 15-19 Female	467
TX_NEW_DSD	By Age/Sex: 20-24 Female	866
TX_NEW_DSD	By Age/Sex: 50+ Female	18
TX_NEW_DSD	Sum of Age/Sex disaggregates	2,949
TX_NEW_DSD	Pregnancy status	699
TX_NEW_DSD	Breastfeeding status	699
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	1,089
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	716
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	469
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	474
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	489
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	642
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	331
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	598
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,082
TX_NEW_TA	By Age/Sex: <1	3
TX_NEW_TA	By Age/Sex: 1-9	36
TX_NEW_TA	By Age/Sex: 10-14 Male	7
TX_NEW_TA	By Age/Sex: 15-19 Male	20



TX_NEW_TA	By Age/Sex: 20-24 Male	56
TX_NEW_TA	By Age/Sex: 50+ Male	38
TX_NEW_TA	By Age/Sex: 10-14 Female	33
TX_NEW_TA	By Age/Sex: 15-19 Female	68
TX_NEW_TA	By Age/Sex: 20-24 Female	125
TX_NEW_TA	By Age/Sex: 50+ Female	2
TX_NEW_TA	Sum of Age/Sex disaggregates	349
TX_NEW_TA	Pregnancy status	99
TX_NEW_TA	Breastfeeding status	99
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	162
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	101
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	68
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	68
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	70
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	92
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	48
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	85
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	74,863
TX_PVLS_DSD	Denominator: Indication: Routine	65,131
TX_PVLS_DSD	Denominator: Indication: Targeted	9,732
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	207
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+	2,915



	Male Targeted	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	411
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	6,199
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,498
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	19,464
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2,996
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	41,173
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	11,790
TX_PVLS_TA	Denominator: Indication: Routine	10,257
TX_PVLS_TA	Denominator: Indication: Targeted	1,533
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	472
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	67
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	236
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	28
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	6,483
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	982
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	3,066
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	456



TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	23,861
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	26,512
TX_RET_DSD	Numerator by Status: Pregnant	2,298
TX_RET_DSD	Numerator by Status: Breastfeeding	2,298
TX_RET_DSD	Denominator by Status: Pregnant	2,550
TX_RET_DSD	Denominator by Status: Breastfeeding	2,550
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	320
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10,790
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	589
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	12,162
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	353
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	11,990
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	656



	including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	13,513
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,035
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,261
TX_RET_TA	Numerator by Status: Pregnant	195
TX_RET_TA	Numerator by Status: Breastfeeding	195
TX_RET_TA	Denominator by Status: Pregnant	222
TX_RET_TA	Denominator by Status: Breastfeeding	222
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	19
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	926
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	40
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,050
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	23
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total	1,029



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	44
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,165
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	275
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	719
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	724
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	2,155
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	431
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	1,435
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34,	245



	Female, Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	575
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	100
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	286
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	29
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	71
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	7,181
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	357
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted	1,078
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	71
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Unassisted	71
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	12,598
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	14,821
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	890
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	595



TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	9,039
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	4,297
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	755
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	504
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	7,688
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	3,651
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	12,892
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	1,483
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	384
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	62
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	10,955
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	1,260
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	329
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	54
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	1,986
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting	2,336



	period).	
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	139
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	93
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	1,427
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	677
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	119
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	80
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	1,208
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	579
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	2,032
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	234
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	63
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	7
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	1,729
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	200
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	51
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	6
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	83,175
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	4,991
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	3,329
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	50,732
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	24,123



TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	3,329
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	172
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	666
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	2,491
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	72,359
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	2,164
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	8,318
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	334
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	13,105
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	786
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	523
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	7,998
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	3,798
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	523
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	22
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	104
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	397
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	11,403



TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	340
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	1,310
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	52

Implementing Mechanism Details

Mechanism ID: 17651	Mechanism Name: Regional Health Integration to Enhance Services in the Eastern region (RHITES-E)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: IntraHealth International, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 6,711,431	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 6,711,431	
Funding Source	Funding Amount
GHP-State	6,711,431

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	17,814
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and



	operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Key Populations: FSW	26,721
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Gender: GBV	250,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation



Gender: Gender Equality	31,969
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Condom programming	71,256
Water	175,000
Food and Nutrition: Policy, Tools, and Service Delivery	53,442



Budget Code Information

Mechanism ID:	17651	
Mechanism Name:	Regional Health Integration to Enhance Services in the Eastern region (RHITES-E)	
Prime Partner Name:	IntraHealth International, Inc	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	1,072,327
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	284,542
Strategic Area	Budget Code	Planned Amount
Care	PDCS	556,231
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	55,700
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	616,922
Strategic Area	Budget Code	Planned Amount



Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	498,837
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	235,326
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	492,425
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	2,643,857
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	255,264

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received	925



	ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	31,831
PMTCT_ART_DSD	New on ART	288
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	637
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	2,555
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	87,434
PMTCT_ART_TA	New on ART	806
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	1,749
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	31,831
PMTCT_STAT_DSD	Number of new ANC and L&D clients	31,831
PMTCT_STAT_DSD	By Age (Denominator): <15-19	6,044
PMTCT_STAT_DSD	By Age (Denominator): 20-24	10,503
PMTCT_STAT_DSD	By Number of known positives: 15-19	4
PMTCT_STAT_DSD	By Number of known positives: 20-24	18
PMTCT_STAT_DSD	By Number of new positives: 15-19	63
PMTCT_STAT_DSD	By Number of new positives: 20-24	106
PMTCT_STAT_DSD	By Number of new negative: 15-19	5,977
PMTCT_STAT_DSD	By Number of new negative: 20-24	10,379
PMTCT_STAT_DSD	By Age (Numerator): 15-19	6,044
PMTCT_STAT_DSD	By Age (Numerator): 20-24	10,503
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	7,005
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	5,412
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	2,231
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	636



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	290
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	6,644
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	71
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	225
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	5,133
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	54
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	93
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	2,114
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	24
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	28
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	600
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	8
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	7,005
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	5,412
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	2,231
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	636
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	87,434
PMTCT_STAT_TA	Number of new ANC and L&D clients	87,434
PMTCT_STAT_TA	By Age (Denominator): 15-19	16,615
PMTCT_STAT_TA	By Age (Denominator): 20-24	28,858



PMTCT_STAT_TA	By known positives: 15-19	9
PMTCT_STAT_TA	By known positives: 20-24	50
PMTCT_STAT_TA	By new positives: 15-19	172
PMTCT_STAT_TA	By new positives: 20-24	304
PMTCT_STAT_TA	By new negatives: 15-19	16,434
PMTCT_STAT_TA	By new negatives: 20-24	28,504
PMTCT_STAT_TA	By Age (Numerator): : 15-19	16,615
PMTCT_STAT_TA	By Age (Numerator): 20-24	28,858
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 25-29, Female	19,232
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 30-34, Female	14,862
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 35-39, Female	6,116
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 40-49, Female	1,751
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	782
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	18,248
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	202
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	604
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	14,102
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	156
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	252
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	5,803
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	61
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	74
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult	1,661



	40-49, Female, Newly Identified Negative	
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	16
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 25-29, Female	19,232
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 30-34, Female	14,862
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 35-39, Female	6,116
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 40-49, Female	1,751
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	26,453
VMMC_CIRC_DSD	By Age: 10-14	1,324
VMMC_CIRC_DSD	By Age: 15-19	6,615
VMMC_CIRC_DSD	By Age: 20-24	6,615
VMMC_CIRC_DSD	By Age: 25-29	7,940
VMMC_CIRC_DSD	By Age: 50+	785
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	15,339
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	23,279
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	26,453
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	1,058
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	1,058
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	1,058
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	205
PrEP_NEW_DSD	Male 15-19	2
PrEP_NEW_DSD	Male 20-24	14
PrEP_NEW_DSD	Male 50+	4
PrEP_NEW_DSD	Female 15-19	12
PrEP_NEW_DSD	Female 20-24	47
PrEP_NEW_DSD	Female 50+	2
PrEP_NEW_DSD	FSW	144
PrEP_NEW_DSD	MSM	8



PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	21
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	10
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	21
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	10
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	21
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	10
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	21
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	10
PrEP_NEW_DSD	PrEP_NEW_N_DSD_KeyPopAbr Other Key Populations	1
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	4,013
PP_PREV_DSD	Age/sex: 15-19 Male	109
PP_PREV_DSD	Age/sex: 20-24 Male	291
PP_PREV_DSD	Age/sex: 50+ Male	303
PP_PREV_DSD	Age/sex: 10-14 Female	8
PP_PREV_DSD	Age/sex: 15-19 Female	415
PP_PREV_DSD	Age/sex: 20-24 Female	401
PP_PREV_DSD	Age/sex: 50+ Female	171
PP_PREV_DSD	Sum of Age/Sex disaggregates	1,698
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	157
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	287
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	155
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	284
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	253
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	451
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	263
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	465
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	12,136



KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	228
KP_PREV_DSD	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	5
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	14
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	6,683
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	5,206
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	145,089
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	1,242
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	264
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male,	4



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	394
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	127
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	730
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	326
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	246
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	1,145
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	39
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	483
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	243
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	321



	20-24, Female, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	899
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	36
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	5
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	1,018
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	43
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	2,112
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	45
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	446
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	1,900
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	65
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	947
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	2,857
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	91
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	3,066



	Male, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	98
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	38
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	1,313
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	46
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	1,940
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	45
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	3,004
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	65
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	40
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	22
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	128
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	195
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female,	225



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	92
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	55
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	128
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	92
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	850
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	4,252
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	4,252
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	510
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	279
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	63



HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	104
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	57
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	172
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	187
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	146
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	29
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	252
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	13
HTC_TST_DSD	By Key Population: FSW, Negative	2,874
HTC_TST_DSD	By Key Population: FSW, Positive	1,342
HTC_TST_DSD	By Key Population: MSM, Negative	310
HTC_TST_DSD	By Key Population: MSM, Positive	140
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	7,211
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	1,420



HTC_TST_DSD	By Key Population: TG, Negative	114
HTC_TST_DSD	By Key Population: TG, Positive	22
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	482
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	24
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	104
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	121
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	23
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	61
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	81
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	224
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	38
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	256
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	46
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	439



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	8,355
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	86
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	14,503
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	149
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	527
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	97
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	435
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	80
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	127
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	334
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	65
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	239
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	47
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	393
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	73
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	183
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	38



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	503
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	93
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	912
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	49
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	601
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	394
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	398
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	410
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	542
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	277
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	503



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	2,505
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	104
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	2,055
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	83
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	597
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	1,585
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	66
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	1,125
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	46
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	1,883
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	77
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	1,034
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	44
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	2,389
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	100

HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	366
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	626
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	110
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	513
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	88
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	148
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	397
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	69
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	281
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	49
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	471
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	82
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	259
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	47
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	599



HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	106
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	4,647
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	145
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	4,777
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	148
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	1,666
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	56
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	3,069
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	98
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	1,839
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	3,469
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	108
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	1,494
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	52
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	2,816
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	89



HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	9,654
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	99
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	4,178
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	74
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	4,344
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	2,925
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	132
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	49
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	249
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	112
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	317



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	203
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	132
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	133
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	137
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	181
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	95
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	170
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	85



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	92
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	55
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	111
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	78
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	140
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	225
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	35
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	92
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	92
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	18



HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	5,101
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	681
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	681
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	681
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	117,361
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	773
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	23
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	165
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	206
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	9
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	68
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	2



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	384
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	21
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	171
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	9
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	128
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	710
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Positive	23
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	1,601
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	28
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	337
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	1,067
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	29
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	533
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	14
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24,	1,601



	Female, Negative	
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	46
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	1,715
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	50
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	14
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	740
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	17
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Negative	1,461
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Positive	28
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	2,260
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	44
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Negative	18
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Negative	8
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	79
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	120
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Positive	12
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female,	133



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	16
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	57
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	34
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	79
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Negative	57
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 10-14, Negative	470
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 10-14, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Negative	2,349
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Negative	2,349
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Negative	282
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	203
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Positive	9
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Negative	41
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Positive	1



HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	53
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	23
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	94
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	14
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	109
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	14
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	82
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	11
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	187
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Positive	9
HTC_TST_TA	By Key Population: FSW, Negative	156
HTC_TST_TA	By Key Population: FSW, Positive	71
HTC_TST_TA	By Key Population: MSM, Negative	21
HTC_TST_TA	By Key Population: MSM, Positive	9
HTC_TST_TA	By Key Population: People in prisons and other enclosed settings, Negative	1,261
HTC_TST_TA	By Key Population: People in prisons and other enclosed settings, Positive	228
HTC_TST_TA	By Key Population: TG, Negative	7
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	13,608
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	149



HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	23,643
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	261
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Negative	298
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Positive	49
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative	244
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Positive	41
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Negative	71
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Positive	10
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Negative	189
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Positive	29
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Negative	131
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Positive	20
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative	230
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Positive	37
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Negative	104
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Positive	14
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Negative	281
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Positive	46



HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Negative	479
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Positive	25
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Negative	317
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Positive	18
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Negative	208
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Positive	9
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Negative	211
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Positive	9
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Negative	215
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Positive	9
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Negative	282
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Positive	17
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Negative	145
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Positive	7
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Negative	261
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Positive	14
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Negative	278



HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Positive	9
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Negative	2,608
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Positive	81
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Negative	2,674
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Positive	82
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Negative	931
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Positive	24
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Negative	1,718
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Positive	50
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Negative	1,027
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Positive	26
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Negative	1,947
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Positive	60
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Negative	833
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Positive	21
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Negative	1,575
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Positive	46



HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Negative	15,745
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Positive	169
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Negative	6,813
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Positive	135
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Negative	7,068
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Positive	51
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Negative	4,765
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Positive	15
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Negative	75
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Positive	5
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Negative	20
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Negative	138
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Positive	8
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Negative	61
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Negative	170
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Positive	10

HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Negative	114
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Positive	8
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Negative	75
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Positive	5
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Negative	76
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Positive	5
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Negative	77
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Positive	5
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Negative	103
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Positive	8
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Negative	49
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Negative	93
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Positive	8
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Negative	43
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Negative	57



HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Positive	3
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	34
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Negative	66
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Positive	5
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	41
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Negative	84
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Positive	7
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	133
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Positive	16
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Negative	57
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative	57
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Positive	3
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 25-29, Male, Negative	2,819
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 25-29, Male, Positive	2



HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 30-34, Male, Negative	376
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 35-39, Male, Negative	376
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 40-49, Male, Negative	376
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 40-49, Male, Positive	1
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	27
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	71
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	71
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	214
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	3
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	3
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	43
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	143
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	3
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	3
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	24



HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	58
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	10
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	29
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	3
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	7
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Sex Partner	717
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest FSW, Directly-Assisted	36
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest FSW, Unassisted	108
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest MSM, Directly-Assisted	7
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest MSM, Unassisted	7
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,302
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	2,302
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	123
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,384
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	113
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number	682



	of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	123
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,384
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	113
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	682
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,878
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	1,878
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	96
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	104
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	558
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,120
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	104
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with	1,120



	documented HIV status, during the reporting period)	
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	96
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	558
GEND_GBV_DSD	Number of people receiving post-GBV care	10,104
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	5,906
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	4,198
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	1,261
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	77
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	83
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	44
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	8
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	207
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	264
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	76
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	15
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	1,801
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	2,404
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	182
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	88
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	877
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	734
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	437
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	310
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	229
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	30
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	143
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	15



GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	325
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	52
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	227
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	19
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	325
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	52
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	227
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	19
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	325
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	52
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	227
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	19
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	107
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	20
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	77
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	7
GEND_GBV_TA	Number of people receiving post-GBV care	876
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence	640



	(Other Post-GBV Care)	
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	236
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	71
GEND_GBV_TA	<10, Female, Physical and/or Emotional Violence	8
GEND_GBV_TA	<10, Female, Sexual Violence (Post-Rape Care)	5
GEND_GBV_TA	<10, Male, Physical and/or Emotional Violence	5
GEND_GBV_TA	<10, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_TA	10-14, Female, Physical and/or Emotional Violence	23
GEND_GBV_TA	10-14, Female, Sexual Violence (Post-Rape Care)	15
GEND_GBV_TA	10-14, Male, Physical and/or Emotional Violence	8
GEND_GBV_TA	10-14, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_TA	15-19, Female, Physical and/or Emotional Violence	197
GEND_GBV_TA	15-19, Female, Sexual Violence (Post-Rape Care)	135
GEND_GBV_TA	15-19, Male, Physical and/or Emotional Violence	20
GEND_GBV_TA	15-19, Male, Sexual Violence (Post-Rape Care)	5
GEND_GBV_TA	20-24, Female, Physical and/or Emotional Violence	95
GEND_GBV_TA	20-24, Female, Sexual Violence (Post-Rape Care)	41
GEND_GBV_TA	20-24, Male, Physical and/or Emotional Violence	47
GEND_GBV_TA	20-24, Male, Sexual Violence (Post-Rape Care)	17
GEND_GBV_TA	50+, Female, Physical and/or Emotional Violence	25
GEND_GBV_TA	50+, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_TA	50+, Male, Physical and/or Emotional Violence	15
GEND_GBV_TA	50+, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	35
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	3
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	24
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	1

GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	35
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	3
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	24
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	35
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	3
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	24
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	12
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	8
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	654
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	37
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	362
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The	39



	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	216
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	553
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	23
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	320
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	27
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	183
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	925
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	782
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	143
PMTCT_EID_DSD	Sum of Infant Age disaggregates	925
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,555



PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	2,142
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	413
PMTCT_EID_TA	Sum of Infant Age disaggregates	2,555
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	32,423
TX_CURR_DSD	Age/Sex: 15-19 Male	107
TX_CURR_DSD	Age/Sex: 15-19 Female	645
TX_CURR_DSD	Sum of age/sex disaggregates	752
TX_CURR_DSD	Age/Sex: <1	175
TX_CURR_DSD	Age/Sex: <1-9	1,067
TX_CURR_DSD	Age/Sex: 10-14 Male	377
TX_CURR_DSD	Age/Sex: 10-14 Female	874
TX_CURR_DSD	Age/Sex: 20-24 Male	165
TX_CURR_DSD	Age/Sex: 50+ Male	2,279
TX_CURR_DSD	Age/Sex: 20-24 Female	1,904
TX_CURR_DSD	Age/Sex: 50+ Female	3,418
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	2,717
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	479
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	3,880
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,140
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	3,172
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,486
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	4,674
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male,	3,864



	Positive	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	27,128
TX_CURR_TA	Age/Sex: 15-19 Male	89
TX_CURR_TA	Age/Sex: 15-19 Female	507
TX_CURR_TA	Sum of Age/Sex disaggregations	596
TX_CURR_TA	Age/Sex: <1	232
TX_CURR_TA	Age/Sex: 1-9	1,450
TX_CURR_TA	Age/Sex: 10-14 Male	498
TX_CURR_TA	Age/Sex: 10-14 Female	1,172
TX_CURR_TA	Age/Sex: 20-24 Male	130
TX_CURR_TA	Age/Sex: 50+ Male	1,809
TX_CURR_TA	Age/Sex: 20-24 Female	1,511
TX_CURR_TA	Age/Sex: 50+ Female	2,717
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	2,156
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	380
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	3,085
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	905
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	2,521
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	1,182
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	3,709
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	3,075
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,569
TX_NEW_DSD	By Age/Sex: <1	22



TX_NEW_DSD	By Age/Sex: 1-9	105
TX_NEW_DSD	By Age/Sex: 10-14 Male	28
TX_NEW_DSD	By Age/Sex: 15-19 Male	76
TX_NEW_DSD	By Age/Sex: 20-24 Male	183
TX_NEW_DSD	By Age/Sex: 50+ Male	136
TX_NEW_DSD	By Age/Sex: 10-14 Female	94
TX_NEW_DSD	By Age/Sex: 15-19 Female	224
TX_NEW_DSD	By Age/Sex: 20-24 Female	414
TX_NEW_DSD	By Age/Sex: 50+ Female	9
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,164
TX_NEW_DSD	Pregnancy status	334
TX_NEW_DSD	Breastfeeding status	334
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	501
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	342
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	225
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	228
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	234
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	305
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	157
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	286
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,820
TX_NEW_TA	By Age/Sex: <1	13
TX_NEW_TA	By Age/Sex: 1-9	103
TX_NEW_TA	By Age/Sex: 10-14 Male	20



TX_NEW_TA	By Age/Sex: 15-19 Male	51
TX_NEW_TA	By Age/Sex: 20-24 Male	137
TX_NEW_TA	By Age/Sex: 50+ Male	106
TX_NEW_TA	By Age/Sex: 10-14 Female	95
TX_NEW_TA	By Age/Sex: 15-19 Female	170
TX_NEW_TA	By Age/Sex: 20-24 Female	314
TX_NEW_TA	By Age/Sex: 50+ Female	6
TX_NEW_TA	Sum of Age/Sex disaggregates	899
TX_NEW_TA	Pregnancy status	256
TX_NEW_TA	Breastfeeding status	256
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	448
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	260
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	170
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	173
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	179
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	236
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	120
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	219
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	29,183
TX_PVLS_DSD	Denominator: Indication: Routine	25,389
TX_PVLS_DSD	Denominator: Indication: Targeted	3,794
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	83



TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	1,137
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	163
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	2,411
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	588
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	7,591
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,170
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	16,040
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	24,414
TX_PVLS_TA	Denominator: Indication: Routine	21,242
TX_PVLS_TA	Denominator: Indication: Targeted	3,172
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	975
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	133
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	484
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	65
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	13,438
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	2,027
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	6,345
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+	947



	Male Targeted	
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	6,433
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	7,148
TX_RET_DSD	Numerator by Status: Pregnant	625
TX_RET_DSD	Numerator by Status: Breastfeeding	625
TX_RET_DSD	Denominator by Status: Pregnant	696
TX_RET_DSD	Denominator by Status: Breastfeeding	696
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	72
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,931
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	133
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,297
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	79
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,257
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the	149



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,663
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	5,644
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	6,268
TX_RET_TA	Numerator by Status: Pregnant	525
TX_RET_TA	Numerator by Status: Breastfeeding	525
TX_RET_TA	Denominator by Status: Pregnant	583
TX_RET_TA	Denominator by Status: Breastfeeding	583
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	138
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,460
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	260
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,786
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	153



TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,734
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	287
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,094
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	117
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	305
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	306
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	914
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	15
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	15
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	182
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	609
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	15
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	15



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	105
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	244
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	42
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	122
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	11
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	30
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	3,042
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	152
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted	456
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	30
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Unassisted	30
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	4,909
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	5,779
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	348



TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	232
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	3,522
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	1,677
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	293
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	199
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	2,989
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	1,428
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	5,023
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	580
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	149
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	27
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	4,265
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	492
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	128
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	24
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	4,110
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the	4,832



	minimum requirements for the previous reporting period).	
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	288
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	192
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	2,952
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	1,400
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	249
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	161
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	2,512
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	1,188
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	4,207
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	482
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	126
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	17
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	3,582
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	410
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	106
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	12
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	32,423
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	1,945
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	1,296
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	19,778



TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	9,404
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	1,296
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	71
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	260
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	965
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	28,204
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	849
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	3,241
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	129
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	27,128
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	1,627
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	1,085
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	16,551
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	7,865
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	1,085
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	50
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	217
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	818
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV	23,605



	Life-long ART, Already, TB Screen - Negative, Positive	
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	700
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	2,714
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	109

Implementing Mechanism Details

Mechanism ID: 17654	Mechanism Name: Regional Health Integration to Enhance Services in South West Region (RHITES-SW)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 16,056,066	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 16,056,066	
Funding Source	Funding Amount
GHP-State	16,056,066

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	150,556
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information



Key Populations: FSW	225,834
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Gender: GBV	400,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Gender: Gender Equality	270,185
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Key Populations: MSM and TG	150,556
Focus Area:	Conducting epidemiologic, social science, and



	operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Key Populations: FSW	225,834
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Gender: GBV	400,000
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	270,185
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation



Renovation	401,515
Food and Nutrition: Policy, Tools, and Service Delivery	451,668
Water	406,597
Condom programming	602,223

Budget Code Information

Mechanism ID:	17654	
Mechanism Name:	Regional Health Integration to Enhance Services in South West Region (RHITES-SW)	
Prime Partner Name:	Elizabeth Glaser Pediatric AIDS Foundation	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	2,497,672
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	672,360
Strategic Area	Budget Code	Planned Amount
Care	PDCS	976,809
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	155,700
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	3,204,719
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	1,332,988
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	450,133
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	713,025
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	5,723,152
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	329,508



Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	7,901
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	114,847
PMTCT_ART_DSD	New on ART	2,395
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	5,506
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	1,647
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	28,049
PMTCT_ART_TA	New on ART	493
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	1,154
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	114,847
PMTCT_STAT_DSD	Number of new ANC and L&D clients	114,847
PMTCT_STAT_DSD	By Age (Denominator): <15-19	21,823
PMTCT_STAT_DSD	By Age (Denominator): 20-24	37,893
PMTCT_STAT_DSD	By Number of known positives: 15-19	29
PMTCT_STAT_DSD	By Number of known positives: 20-24	171
PMTCT_STAT_DSD	By Number of new positives: 15-19	501
PMTCT_STAT_DSD	By Number of new positives: 20-24	864
PMTCT_STAT_DSD	By Number of new negative: 15-19	21,293
PMTCT_STAT_DSD	By Number of new negative: 20-24	36,858
PMTCT_STAT_DSD	By Age (Numerator): 15-19	21,823



PMTCT_STAT_DSD	By Age (Numerator): 20-24	37,893
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	25,270
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	19,524
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	8,040
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	2,297
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	2,520
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	22,167
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	583
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	1,947
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	17,129
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	448
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	809
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	7,041
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	190
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	243
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	1,997
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	57
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	25,270
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	19,524
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	8,040
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	2,297



PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	28,049
PMTCT_STAT_TA	Number of new ANC and L&D clients	28,049
PMTCT_STAT_TA	By Age (Denominator): 15-19	5,328
PMTCT_STAT_TA	By Age (Denominator): 20-24	9,262
PMTCT_STAT_TA	By known positives: 15-19	3
PMTCT_STAT_TA	By known positives: 20-24	28
PMTCT_STAT_TA	By new positives: 15-19	99
PMTCT_STAT_TA	By new positives: 20-24	179
PMTCT_STAT_TA	By new negatives: 15-19	5,226
PMTCT_STAT_TA	By new negatives: 20-24	9,055
PMTCT_STAT_TA	By Age (Numerator): : 15-19	5,328
PMTCT_STAT_TA	By Age (Numerator): 20-24	9,262
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 25-29, Female	6,168
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 30-34, Female	4,770
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 35-39, Female	1,962
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 40-49, Female	559
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	521
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	5,535
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	112
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	404
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	4,276
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	90
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	162
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult	1,767



	35-39, Female, Newly Identified Negative	
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	33
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	43
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	511
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	5
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 25-29, Female	6,168
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 30-34, Female	4,770
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 35-39, Female	1,962
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 40-49, Female	559
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	136,971
VMMC_CIRC_DSD	By Age: 10-14	6,849
VMMC_CIRC_DSD	By Age: 15-19	34,254
VMMC_CIRC_DSD	By Age: 20-24	34,254
VMMC_CIRC_DSD	By Age: 25-29	41,097
VMMC_CIRC_DSD	By Age: 50+	4,066
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	79,423
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	120,520
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	136,971
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	5,484
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	5,484
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	5,483
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	4,569
PrEP_NEW_DSD	Male 15-19	41
PrEP_NEW_DSD	Male 20-24	318
PrEP_NEW_DSD	Male 50+	94



PrEP_NEW_DSD	Female 15-19	274
PrEP_NEW_DSD	Female 20-24	1,057
PrEP_NEW_DSD	Female 50+	41
PrEP_NEW_DSD	FSW	3,026
PrEP_NEW_DSD	MSM	178
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	458
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	228
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	458
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	228
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	458
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	228
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	458
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	228
PrEP_NEW_DSD	PrEP_NEW_N_DSD_KeyPopAbr Other Key Populations	29
PrEP_NEW_TA	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	250
PrEP_NEW_TA	Male 15-19	1
PrEP_NEW_TA	Male 20-24	20
PrEP_NEW_TA	Male 50+	2
PrEP_NEW_TA	Female 15-19	13
PrEP_NEW_TA	Female 20-24	69
PrEP_NEW_TA	Female 50+	1
PrEP_NEW_TA	FSW	172
PrEP_NEW_TA	MSM	11
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 25-29, Female	24
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 25-29, Male	12
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 30-34, Female	24
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 30-34, Male	12
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 35-39, Female	24
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 35-39, Male	12



PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 40-49, Female	24
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 40-49, Male	12
PrEP_NEW_TA	PrEP_NEW_N_TA_KeyPopAbr Other Key Populations	1
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	7,097
PP_PREV_DSD	Age/sex: 15-19 Male	241
PP_PREV_DSD	Age/sex: 20-24 Male	532
PP_PREV_DSD	Age/sex: 50+ Male	479
PP_PREV_DSD	Age/sex: 10-14 Female	36
PP_PREV_DSD	Age/sex: 15-19 Female	940
PP_PREV_DSD	Age/sex: 20-24 Female	762
PP_PREV_DSD	Age/sex: 50+ Female	273
PP_PREV_DSD	Sum of Age/Sex disaggregates	3,263
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	271
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	495
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	263
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	496
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	402
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	732
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	416
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	759
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	16,872
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	190
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations	16



	reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	5,379
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	11,287
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	557,702
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	4,891
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	152
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	1,042
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	1,779
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	94
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	581
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	3,304
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24,	174



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	1,473
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	78
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	41
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	1,115
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	61
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	4,475
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	150
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	1,487
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	62
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	744
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	32
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	993
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	41
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	2,760
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	116
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	22
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	3,123



	50+, Male, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	129
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	7,578
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	151
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	1,603
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	8,135
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	259
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	4,063
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	129
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	12,225
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	385
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	13,120
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	413
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	152
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	5,637
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male,	179



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	6,933
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	151
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	10,733
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	225
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	62
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	30
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	216
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	67
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	329
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	102
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	369
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	117
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	154
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	47
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	94
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	30



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	216
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	67
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	154
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	47
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	6,441
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	62
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	32,208
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	304
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	32,208
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	304
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	3,866
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	36
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	984
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	53
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	215
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	443
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	81
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	223
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	40



HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	738
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	134
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	818
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	149
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	632
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	116
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	902
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	48
HTC_TST_DSD	By Key Population: FSW, Negative	5,018
HTC_TST_DSD	By Key Population: FSW, Positive	2,366
HTC_TST_DSD	By Key Population: MSM, Negative	485
HTC_TST_DSD	By Key Population: MSM, Positive	217
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	14,395
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	2,841
HTC_TST_DSD	By Key Population: TG, Negative	177
HTC_TST_DSD	By Key Population: TG, Positive	32
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	1,160
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	60
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	248
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	10



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	364
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	64
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	184
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	33
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	242
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	43
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	676
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	120
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	766
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	134
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	1,063
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	54
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	20,243
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	501
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	35,159
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	864
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	2,271
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	408



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	1,856
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	332
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	546
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	99
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	1,433
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	257
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	1,022
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	185
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	1,700
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	308
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	792
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	144
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	2,157
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	387
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	4,115
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	217
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	2,718



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	143
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	1,780
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	94
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	1,805
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	95
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	1,849
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	98
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	2,434
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	131
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	1,248
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	66
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	2,269
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	119
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	7,700
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	321
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	6,319
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	262



HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	1,834
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	76
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	4,874
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	202
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	3,461
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	144
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	5,791
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	241
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	3,176
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	131
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	7,325
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	305
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	1,320
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	57
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	1,890
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	333
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	1,549



HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	272
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	449
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	79
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	1,195
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	210
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	849
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	150
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	1,418
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	250
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	779
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	136
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	1,813
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	317
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	19,914
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	621
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	20,479
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	643

HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	7,124
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	225
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	13,127
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	413
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	7,862
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	249
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	14,864
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	468
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	6,391
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	201
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	12,042
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	380
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	23,405
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	573
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	10,129
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	441
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	10,512



HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	194
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	7,087
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	70
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	578
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	189
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	1,064
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	82
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	476
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	1,326
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	103
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	876
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	68
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	579
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	43



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	586
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	599
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	46
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	784
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	60
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	408
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	735
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	58
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	23
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	353
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	154
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	47
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	94



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	186
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	58
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	123
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	232
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	72
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	369
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	117
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	154
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	47
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	154
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	47
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	38,655
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	360
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	5,151
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	48



HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	5,151
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	48
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	5,151
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	48
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	44,565
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	18
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	4
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	19
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	6
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	34
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	15
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	12
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	17
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	436
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	4



HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	87
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	411
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	206
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	621
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	13
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	666
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	14
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	285
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Negative	402
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	625
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	5
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	12



HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	22
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	24
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	6
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	12
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Negative	6
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 10-14, Negative	345
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 10-14, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Negative	1,722
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Positive	12
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Negative	1,722
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Positive	12
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Negative	207
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	47
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Negative	5



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	15
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	6
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	29
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	35
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	25
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	46
HTC_TST_TA	By Key Population: FSW, Negative	75
HTC_TST_TA	By Key Population: FSW, Positive	37
HTC_TST_TA	By Key Population: MSM, Negative	7
HTC_TST_TA	By Key Population: MSM, Positive	3
HTC_TST_TA	By Key Population: People in prisons and other enclosed settings, Negative	214
HTC_TST_TA	By Key Population: People in prisons and other enclosed settings, Positive	43
HTC_TST_TA	By Key Population: TG, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	4,998
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	99
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	8,683
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	179
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Negative	109
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Positive	13



HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative	93
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Positive	9
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Negative	18
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Negative	71
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Positive	9
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Negative	48
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative	85
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Positive	8
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Negative	34
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Negative	105
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Positive	13
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Negative	43
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Negative	29
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Positive	2



HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Negative	19
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Negative	19
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Negative	19
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Negative	27
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Negative	14
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Negative	24
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Negative	73
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Negative	1,001
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Positive	24
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Negative	1,038
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Positive	24
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Negative	360



HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Positive	5
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Negative	666
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Positive	14
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Negative	397
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Positive	6
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Negative	753
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Positive	15
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Negative	318
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Positive	5
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Negative	613
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Positive	13
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Negative	5,783
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Positive	112
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Negative	2,502
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Positive	89
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Negative	2,598
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Positive	34



HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Negative	1,752
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Positive	5
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Negative	19
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Negative	3
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Negative	47
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Negative	16
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Negative	63
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Negative	37
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Negative	19
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Negative	19
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Negative	20
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Negative	34
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Negative	13
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Negative	28
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Negative	11
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Negative	6
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Positive	1



HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	3
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Negative	9
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	4
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Negative	13
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Positive	4
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	24
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Positive	5
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Negative	6
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative	6
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 25-29, Male, Negative	2,065
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 25-29, Male, Positive	16
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 30-34, Male, Negative	276
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 35-39, Male, Negative	276



HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 40-49, Male, Negative	276
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	4,806
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	4,806
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	267
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,863
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	247
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,429
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	267
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,863
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	247
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,429
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	888
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	888
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total	36



	number of registered new and relapsed TB cases, during the reporting period)	
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	39
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	259
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	554
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	39
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	554
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	36
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	259
GEND_GBV_DSD	Number of people receiving post-GBV care	10,273
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	6,480
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	3,793
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	1,138
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	86
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	76
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	49
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	8
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	225



GEND_GBVDSD	10-14, Female, Sexual Violence (Post-Rape Care)	239
GEND_GBVDSD	10-14, Male, Physical and/or Emotional Violence	82
GEND_GBVDSD	10-14, Male, Sexual Violence (Post-Rape Care)	14
GEND_GBVDSD	15-19, Female, Physical and/or Emotional Violence	1,967
GEND_GBVDSD	15-19, Female, Sexual Violence (Post-Rape Care)	2,177
GEND_GBVDSD	15-19, Male, Physical and/or Emotional Violence	201
GEND_GBVDSD	15-19, Male, Sexual Violence (Post-Rape Care)	80
GEND_GBVDSD	20-24, Female, Physical and/or Emotional Violence	967
GEND_GBVDSD	20-24, Female, Sexual Violence (Post-Rape Care)	660
GEND_GBVDSD	20-24, Male, Physical and/or Emotional Violence	480
GEND_GBVDSD	20-24, Male, Sexual Violence (Post-Rape Care)	282
GEND_GBVDSD	50+, Female, Physical and/or Emotional Violence	250
GEND_GBVDSD	50+, Female, Sexual Violence (Post-Rape Care)	28
GEND_GBVDSD	50+, Male, Physical and/or Emotional Violence	156
GEND_GBVDSD	50+, Male, Sexual Violence (Post-Rape Care)	14
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	359
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	47
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	247
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	18
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	359
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	47
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	247
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	18
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	359



GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	47
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	247
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	18
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	118
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	14
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	82
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	5
GEND_GBV_TA	Number of people receiving post-GBV care	1,388
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1,038
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	350
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	107
GEND_GBV_TA	<10, Female, Physical and/or Emotional Violence	13
GEND_GBV_TA	<10, Female, Sexual Violence (Post-Rape Care)	7
GEND_GBV_TA	<10, Male, Physical and/or Emotional Violence	7
GEND_GBV_TA	<10, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_TA	10-14, Female, Physical and/or Emotional Violence	39
GEND_GBV_TA	10-14, Female, Sexual Violence (Post-Rape Care)	22
GEND_GBV_TA	10-14, Male, Physical and/or Emotional Violence	13
GEND_GBV_TA	10-14, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_TA	15-19, Female, Physical and/or Emotional Violence	328
GEND_GBV_TA	15-19, Female, Sexual Violence (Post-Rape Care)	204
GEND_GBV_TA	15-19, Male, Physical and/or Emotional Violence	33
GEND_GBV_TA	15-19, Male, Sexual Violence (Post-Rape Care)	7
GEND_GBV_TA	20-24, Female, Physical and/or Emotional Violence	152



GEND_GBV_TA	20-24, Female, Sexual Violence (Post-Rape Care)	63
GEND_GBV_TA	20-24, Male, Physical and/or Emotional Violence	77
GEND_GBV_TA	20-24, Male, Sexual Violence (Post-Rape Care)	24
GEND_GBV_TA	50+, Female, Physical and/or Emotional Violence	42
GEND_GBV_TA	50+, Female, Sexual Violence (Post-Rape Care)	3
GEND_GBV_TA	50+, Male, Physical and/or Emotional Violence	25
GEND_GBV_TA	50+, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	53
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	4
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	40
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	53
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	4
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	40
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	53
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	4
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	40
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	17
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	1



	Female, Sexual Violence (Post-Rape Care)	
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	13
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	1
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2,089
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	111
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,163
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	120
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	695
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	324
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	10
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	198



TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	12
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	104
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	7,901
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	6,688
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,213
PMTCT_EID_DSD	Sum of Infant Age disaggregates	7,901
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,647
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	1,344
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	303
PMTCT_EID_TA	Sum of Infant Age disaggregates	1,647
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	156,291
TX_CURR_DSD	Age/Sex: 15-19 Male	541
TX_CURR_DSD	Age/Sex: 15-19 Female	3,167
TX_CURR_DSD	Sum of age/sex disaggregates	3,708
TX_CURR_DSD	Age/Sex: <1	632
TX_CURR_DSD	Age/Sex: <1-9	3,815
TX_CURR_DSD	Age/Sex: 10-14 Male	1,339
TX_CURR_DSD	Age/Sex: 10-14 Female	3,110
TX_CURR_DSD	Age/Sex: 20-24 Male	819
TX_CURR_DSD	Age/Sex: 50+ Male	11,227
TX_CURR_DSD	Age/Sex: 20-24 Female	9,377



TX_CURR_DSD	Age/Sex: 50+ Female	16,840
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	13,374
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	2,359
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	19,120
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	5,613
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	15,627
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	7,327
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	22,955
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	19,049
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	11,405
TX_CURR_TA	Age/Sex: 15-19 Male	30
TX_CURR_TA	Age/Sex: 15-19 Female	224
TX_CURR_TA	Sum of Age/Sex disaggregations	254
TX_CURR_TA	Age/Sex: <1	38
TX_CURR_TA	Age/Sex: 1-9	299
TX_CURR_TA	Age/Sex: 10-14 Male	99
TX_CURR_TA	Age/Sex: 10-14 Female	243
TX_CURR_TA	Age/Sex: 20-24 Male	50
TX_CURR_TA	Age/Sex: 50+ Male	809
TX_CURR_TA	Age/Sex: 20-24 Female	676
TX_CURR_TA	Age/Sex: 50+ Female	1,221
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	969
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male,	168



	Positive	
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	1,387
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	406
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	1,131
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	530
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	1,745
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	1,380
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	17,091
TX_NEW_DSD	By Age/Sex: <1	73
TX_NEW_DSD	By Age/Sex: 1-9	417
TX_NEW_DSD	By Age/Sex: 10-14 Male	101
TX_NEW_DSD	By Age/Sex: 15-19 Male	361
TX_NEW_DSD	By Age/Sex: 20-24 Male	903
TX_NEW_DSD	By Age/Sex: 50+ Male	669
TX_NEW_DSD	By Age/Sex: 10-14 Female	386
TX_NEW_DSD	By Age/Sex: 15-19 Female	1,087
TX_NEW_DSD	By Age/Sex: 20-24 Female	2,014
TX_NEW_DSD	By Age/Sex: 50+ Female	41
TX_NEW_DSD	Sum of Age/Sex disaggregates	5,562
TX_NEW_DSD	Pregnancy status	1,615
TX_NEW_DSD	Breastfeeding status	1,615
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	2,426
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,656
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34,	1,089



	Female, Positive	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,102
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	1,128
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,484
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	770
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	1,384
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,399
TX_NEW_TA	By Age/Sex: <1	2
TX_NEW_TA	By Age/Sex: 1-9	31
TX_NEW_TA	By Age/Sex: 10-14 Male	4
TX_NEW_TA	By Age/Sex: 15-19 Male	17
TX_NEW_TA	By Age/Sex: 20-24 Male	64
TX_NEW_TA	By Age/Sex: 50+ Male	45
TX_NEW_TA	By Age/Sex: 10-14 Female	27
TX_NEW_TA	By Age/Sex: 15-19 Female	82
TX_NEW_TA	By Age/Sex: 20-24 Female	154
TX_NEW_TA	Sum of Age/Sex disaggregates	393
TX_NEW_TA	Pregnancy status	129
TX_NEW_TA	Breastfeeding status	129
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	310
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	129
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	82
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	85



TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	88
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	120
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	50
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	109
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	140,664
TX_PVLS_DSD	Denominator: Indication: Routine	122,378
TX_PVLS_DSD	Denominator: Indication: Targeted	18,286
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	391
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	5,477
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	784
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	11,634
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	2,820
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	36,566
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	5,632
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	77,360
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	10,263
TX_PVLS_TA	Denominator: Indication: Routine	8,929
TX_PVLS_TA	Denominator: Indication: Targeted	1,334



TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	406
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	45
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	200
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	17
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	5,650
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	875
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	2,673
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	397
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	26,151
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	29,055
TX_RET_DSD	Numerator by Status: Pregnant	2,536
TX_RET_DSD	Numerator by Status: Breastfeeding	2,536
TX_RET_DSD	Denominator by Status: Pregnant	2,821
TX_RET_DSD	Denominator by Status: Breastfeeding	2,821
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	292
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11,905
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on	546



	treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	13,408
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	326
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	13,230
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	604
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	14,895
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,170
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,412
TX_RET_TA	Numerator by Status: Pregnant	205
TX_RET_TA	Numerator by Status: Breastfeeding	205
TX_RET_TA	Denominator by Status: Pregnant	227
TX_RET_TA	Denominator by Status: Breastfeeding	227
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of	16



	adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	988
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	33
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,133
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	19
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,094
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	36
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,263
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	339
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	897



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	903
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	2,687
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	537
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	1,790
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	304
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	717
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	126
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	357
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	89
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	8,957
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	448
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted	1,345



HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	89
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Unassisted	89
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	23,672
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	27,850
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	1,675
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	1,119
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	16,979
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	8,077
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	1,422
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	953
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	14,432
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	6,865
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	24,206
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	2,791
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	735
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	118
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already,	20,575



	Positive	
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	2,373
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	623
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	101
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	1,730
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	2,032
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	117
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	76
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	1,252
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	587
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	98
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	61
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	1,069
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	502
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	1,793
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	198
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	41
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV	1,525



	Alternative TPT Regimen, Life-long ART, Already, Positive	
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	168
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	37
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	156,291
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	9,388
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	6,257
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	95,321
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	45,325
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	6,257
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	324
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	1,255
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	4,678
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	135,962
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	4,063
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	15,632
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	634
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	11,405
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	677
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	451
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	6,970



TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	3,307
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	451
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	11
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	85
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	355
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	9,933
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	296
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	1,138
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	38

Implementing Mechanism Details

Mechanism ID: 17688	Mechanism Name: Strategic Information Technical Support (SITES)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Social and Scientific Systems	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 3,119,600	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,119,600	
Funding Source	Funding Amount
GHP-State	3,119,600



Cross-Cutting Budget Attribution(s)

Gender: GBV	20,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Budget Code Information

Mechanism ID: 17688		
Mechanism Name: Strategic Information Technical Support (SITES)		
Prime Partner Name: Social and Scientific Systems		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	988,000
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0



Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	2,131,600
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount



Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17690	Mechanism Name: Strengthening HRH
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: IntraHealth International, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,322,148	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,322,148	
Funding Source	Funding Amount
GHP-State	1,322,148

Cross-Cutting Budget Attribution(s)

Human Resources for Health	137,695
----------------------------	---------



Budget Code Information

Mechanism ID: 17690		
Mechanism Name: Strengthening HRH		
Prime Partner Name: IntraHealth International, Inc		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	350,000
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	97,215
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	777,718
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	97,215

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17696	Mechanism Name: Better Outcomes for Children and Youth Eastern and Northern Regions
----------------------------	--



	(BOCY)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: World Education	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 8,487,431	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 8,487,431	
Funding Source	Funding Amount
GHP-State	8,487,431

Cross-Cutting Budget Attribution(s)

Gender: GBV	455,412
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Gender: Gender Equality	200,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Adolescent Girls and Young Women (AGYW)	1,177,336
Economic Strengthening	2,260,000
Education	1,600,000
Food and Nutrition: Policy, Tools, and Service Delivery	30,000
Food and Nutrition: Commodities	200,000
Water	95,604



Budget Code Information

Mechanism ID: 17696 Mechanism Name: Better Outcomes for Children and Youth Eastern and Northern Regions (BOCY) Prime Partner Name: World Education		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	8,487,431
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	137,273
OVC_SERV_DSD	Age/Sex: 10-14 Male	15,096



OVC_SERV_DSD	Age/Sex: 15-17 Male	12,356
OVC_SERV_DSD	By: Age/sex: Male 18-24	12,351
OVC_SERV_DSD	By: Age/sex: Male 25+	2,742
OVC_SERV_DSD	Age/Sex: 10-14 Female	16,469
OVC_SERV_DSD	Age/Sex: 15-17 Female	15,102
OVC_SERV_DSD	By: Age/sex: 18-24 Female	15,111
OVC_SERV_DSD	By: Age/sex: 25+ Female	4,115
OVC_SERV_DSD	Sum of Age/Sex disaggregates	59,023
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	12,176
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	3,042
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	10,582
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	2,647
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	7,304
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	1,828
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	6,352
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	1,590
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	2,383
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	367
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	2,186
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	299
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	1,656



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	3,308
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	11,583
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	1,324
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	2,646
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	9,260
OVC_SERV_DSD	Age/Sex: <1	5,492
OVC_SERV_DSD	Age/Sex: 1-9	38,439
OVC_SERV_DSD	Program Completion: Active	130,414
OVC_SERV_DSD	Program Completion: Graduation	6,859
OVC_SERV_DSD	OVC_SERV_N_DSD_Age_Sex_Service_v4 <1, Unknown Sex, Social Protection	795
OVC_SERV_DSD	OVC_SERV_N_DSD_Age_Sex_Service_v4 1-9, Unknown Sex, Social Protection	5,560
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	102,954
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	137,273

Implementing Mechanism Details

Mechanism ID: 17698	Mechanism Name: Provision of comprehensive HIV/AIDS and TB services including prevention, care, support and treatment to prisoners and staff of the prisons service in the Republic of Uganda under PEPFAR
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Uganda Prisons Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC
Total All Funding Sources: 1,802,308	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,802,308	
Funding Source	Funding Amount
GHP-State	1,802,308

Cross-Cutting Budget Attribution(s)

Gender: GBV	262,824
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Gender: Gender Equality	100,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Water	131,112

Budget Code Information

Mechanism ID: Mechanism Name: Prime Partner Name:	17698 Provision of comprehensive HIV/AIDS and TB services including prevention, care, support and treatment to prisoners and staff of the prisons service in the Republic of Uganda under PEPFAR Uganda Prisons Services	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	56,932



Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	13,869
Strategic Area	Budget Code	Planned Amount
Care	PDCS	372
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	50,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	29,923
Strategic Area	Budget Code	Planned Amount



Prevention	HVOP	1,502,269
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	9,002
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	138,917
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	1,024

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	169
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,988
PMTCT_ART_TA	New on ART	50
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	119
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,988
PMTCT_STAT_TA	Number of new ANC and L&D clients	1,988
PMTCT_STAT_TA	By Age (Denominator): 15-19	379



PMTCT_STAT_TA	By Age (Denominator): 20-24	655
PMTCT_STAT_TA	By known positives: 15-19	1
PMTCT_STAT_TA	By known positives: 20-24	4
PMTCT_STAT_TA	By new positives: 15-19	10
PMTCT_STAT_TA	By new positives: 20-24	17
PMTCT_STAT_TA	By new negatives: 15-19	368
PMTCT_STAT_TA	By new negatives: 20-24	634
PMTCT_STAT_TA	By Age (Numerator): : 15-19	379
PMTCT_STAT_TA	By Age (Numerator): 20-24	655
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 25-29, Female	437
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 30-34, Female	338
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 35-39, Female	138
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 40-49, Female	41
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	53
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	373
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	11
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	42
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	287
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	9
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	16
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	118
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	4
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	6



PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	33
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	2
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 25-29, Female	437
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 30-34, Female	338
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 35-39, Female	138
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 40-49, Female	41
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	1,968
PP_PREV_DSD	Age/sex: 15-19 Male	45
PP_PREV_DSD	Age/sex: 20-24 Male	115
PP_PREV_DSD	Age/sex: 50+ Male	151
PP_PREV_DSD	Age/sex: 10-14 Female	17
PP_PREV_DSD	Age/sex: 15-19 Female	184
PP_PREV_DSD	Age/sex: 20-24 Female	169
PP_PREV_DSD	Age/sex: 50+ Female	78
PP_PREV_DSD	Sum of Age/Sex disaggregates	759
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	82
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	149
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	78
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	154
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	134
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	236
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	136
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	240
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	103,443
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations	103,443



	reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	8,265
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	65
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	14
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	30
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	10
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	57
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	25
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	19
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	59
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Positive	2



HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	154
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	35
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	219
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	107
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	324
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	10
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	350
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	11
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	5
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	151
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Negative	141
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Positive	3



HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	221
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	5
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Negative	7
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	20
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	29
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Positive	12
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	33
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	14
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	15
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	10
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	20
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Negative	15



HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	20
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Negative	4
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	13
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	7
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	20
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	21
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	17
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	18
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Positive	1
HTC_TST_TA	By Key Population: FSW, Negative	553
HTC_TST_TA	By Key Population: FSW, Positive	263
HTC_TST_TA	By Key Population: MSM, Negative	57
HTC_TST_TA	By Key Population: MSM, Positive	19
HTC_TST_TA	By Key Population: People in prisons and other	1,257



	enclosed settings, Negative	
HTC_TST_TA	By Key Population: People in prisons and other enclosed settings, Positive	234
HTC_TST_TA	By Key Population: PWID, Negative	38
HTC_TST_TA	By Key Population: PWID, Positive	9
HTC_TST_TA	By Key Population: TG, Negative	13
HTC_TST_TA	By Key Population: TG, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	344
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	10
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	598
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	17
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Negative	62
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Positive	10
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative	49
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Positive	9
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Negative	14
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Negative	39
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Positive	7
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Negative	28
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Positive	6
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative	46



HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Positive	8
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Negative	21
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Positive	4
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Negative	57
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Positive	10
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Negative	70
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Positive	3
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Negative	46
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Negative	30
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Negative	30
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Negative	31
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Negative	41
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Positive	2



HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Negative	21
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Negative	39
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Negative	28
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Positive	1
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Negative	532
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Positive	17
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Negative	548
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Positive	17
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Negative	191
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Positive	7
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Negative	350
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Positive	11
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Negative	212
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Positive	7
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Negative	398



HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Positive	13
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Negative	172
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Positive	7
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Negative	321
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Positive	10
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Negative	397
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Positive	10
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Negative	172
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Positive	9
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Negative	176
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Positive	4
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Negative	121
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Negative	17
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Negative	6
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Negative	29



HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Positive	3
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Negative	14
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Negative	36
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Positive	3
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Negative	23
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Positive	3
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Negative	17
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Negative	17
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Negative	17
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Negative	21
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Negative	11
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Positive	1



HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Negative	20
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Female, Negative	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Negative	9
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Negative	15
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Positive	8
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	10
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Positive	6
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Negative	17
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Positive	8
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	13
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Positive	7
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Negative	21
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Positive	9
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	33
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Positive	14



HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Negative	15
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Positive	8
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative	15
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Positive	8
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	57
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	148
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	149
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	445
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	7
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	7
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	88
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	297
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	7
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	7
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	50
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	119
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	20



HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	59
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	7
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	15
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Sex Partner	1,483
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest FSW, Directly-Assisted	75
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest FSW, Unassisted	223
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest MSM, Directly-Assisted	15
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest MSM, Unassisted	15
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	526
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	526
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	27
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	30
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	156
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	313
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with	30



	documented HIV status, during the reporting period)	
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	313
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	27
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	156
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	259
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	14
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	143
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	16
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	86
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	169
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	140
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	29



PMTCT_EID_TA	Sum of Infant Age disaggregates	169
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	6,041
TX_CURR_TA	Age/Sex: 15-19 Male	28
TX_CURR_TA	Age/Sex: 15-19 Female	49
TX_CURR_TA	Sum of Age/Sex disaggregations	77
TX_CURR_TA	Age/Sex: <1	26
TX_CURR_TA	Age/Sex: 1-9	161
TX_CURR_TA	Age/Sex: 10-14 Male	58
TX_CURR_TA	Age/Sex: 10-14 Female	132
TX_CURR_TA	Age/Sex: 20-24 Male	34
TX_CURR_TA	Age/Sex: 50+ Male	397
TX_CURR_TA	Age/Sex: 20-24 Female	285
TX_CURR_TA	Age/Sex: 50+ Female	171
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	339
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	225
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	454
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	454
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	454
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	568
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	562
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	1,644
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	504
TX_NEW_TA	By Age/Sex: <1	2



TX_NEW_TA	By Age/Sex: 1-9	8
TX_NEW_TA	By Age/Sex: 10-14 Male	3
TX_NEW_TA	By Age/Sex: 15-19 Male	12
TX_NEW_TA	By Age/Sex: 20-24 Male	27
TX_NEW_TA	By Age/Sex: 50+ Male	20
TX_NEW_TA	By Age/Sex: 10-14 Female	11
TX_NEW_TA	By Age/Sex: 15-19 Female	32
TX_NEW_TA	By Age/Sex: 20-24 Female	61
TX_NEW_TA	By Age/Sex: 50+ Female	1
TX_NEW_TA	Sum of Age/Sex disaggregates	167
TX_NEW_TA	Pregnancy status	49
TX_NEW_TA	Breastfeeding status	49
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	70
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	49
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	32
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	33
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	34
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	44
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	23
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	42
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	5,437
TX_PVLS_TA	Denominator: Indication: Routine	4,729
TX_PVLS_TA	Denominator: Indication: Targeted	708



TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	218
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	30
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	109
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	14
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	2,990
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	452
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	1,412
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	212
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,104
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,228
TX_RET_TA	Numerator by Status: Pregnant	110
TX_RET_TA	Numerator by Status: Breastfeeding	110
TX_RET_TA	Denominator by Status: Pregnant	120
TX_RET_TA	Denominator by Status: Breastfeeding	120
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	509
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on	16



	treatment at 12 months after initiating ART)	
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	571
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	565
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	17
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	637
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	914
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	1,077



TB_PREV_TA	By Age/Sex (Denominator): <15, Female	64
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	43
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	656
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	314
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	57
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	37
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	556
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	264
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	937
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	107
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	28
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	5
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	795
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	91
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	24
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	4
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	6,041
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	362
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	241
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	3,685
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	1,753
TX_TB_TA	Denominator: By Specimen Sent: Number of ART	241



	patients who had a specimen sent for bacteriologic diagnosis of active TB disease	
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	13
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	48
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	180
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	5,255
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	158
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	603
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	25

Implementing Mechanism Details

Mechanism ID: 17703	Mechanism Name: Monitoring and Evaluation Technical Support (METS)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Makerere University School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 7,150,684	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 7,150,684	
Funding Source	Funding Amount
GHP-State	7,150,684



Cross-Cutting Budget Attribution(s)

Gender: GBV	350,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Gender: Gender Equality	125,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Monitoring and Evaluation
Water	32,483
Adolescent Girls and Young Women (AGYW)	697,739

Budget Code Information

Mechanism ID: 17703		
Mechanism Name: Monitoring and Evaluation Technical Support (METS)		
Prime Partner Name: Makerere University School of Public Health		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	112,500
Strategic Area	Budget Code	Planned Amount
Care	HKID	746,500
Strategic Area	Budget Code	Planned Amount
Care	HVTB	75,000
Strategic Area	Budget Code	Planned Amount
Care	PDCS	112,500
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HLAB	95,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	3,471,651
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	664,793
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	135,000
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	240,000
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	1,047,740
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	75,000
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	262,500
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	112,500

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17704	Mechanism Name: African Society for Laboratory Medicine - LIMS Support for hubs
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Society for Laboratory Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information



Mechanism ID:	17704	
Mechanism Name:	African Society for Laboratory Medicine - LIMS Support for hubs	
Prime Partner Name:	African Society for Laboratory Medicine	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17705	Mechanism Name: Hospital-based birth defects surveillance in Kampala, Uganda
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Makerere University John Hopkins University Collaboration	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 400,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 400,000	
Funding Source	Funding Amount
GHP-State	400,000

Cross-Cutting Budget Attribution(s)

Water	4,175
-------	-------

Budget Code Information

Mechanism ID: 17705		
Mechanism Name: Hospital-based birth defects surveillance in Kampala, Uganda		
Prime Partner Name: Makerere University John Hopkins University Collaboration		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	400,000
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17706	Mechanism Name: Scaling up HIV services in Western and West Nile Regions of Uganda
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Infectious Disease Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 12,250,971	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 12,250,971	
Funding Source	Funding Amount
GHP-State	12,250,971

Cross-Cutting Budget Attribution(s)

Water	86,333
Renovation	1,000,038



Budget Code Information

Mechanism ID:	17706	
Mechanism Name:	Scaling up HIV services in Western and West Nile Regions of	
Prime Partner Name:	Uganda	
Prime Partner Name:	Infectious Disease Institute	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	1,777,783
Strategic Area	Budget Code	Planned Amount
Care	HKID	436,685
Strategic Area	Budget Code	Planned Amount
Care	HVTB	483,196
Strategic Area	Budget Code	Planned Amount
Care	PDCS	840,481
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	92,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	1,899,595
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	999,725
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	261,136
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	766,877
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	4,337,589
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	355,904

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	4,125



PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	109,744
PMTCT_ART_DSD	New on ART	1,577
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,548
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	3,100
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	77,418
PMTCT_ART_TA	New on ART	1,103
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	1,997
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	109,744
PMTCT_STAT_DSD	Number of new ANC and L&D clients	109,744
PMTCT_STAT_DSD	By Age (Denominator): <15-19	20,850
PMTCT_STAT_DSD	By Age (Denominator): 20-24	36,212
PMTCT_STAT_DSD	By Number of known positives: 15-19	18
PMTCT_STAT_DSD	By Number of known positives: 20-24	84
PMTCT_STAT_DSD	By Number of new positives: 15-19	321
PMTCT_STAT_DSD	By Number of new positives: 20-24	560
PMTCT_STAT_DSD	By Number of new negative: 15-19	20,511
PMTCT_STAT_DSD	By Number of new negative: 20-24	35,568
PMTCT_STAT_DSD	By Age (Numerator): 15-19	20,850
PMTCT_STAT_DSD	By Age (Numerator): 20-24	36,212
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	24,149
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	18,658
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	7,679
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	2,196
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	1,176



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	22,601
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	372
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	907
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	17,465
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	286
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	376
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	7,177
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	126
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	113
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	2,048
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	35
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	24,149
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	18,658
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	7,679
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	2,196
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	77,418
PMTCT_STAT_TA	Number of new ANC and L&D clients	77,418
PMTCT_STAT_TA	By Age (Denominator): 15-19	14,710
PMTCT_STAT_TA	By Age (Denominator): 20-24	25,548
PMTCT_STAT_TA	By known positives: 15-19	6
PMTCT_STAT_TA	By known positives: 20-24	53



PMTCT_STAT_TA	By new positives: 15-19	226
PMTCT_STAT_TA	By new positives: 20-24	390
PMTCT_STAT_TA	By new negatives: 15-19	14,478
PMTCT_STAT_TA	By new negatives: 20-24	25,105
PMTCT_STAT_TA	By Age (Numerator): : 15-19	14,710
PMTCT_STAT_TA	By Age (Numerator): 20-24	25,548
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 25-29, Female	17,026
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 30-34, Female	13,162
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 35-39, Female	5,422
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 40-49, Female	1,550
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	912
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	15,852
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	262
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	708
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	12,250
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	204
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	291
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	5,054
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	77
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	83
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	1,446
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult	21



	40-49, Female, Newly Identified Positive	
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 25-29, Female	17,026
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 30-34, Female	13,162
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 35-39, Female	5,422
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 40-49, Female	1,550
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	67,981
VMMC_CIRC_DSD	By Age: 10-14	3,401
VMMC_CIRC_DSD	By Age: 15-19	16,998
VMMC_CIRC_DSD	By Age: 20-24	16,998
VMMC_CIRC_DSD	By Age: 25-29	20,394
VMMC_CIRC_DSD	By Age: 50+	2,036
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	39,433
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	59,827
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	67,681
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	300
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	2,718
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	2,718
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	2,718
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	806
PrEP_NEW_DSD	Male 15-19	8
PrEP_NEW_DSD	Male 20-24	56
PrEP_NEW_DSD	Male 50+	17
PrEP_NEW_DSD	Female 15-19	49
PrEP_NEW_DSD	Female 20-24	176
PrEP_NEW_DSD	Female 50+	8
PrEP_NEW_DSD	FSW	566
PrEP_NEW_DSD	MSM	32
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	82



PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	41
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	82
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	41
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	82
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	41
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	82
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	41
PrEP_NEW_DSD	PrEP_NEW_N_DSD_KeyPopAbr Other Key Populations	5
PrEP_NEW_TA	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	287
PrEP_NEW_TA	Male 15-19	3
PrEP_NEW_TA	Male 20-24	20
PrEP_NEW_TA	Male 50+	5
PrEP_NEW_TA	Female 15-19	17
PrEP_NEW_TA	Female 20-24	67
PrEP_NEW_TA	Female 50+	3
PrEP_NEW_TA	FSW	200
PrEP_NEW_TA	MSM	12
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 25-29, Female	28
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 25-29, Male	15
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 30-34, Female	28
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 30-34, Male	15
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 35-39, Female	28
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 35-39, Male	15
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 40-49, Female	28
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 40-49, Male	15
PrEP_NEW_TA	PrEP_NEW_N_TA_KeyPopAbr Other Key Populations	2
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	11,046



PP_PREV_DSD	Age/sex: 15-19 Male	219
PP_PREV_DSD	Age/sex: 20-24 Male	590
PP_PREV_DSD	Age/sex: 50+ Male	626
PP_PREV_DSD	Age/sex: 10-14 Female	662
PP_PREV_DSD	Age/sex: 15-19 Female	2,189
PP_PREV_DSD	Age/sex: 20-24 Female	1,649
PP_PREV_DSD	Age/sex: 50+ Female	346
PP_PREV_DSD	Sum of Age/Sex disaggregates	6,281
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	326
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	586
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	315
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	571
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	522
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	938
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	540
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	967
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	17,294
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	7,687
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	9,607
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	312,775
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14,	4,944



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	152
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	1,051
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	1,299
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	69
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	422
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	2,411
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	128
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	1,074
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	57
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	28
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	813
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	43
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	4,512
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	150
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	820



	15-19, Female, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	33
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	410
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	546
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	1,518
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	64
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	11
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	1,721
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	71
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	5,626
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	115
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	1,187
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	3,722
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	124
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19,	1,858



	Male, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	64
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	5,599
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	181
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	6,005
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	196
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	77
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	2,581
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	85
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	5,155
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	115
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	7,977
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	171
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	71
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	40
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female,	226



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	334
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	61
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	386
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	69
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	169
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	103
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	226
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	169
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	3,214
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	16,074
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	16,074
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	1,929



HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	735
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	46
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	163
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	214
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	43
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	114
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	348
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	66
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	384
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	77
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	300
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	56
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	670
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	43
HTC_TST_DSD	By Key Population: FSW, Negative	2,793



HTC_TST_DSD	By Key Population: FSW, Positive	1,435
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	7,646
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	1,691
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	1,166
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	61
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	251
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	285
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	50
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	143
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	24
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	189
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	33
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	528
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	94
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	599
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+,	105



	Male, Positive	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	1,068
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	56
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	12,539
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	197
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	21,771
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	345
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	1,062
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	195
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	871
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	163
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	259
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	52
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	671
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	127
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	482
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	93
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	800
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	153
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49,	373



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	73
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	1,011
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	185
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	3,001
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	157
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	1,982
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	105
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	1,300
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	69
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	1,318
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	71
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	1,349
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	72
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	1,779
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	94
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	911
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	47



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	1,658
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	87
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	4,236
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	176
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	3,474
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	145
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	1,010
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	2,681
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	111
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	1,904
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	79
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	3,188
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	132
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	1,745
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	73
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49,	4,028



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	167
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	982
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	48
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	1,477
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	260
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	1,211
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	214
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	353
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	934
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	164
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	666
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	116
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	1,113
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	195
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	611
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	108



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	1,408
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	247
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	9,117
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	285
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	9,380
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	295
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	3,260
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	111
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	6,009
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	196
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	3,602
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	122
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	6,803
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	220
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	2,926
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	99
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49,	5,511

	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	178
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	14,499
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	223
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	6,274
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	171
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	6,509
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	77
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	4,388
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	258
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	90
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	467
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	44
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	218
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	21



	Positive	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	579
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	51
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	389
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	258
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	262
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	270
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	349
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	188
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	326
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female,	13



	Negative	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	164
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	169
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	103
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	196
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	131
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	243
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	386
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	69
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	169
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	31



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	169
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	19,285
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	2,572
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	2,572
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	2,572
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	4
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	200,206
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	27
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	6
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	14
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	1



HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	4
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	25
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	12
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	9
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	25
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	3,384
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	60
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	713
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	11
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	3,035
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	84
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	1,514
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	40
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	4,555
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	131



HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	4,891
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	141
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	45
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	2,099
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	57
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Negative	3,092
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Positive	60
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	4,798
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	89
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Negative	30
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Negative	13
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	128
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Positive	17
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	184
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Positive	23



HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	219
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	26
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	86
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	10
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	49
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	128
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	17
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Negative	86
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Positive	10
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 10-14, Negative	179
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Negative	897
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Negative	897
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Negative	108
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	427
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Positive	15
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Negative	87
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Positive	2



HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	158
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	23
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	72
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	9
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	272
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	42
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	307
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	46
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	235
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	38
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	394
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Positive	13
HTC_TST_TA	By Key Population: FSW, Negative	634
HTC_TST_TA	By Key Population: FSW, Positive	326
HTC_TST_TA	By Key Population: People in prisons and other enclosed settings, Negative	3,241
HTC_TST_TA	By Key Population: People in prisons and other enclosed settings, Positive	652
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	21,576
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	350
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	37,479
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	605



HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Negative	866
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Positive	145
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative	708
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Positive	116
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Negative	200
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Positive	30
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Negative	544
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Positive	88
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Negative	384
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Positive	61
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative	648
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Positive	102
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Negative	298
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Positive	45
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Negative	822
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Positive	137
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Negative	34



HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Negative	22
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Negative	14
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Negative	14
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Negative	14
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Negative	19
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Negative	10
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Negative	18
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Negative	585
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Positive	17
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Negative	7,414



HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Positive	225
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Negative	7,642
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Positive	229
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Negative	2,655
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Positive	73
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Negative	4,894
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Positive	141
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Negative	2,928
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Positive	82
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Negative	5,540
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Positive	161
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Negative	2,378
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Positive	64
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Negative	4,491
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Positive	128
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Negative	24,950
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Positive	398



HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Negative	10,796
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Positive	314
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Negative	11,216
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Positive	132
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Negative	7,554
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Positive	40
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Negative	202
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Positive	11
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Negative	59
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Positive	3
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Negative	382
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Positive	21
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Negative	162
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Positive	6
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Negative	477
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Positive	30
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Negative	310



HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Positive	19
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Negative	202
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Positive	11
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Negative	202
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Positive	11
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Negative	206
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Positive	12
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Negative	277
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Positive	17
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Negative	135
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Positive	6
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Negative	256
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Positive	15
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Female, Negative	5
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Negative	116
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Positive	6



HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Negative	86
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Positive	10
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	49
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Positive	5
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Negative	109
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Positive	13
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	71
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Positive	6
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Negative	136
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Positive	18
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	219
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Positive	26
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Negative	86
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Positive	10
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative	86
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Positive	10
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 25-29, Male, Negative	1,078



HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 25-29, Male, Positive	3
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 30-34, Male, Negative	144
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 35-39, Male, Negative	144
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 40-49, Male, Negative	144
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	14
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	36
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	36
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	109
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	2
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	2
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	22
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	73
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	2
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	2
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	12
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	29
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	5



HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	15
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	2
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	3
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Sex Partner	364
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest FSW, Directly-Assisted	19
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest FSW, Unassisted	55
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest MSM, Directly-Assisted	3
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest MSM, Unassisted	3
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	3,458
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	3,458
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	186
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,074
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	172
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,026
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases,	186



	during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,074
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	172
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,026
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	4,067
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	4,067
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	207
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	221
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,205
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,434
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	221
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,434
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	207



TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,205
GEND_GBVDSD	Number of people receiving post-GBV care	12,332
GEND_GBVDSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	9,639
GEND_GBVDSD	By type of service: Sexual Violence (Post-Rape Care)	2,693
GEND_GBVDSD	By PEP service provision (related to sexual violence services provided)	808
GEND_GBVDSD	<10, Female, Physical and/or Emotional Violence	128
GEND_GBVDSD	<10, Female, Sexual Violence (Post-Rape Care)	54
GEND_GBVDSD	<10, Male, Physical and/or Emotional Violence	70
GEND_GBVDSD	<10, Male, Sexual Violence (Post-Rape Care)	3
GEND_GBVDSD	10-14, Female, Physical and/or Emotional Violence	341
GEND_GBVDSD	10-14, Female, Sexual Violence (Post-Rape Care)	169
GEND_GBVDSD	10-14, Male, Physical and/or Emotional Violence	122
GEND_GBVDSD	10-14, Male, Sexual Violence (Post-Rape Care)	9
GEND_GBVDSD	15-19, Female, Physical and/or Emotional Violence	2,940
GEND_GBVDSD	15-19, Female, Sexual Violence (Post-Rape Care)	1,550
GEND_GBVDSD	15-19, Male, Physical and/or Emotional Violence	301
GEND_GBVDSD	15-19, Male, Sexual Violence (Post-Rape Care)	57
GEND_GBVDSD	20-24, Female, Physical and/or Emotional Violence	1,431
GEND_GBVDSD	20-24, Female, Sexual Violence (Post-Rape Care)	468
GEND_GBVDSD	20-24, Male, Physical and/or Emotional Violence	711
GEND_GBVDSD	20-24, Male, Sexual Violence (Post-Rape Care)	201
GEND_GBVDSD	50+, Female, Physical and/or Emotional Violence	376
GEND_GBVDSD	50+, Female, Sexual Violence (Post-Rape Care)	20
GEND_GBVDSD	50+, Male, Physical and/or Emotional Violence	232
GEND_GBVDSD	50+, Male, Sexual Violence (Post-Rape Care)	9
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	527
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	33



GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	368
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	13
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	529
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	33
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	368
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	13
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	529
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	33
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	368
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	13
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	176
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	11
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	123
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	3
OVC_SERVDSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	7,364
OVC_SERVDSD	Age/Sex: 10-14 Male	812
OVC_SERVDSD	Age/Sex: 15-17 Male	662
OVC_SERVDSD	By: Age/sex: Male 18-24	660



OVC_SERV_DSD	By: Age/sex: Male 25+	146
OVC_SERV_DSD	Age/Sex: 10-14 Female	883
OVC_SERV_DSD	Age/Sex: 15-17 Female	808
OVC_SERV_DSD	By: Age/sex: 18-24 Female	814
OVC_SERV_DSD	By: Age/sex: 25+ Female	221
OVC_SERV_DSD	Sum of Age/Sex disaggregates	3,165
OVC_SERV_DSD	Age/Sex: <1	297
OVC_SERV_DSD	Age/Sex: 1-9	2,061
OVC_SERV_DSD	Program Completion: Active	6,996
OVC_SERV_DSD	Program Completion: Graduation	368
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	5,523
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	7,364
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,288
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	66
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	724
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	71
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	427



	TB treatment during the reporting period)	
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,184
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	59
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	670
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	64
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	391
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	4,125
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	3,493
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	632
PMTCT_EID_DSD	Sum of Infant Age disaggregates	4,125
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	3,100
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	2,584
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	516
PMTCT_EID_TA	Sum of Infant Age disaggregates	3,100



TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	114,465
TX_CURR_DSD	Age/Sex: 15-19 Male	388
TX_CURR_DSD	Age/Sex: 15-19 Female	2,265
TX_CURR_DSD	Sum of age/sex disaggregates	2,653
TX_CURR_DSD	Age/Sex: <1	620
TX_CURR_DSD	Age/Sex: <1-9	3,808
TX_CURR_DSD	Age/Sex: 10-14 Male	1,329
TX_CURR_DSD	Age/Sex: 10-14 Female	3,098
TX_CURR_DSD	Age/Sex: 20-24 Male	583
TX_CURR_DSD	Age/Sex: 50+ Male	8,038
TX_CURR_DSD	Age/Sex: 20-24 Female	6,711
TX_CURR_DSD	Age/Sex: 50+ Female	12,063
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	9,580
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,688
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	13,697
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	4,015
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	11,193
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	5,249
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	16,494
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	13,646
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	5,183
TX_CURR_TA	Age/Sex: 15-19 Male	12
TX_CURR_TA	Age/Sex: 15-19 Female	94



TX_CURR_TA	Sum of Age/Sex disaggregations	106
TX_CURR_TA	Age/Sex: <1	59
TX_CURR_TA	Age/Sex: 1-9	363
TX_CURR_TA	Age/Sex: 10-14 Male	128
TX_CURR_TA	Age/Sex: 10-14 Female	296
TX_CURR_TA	Age/Sex: 20-24 Male	22
TX_CURR_TA	Age/Sex: 50+ Male	332
TX_CURR_TA	Age/Sex: 20-24 Female	280
TX_CURR_TA	Age/Sex: 50+ Female	496
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	393
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	67
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	562
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	168
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	461
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	215
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	675
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	560
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	13,727
TX_NEW_DSD	By Age/Sex: <1	79
TX_NEW_DSD	By Age/Sex: 1-9	486
TX_NEW_DSD	By Age/Sex: 10-14 Male	111
TX_NEW_DSD	By Age/Sex: 15-19 Male	278
TX_NEW_DSD	By Age/Sex: 20-24 Male	696
TX_NEW_DSD	By Age/Sex: 50+ Male	516



TX_NEW_DSD	By Age/Sex: 10-14 Female	453
TX_NEW_DSD	By Age/Sex: 15-19 Female	846
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,572
TX_NEW_DSD	By Age/Sex: 50+ Female	31
TX_NEW_DSD	Sum of Age/Sex disaggregates	4,503
TX_NEW_DSD	Pregnancy status	1,262
TX_NEW_DSD	Breastfeeding status	1,262
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	1,940
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,295
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	849
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	859
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	881
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,162
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	595
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	1,078
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	525
TX_NEW_TA	By Age/Sex: <1	4
TX_NEW_TA	By Age/Sex: 1-9	19
TX_NEW_TA	By Age/Sex: 10-14 Male	6
TX_NEW_TA	By Age/Sex: 15-19 Male	7
TX_NEW_TA	By Age/Sex: 20-24 Male	23
TX_NEW_TA	By Age/Sex: 50+ Male	18
TX_NEW_TA	By Age/Sex: 10-14 Female	19
TX_NEW_TA	By Age/Sex: 15-19 Female	30



TX_NEW_TA	By Age/Sex: 20-24 Female	55
TX_NEW_TA	By Age/Sex: 50+ Female	1
TX_NEW_TA	Sum of Age/Sex disaggregates	159
TX_NEW_TA	Pregnancy status	47
TX_NEW_TA	Breastfeeding status	47
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	102
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	47
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	30
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	30
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	32
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	41
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	21
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	40
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	103,020
TX_PVLS_DSD	Denominator: Indication: Routine	89,631
TX_PVLS_DSD	Denominator: Indication: Targeted	13,389
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	283
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	4,003
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	567
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	8,536



TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	2,062
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	26,787
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	4,119
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	56,663
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	4,664
TX_PVLS_TA	Denominator: Indication: Routine	4,055
TX_PVLS_TA	Denominator: Indication: Targeted	609
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	189
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	24
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	93
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	10
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	2,562
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	391
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	1,211
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	184
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	32,329
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	35,917



	stopped ART, and those lost to follow-up	
TX_RET_DSD	Numerator by Status: Pregnant	3,055
TX_RET_DSD	Numerator by Status: Breastfeeding	3,055
TX_RET_DSD	Denominator by Status: Pregnant	3,392
TX_RET_DSD	Denominator by Status: Breastfeeding	3,392
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	630
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	14,349
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,164
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	16,186
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	697
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	15,945
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,293
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	17,982



	including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,148
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,391
TX_RET_TA	Numerator by Status: Pregnant	189
TX_RET_TA	Numerator by Status: Breastfeeding	189
TX_RET_TA	Denominator by Status: Pregnant	211
TX_RET_TA	Denominator by Status: Breastfeeding	211
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	87
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	894
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	163
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,004
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	97
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	993
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total	182



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,119
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	195
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	513
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	514
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	1,536
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	25
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	25
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	308
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	1,025
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	25
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	25
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	176
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	408
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39,	71



	Female, Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	205
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	51
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	5,121
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	256
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted	769
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	51
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Unassisted	51
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	17,338
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	20,397
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	1,227
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	818
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	12,439
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	5,913
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	1,040
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	691



TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	10,575
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	5,032
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	17,743
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	2,042
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	532
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	80
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	15,083
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	1,735
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	452
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	68
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	784
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	923
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	53
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	37
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	564



TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	269
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	48
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	33
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	479
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	224
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	804
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	91
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	23
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	5
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	682
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	77
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	20
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	5
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	114,465
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	6,866
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	4,577
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	69,824
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	33,198
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	4,577
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	230



TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	917
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	3,430
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	99,580
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	2,977
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	11,449
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	459
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	5,183
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	314
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	208
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	3,160
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	1,501
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	208
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	9
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	41
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	158
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	4,510
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	135
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	518
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV	20



	Life-long ART, New, TB Screen - Positive, Positive	
--	--	--

Implementing Mechanism Details

Mechanism ID: 17855	Mechanism Name: Comprehensive HIV/AIDS Prevention, Care, Treatment and Support Project with the Uganda People Defense Forces	
Funding Agency: DOD	Procurement Type: Grant	
Prime Partner Name: Research Triangle International		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17855	
Mechanism Name:	Comprehensive HIV/AIDS Prevention, Care, Treatment and Support Project with the Uganda People Defense Forces	
Prime Partner Name:	Research Triangle International	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17874	Mechanism Name: NAMERU
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: National Medical Research Unit	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17874 Mechanism Name: NAMERU Prime Partner Name: National Medical Research Unit		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 17976	Mechanism Name: Supporting Laboratory Strengthening Activities in Resource-Limited Countries Under the President's Emergency Plan for AIDS Relief	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Association of Public Health Laboratories		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17976	
Mechanism Name:	Supporting Laboratory Strengthening Activities in Resource-Limited Countries Under the President's Emergency Plan for AIDS Relief	
Prime Partner Name:	Association of Public Health Laboratories	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17977	Mechanism Name: Biomedical Engineering Support for Equipment Maintenance and Training in Clinical Laboratory Sites Providing HIV/AIDS Care and Treatment
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: American International Health Alliance Twinning Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 350,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	



Total All Funding Sources and Applied Pipeline Amount: 350,000	
Funding Source	Funding Amount
GHP-State	350,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17977 Mechanism Name: Biomedical Engineering Support for Equipment Maintenance and Training in Clinical Laboratory Sites Providing HIV/AIDS Prime Partner Name: Care and Treatment American International Health Alliance Twinning Center		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	350,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount



Treatment	PDTX	0
-----------	------	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17978	Mechanism Name: Acceleration of Regional Comprehensive HIV & AIDS Service Delivery through HSS
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Infectious Disease Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 21,287,615	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 704,490	
Total All Funding Sources and Applied Pipeline Amount: 21,992,105	
Funding Source	Funding Amount
GHP-State	21,287,615

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	100,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Gender: GBV	250,000
Focus Area:	GBV Prevention
Motor Vehicles: Purchased	53,433



Water	351,182
Renovation	45,000

Budget Code Information

Mechanism ID:	17978	
Mechanism Name:	Acceleration of Regional Comprehensive HIV & AIDS Service	
Prime Partner Name:	Delivery through HSS Infectious Disease Institute	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	3,210,212
Strategic Area	Budget Code	Planned Amount
Care	HKID	2,429,967
Strategic Area	Budget Code	Planned Amount
Care	HVTB	895,919
Strategic Area	Budget Code	Planned Amount
Care	PDCS	1,375,736
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	297,700
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	1,428,110
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	1,116,419
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	1,135,849
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	233,553
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	806,877
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	7,941,364
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	415,909

Implementing Mechanism Indicator Information



Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	11,737
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	137,866
PMTCT_ART_DSD	New on ART	4,128
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	7,609
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	1,965
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	22,974
PMTCT_ART_TA	New on ART	627
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	1,338
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	137,866
PMTCT_STAT_DSD	Number of new ANC and L&D clients	137,866
PMTCT_STAT_DSD	By Age (Denominator): <15-19	26,193
PMTCT_STAT_DSD	By Age (Denominator): 20-24	45,497
PMTCT_STAT_DSD	By Number of known positives: 15-19	39
PMTCT_STAT_DSD	By Number of known positives: 20-24	230
PMTCT_STAT_DSD	By Number of new positives: 15-19	834
PMTCT_STAT_DSD	By Number of new positives: 20-24	1,443
PMTCT_STAT_DSD	By Number of new negative: 15-19	25,320
PMTCT_STAT_DSD	By Number of new negative: 20-24	43,824
PMTCT_STAT_DSD	By Age (Numerator): 15-19	26,193
PMTCT_STAT_DSD	By Age (Numerator): 20-24	45,497
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	30,331



PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	23,437
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	9,654
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	2,754
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	3,524
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	25,843
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	964
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	2,725
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	19,969
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	743
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	1,128
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	8,222
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	304
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	333
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	2,328
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	93
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	30,331
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	23,437
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	9,654
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	2,754
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	22,974



PMTCT_STAT_TA	Number of new ANC and L&D clients	22,974
PMTCT_STAT_TA	By Age (Denominator): 15-19	4,367
PMTCT_STAT_TA	By Age (Denominator): 20-24	7,581
PMTCT_STAT_TA	By known positives: 15-19	6
PMTCT_STAT_TA	By known positives: 20-24	39
PMTCT_STAT_TA	By new positives: 15-19	125
PMTCT_STAT_TA	By new positives: 20-24	221
PMTCT_STAT_TA	By new negatives: 15-19	4,236
PMTCT_STAT_TA	By new negatives: 20-24	7,321
PMTCT_STAT_TA	By Age (Numerator): : 15-19	4,367
PMTCT_STAT_TA	By Age (Numerator): 20-24	7,581
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 25-29, Female	5,056
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 30-34, Female	3,902
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 35-39, Female	1,608
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 40-49, Female	460
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	616
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	4,296
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	144
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	478
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	3,312
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	112
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	199
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	1,366
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	43



PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	58
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	390
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	12
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 25-29, Female	5,056
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 30-34, Female	3,902
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 35-39, Female	1,608
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 40-49, Female	460
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	83,739
VMMC_CIRC_DSD	By Age: 10-14	4,187
VMMC_CIRC_DSD	By Age: 15-19	20,935
VMMC_CIRC_DSD	By Age: 20-24	20,935
VMMC_CIRC_DSD	By Age: 25-29	25,123
VMMC_CIRC_DSD	By Age: 50+	2,509
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	48,566
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	73,689
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	83,739
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	3,350
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	3,350
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	3,350
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	4,393
PrEP_NEW_DSD	Male 15-19	45
PrEP_NEW_DSD	Male 20-24	307
PrEP_NEW_DSD	Male 50+	87
PrEP_NEW_DSD	Female 15-19	264
PrEP_NEW_DSD	Female 20-24	1,013
PrEP_NEW_DSD	Female 50+	45



PrEP_NEW_DSD	FSW	3,084
PrEP_NEW_DSD	MSM	172
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	439
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	219
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	439
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	219
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	439
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	219
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	439
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	219
PrEP_NEW_DSD	PrEP_NEW_N_DSD_KeyPopAbr Other Key Populations	27
PrEP_NEW_TA	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	2,175
PrEP_NEW_TA	Male 15-19	22
PrEP_NEW_TA	Male 20-24	152
PrEP_NEW_TA	Male 50+	43
PrEP_NEW_TA	Female 15-19	130
PrEP_NEW_TA	Female 20-24	498
PrEP_NEW_TA	Female 50+	22
PrEP_NEW_TA	FSW	1,528
PrEP_NEW_TA	MSM	85
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 25-29, Female	218
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 25-29, Male	109
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 30-34, Female	218
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 30-34, Male	109
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 35-39, Female	218
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 35-39, Male	109
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 40-49, Female	218
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 40-49, Male	109
PrEP_NEW_TA	PrEP_NEW_N_TA_KeyPopAbr Other Key Populations	13



PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	100,188
PP_PREV_DSD	Age/sex: 15-19 Male	2,022
PP_PREV_DSD	Age/sex: 20-24 Male	5,392
PP_PREV_DSD	Age/sex: 50+ Male	6,086
PP_PREV_DSD	Age/sex: 15-19 Female	7,228
PP_PREV_DSD	Age/sex: 20-24 Female	7,430
PP_PREV_DSD	Age/sex: 50+ Female	3,246
PP_PREV_DSD	Sum of Age/Sex disaggregates	31,404
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	5,632
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	10,039
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	5,463
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	9,739
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	6,342
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	11,300
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	7,289
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	12,980
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	37,758
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	749
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	5,934
KP_PREV_DSD	By key population type: Transgender who are sex workers (Numerator: Number of key populations	102



	reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	445
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	29,908
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	522
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	98
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	484,584
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	6,563
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	205
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	1,395
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19,	1,196



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	61
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	393
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	2,208
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	118
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	989
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	49
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	27
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	746
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	6,113
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	198
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	1,143
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	48
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	570
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	22
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	758



	20-24, Female, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	35
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	2,114
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	89
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	20
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	2,393
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	102
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	12,157
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	245
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	2,572
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	51
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	6,157
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	189
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	3,077
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	100
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	9,250
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	290



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	9,938
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	312
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	111
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	4,266
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	142
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	11,135
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	245
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	17,235
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	355
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	98
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	46
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	48
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	329
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	158
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	454
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	236



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	553
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	274
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	239
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	115
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	142
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	70
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	329
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	158
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	239
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	115
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	3,861
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	19,301
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	125
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	19,301
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	125
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	2,316
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	1,583
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	87



HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	333
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	334
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	56
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	166
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	550
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	101
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	617
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	109
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	474
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	84
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	1,438
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	79
HTC_TST_DSD	By Key Population: FSW, Negative	13,879
HTC_TST_DSD	By Key Population: FSW, Positive	6,436
HTC_TST_DSD	By Key Population: MSM, Negative	1,878
HTC_TST_DSD	By Key Population: MSM, Positive	453



HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	30,888
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	4,800
HTC_TST_DSD	By Key Population: PWID, Negative	2,297
HTC_TST_DSD	By Key Population: PWID, Positive	581
HTC_TST_DSD	By Key Population: TG, Negative	228
HTC_TST_DSD	By Key Population: TG, Positive	142
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	1,653
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	90
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	345
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	21
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	273
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	47
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	133
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	25
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	178
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	35
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	503
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	91
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	16



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	561
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	100
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	1,506
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	81
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	23,860
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	834
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	41,442
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	1,444
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	1,706
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	303
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	1,399
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	251
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	410
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	73
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	1,087
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	191
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	770
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	138



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	1,286
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	230
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	596
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	108
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	1,618
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	286
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	2,750
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	147
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	1,819
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	96
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	1,193
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	61
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	1,207
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	1,239
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	66
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	1,627



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	84
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	838
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	1,522
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	84
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	5,895
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	247
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	4,837
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	207
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	1,406
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	55
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	3,731
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	156
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	2,646
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	109
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	4,431
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	188



HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	2,429
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	101
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	5,576
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	235
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	2,109
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	90
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	1,387
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	248
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	1,144
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	208
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	333
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	53
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	880
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	158
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	626
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	108
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	1,044



HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	187
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	571
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	98
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	1,289
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	235
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	15,066
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	468
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	15,500
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	481
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	5,391
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	168
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	9,945
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	312
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	5,951
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	184
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	11,247
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	347

HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	4,825
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	152
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	9,120
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	282
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	27,585
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	949
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	11,937
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	734
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	12,398
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	319
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	8,349
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	103
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	436
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	144
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	801



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	63
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	364
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	993
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	80
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	669
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	436
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	35
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	440
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	453
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	596
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	46
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	307
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	28



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	558
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	20
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	257
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	239
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	115
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	142
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	70
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	283
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	133
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	185
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	94
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	343
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	167
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	553



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	274
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	239
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	115
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	239
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	115
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	23,170
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	151
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	3,085
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	3,085
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	3,085
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	27
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	41,675
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	361
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	10
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male,	75



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	126
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	40
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	235
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	11
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	102
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	81
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	332
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Positive	9
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	490
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	102
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	1



	Male, Positive	
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	425
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	12
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	213
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	642
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	18
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	687
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	19
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	5
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	298
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Negative	451
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	697
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	11
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female,	18



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	25
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Positive	11
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	33
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	12
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	11
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	4
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	18
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Negative	11
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 10-14, Negative	298
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 10-14, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Negative	1,487
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Positive	16
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Negative	1,487
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Positive	16
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Negative	179



HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	60
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Negative	10
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	20
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	9
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	37
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	40
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	29
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	57
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Positive	2
HTC_TST_TA	By Key Population: FSW, Negative	1,055



HTC_TST_TA	By Key Population: FSW, Positive	497
HTC_TST_TA	By Key Population: MSM, Negative	132
HTC_TST_TA	By Key Population: MSM, Positive	20
HTC_TST_TA	By Key Population: People in prisons and other enclosed settings, Negative	2,338
HTC_TST_TA	By Key Population: People in prisons and other enclosed settings, Positive	344
HTC_TST_TA	By Key Population: PWID, Negative	248
HTC_TST_TA	By Key Population: PWID, Positive	55
HTC_TST_TA	By Key Population: TG, Negative	3
HTC_TST_TA	By Key Population: TG, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	3,964
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	125
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	6,880
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	220
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Negative	117
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Positive	18
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative	98
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Positive	16
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Negative	23
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Negative	74
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Positive	12
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Negative	52



HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Positive	6
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative	87
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Positive	14
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Negative	40
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Positive	5
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Negative	111
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Positive	18
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Negative	291
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Positive	15
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Negative	192
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Positive	8
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Negative	125
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Positive	5
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Negative	127
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Positive	5
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Negative	131
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Positive	5



HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Negative	171
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Positive	7
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Negative	90
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Negative	159
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Positive	8
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Negative	84
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Positive	3
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Negative	1,045
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Positive	29
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Negative	1,077
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Positive	32
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Negative	374
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Positive	10
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Negative	687
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Positive	19
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Negative	414



HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Positive	11
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Negative	780
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Positive	20
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Negative	336
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Positive	7
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Negative	632
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Positive	18
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Negative	4,582
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Positive	141
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Negative	1,982
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Positive	110
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Negative	2,059
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Positive	45
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Negative	1,389
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Positive	13
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Negative	25
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Positive	2



HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Negative	6
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Negative	54
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Positive	3
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Negative	21
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Negative	67
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Positive	3
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Negative	43
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Negative	26
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Negative	26
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Negative	28
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Negative	40



HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Negative	18
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Negative	37
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Female, Negative	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Negative	16
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Negative	11
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Positive	4
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	4
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Negative	13
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Positive	6
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	9
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Positive	3
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Negative	21



HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Positive	7
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	33
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Positive	12
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Negative	11
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Positive	4
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative	11
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Positive	4
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 25-29, Male, Negative	1,784
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 25-29, Male, Positive	19
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 30-34, Male, Negative	239
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 35-39, Male, Negative	239
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 40-49, Male, Negative	239
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 40-49, Male, Positive	2
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	6
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	17

HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	17
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	52
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	10
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	35
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	6
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	13
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	2
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	7
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	2
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Sex Partner	175
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest FSW, Directly-Assisted	9
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest FSW, Unassisted	27
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest MSM, Directly-Assisted	2
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest MSM, Unassisted	2
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	9,441
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	9,441
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with	509



	documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5,659
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	479
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,794
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	509
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	5,659
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	479
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,794
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	320
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	320
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	17
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	18
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	95



TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	190
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	18
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	190
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	17
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	95
GEND_GBV_DSD	Number of people receiving post-GBV care	11,358
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	8,970
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	2,388
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	715
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	118
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	48
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	65
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	6
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	316
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	149
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	113
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	9
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	2,746
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	1,371
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	279
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	51



GEND_GBVDSD	20-24, Female, Physical and/or Emotional Violence	1,335
GEND_GBVDSD	20-24, Female, Sexual Violence (Post-Rape Care)	417
GEND_GBVDSD	20-24, Male, Physical and/or Emotional Violence	664
GEND_GBVDSD	20-24, Male, Sexual Violence (Post-Rape Care)	177
GEND_GBVDSD	50+, Female, Physical and/or Emotional Violence	348
GEND_GBVDSD	50+, Female, Sexual Violence (Post-Rape Care)	18
GEND_GBVDSD	50+, Male, Physical and/or Emotional Violence	214
GEND_GBVDSD	50+, Male, Sexual Violence (Post-Rape Care)	9
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	491
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	29
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	340
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	11
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	491
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	29
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	340
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	11
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	491
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	29
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	340
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	11
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	164



GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	10
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	114
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	4
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	37,395
OVC_SERV_DSD	Age/Sex: 10-14 Male	4,113
OVC_SERV_DSD	Age/Sex: 15-17 Male	3,365
OVC_SERV_DSD	By: Age/sex: Male 18-24	3,364
OVC_SERV_DSD	By: Age/sex: Male 25+	748
OVC_SERV_DSD	Age/Sex: 10-14 Female	4,487
OVC_SERV_DSD	Age/Sex: 15-17 Female	4,115
OVC_SERV_DSD	By: Age/sex: 18-24 Female	4,116
OVC_SERV_DSD	By: Age/sex: 25+ Female	1,121
OVC_SERV_DSD	Sum of Age/Sex disaggregates	16,080
OVC_SERV_DSD	Age/Sex: <1	1,496
OVC_SERV_DSD	Age/Sex: 1-9	10,470
OVC_SERV_DSD	Program Completion: Active	35,526
OVC_SERV_DSD	Program Completion: Graduation	1,869
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	28,047
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	37,395
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	4,700
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	246



	TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2,637
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	264
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,553
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	155
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	94
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	49
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	11,737
PMTCT_EID_DSD	By infants who received a virologic test within 2 months	9,884



	of birth	
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,853
PMTCT_EID_DSD	Sum of Infant Age disaggregates	11,737
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,965
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	1,644
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	321
PMTCT_EID_TA	Sum of Infant Age disaggregates	1,965
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	217,498
TX_CURR_DSD	Age/Sex: 15-19 Male	1,444
TX_CURR_DSD	Age/Sex: 15-19 Female	5,129
TX_CURR_DSD	Sum of age/sex disaggregates	6,573
TX_CURR_DSD	Age/Sex: <1	1,862
TX_CURR_DSD	Age/Sex: <1-9	6,876
TX_CURR_DSD	Age/Sex: 10-14 Male	3,068
TX_CURR_DSD	Age/Sex: 10-14 Female	5,884
TX_CURR_DSD	Age/Sex: 20-24 Male	1,494
TX_CURR_DSD	Age/Sex: 50+ Male	14,915
TX_CURR_DSD	Age/Sex: 20-24 Female	13,074
TX_CURR_DSD	Age/Sex: 50+ Female	22,340
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	18,226
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	3,284
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	25,662
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	7,492
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39,	20,950



	Female, Positive	
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	9,754
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	30,741
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	25,303
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	5,132
TX_CURR_TA	Age/Sex: 15-19 Male	15
TX_CURR_TA	Age/Sex: 15-19 Female	100
TX_CURR_TA	Sum of Age/Sex disaggregations	115
TX_CURR_TA	Age/Sex: <1	23
TX_CURR_TA	Age/Sex: 1-9	150
TX_CURR_TA	Age/Sex: 10-14 Male	52
TX_CURR_TA	Age/Sex: 10-14 Female	122
TX_CURR_TA	Age/Sex: 20-24 Male	24
TX_CURR_TA	Age/Sex: 50+ Male	366
TX_CURR_TA	Age/Sex: 20-24 Female	304
TX_CURR_TA	Age/Sex: 50+ Female	546
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	433
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	75
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	621
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	181
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	506
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	237
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female,	758



	Positive	
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	619
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	18,755
TX_NEW_DSD	By Age/Sex: <1	186
TX_NEW_DSD	By Age/Sex: 1-9	760
TX_NEW_DSD	By Age/Sex: 10-14 Male	243
TX_NEW_DSD	By Age/Sex: 15-19 Male	425
TX_NEW_DSD	By Age/Sex: 20-24 Male	951
TX_NEW_DSD	By Age/Sex: 50+ Male	682
TX_NEW_DSD	By Age/Sex: 10-14 Female	720
TX_NEW_DSD	By Age/Sex: 15-19 Female	1,185
TX_NEW_DSD	By Age/Sex: 20-24 Female	2,107
TX_NEW_DSD	By Age/Sex: 50+ Female	47
TX_NEW_DSD	Sum of Age/Sex disaggregates	6,360
TX_NEW_DSD	Pregnancy status	1,714
TX_NEW_DSD	Breastfeeding status	1,714
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	2,570
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,703
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	1,138
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,129
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	1,171
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,517
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	803
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male,	1,418



	Positive	
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	436
TX_NEW_TA	By Age/Sex: <1	1
TX_NEW_TA	By Age/Sex: 1-9	13
TX_NEW_TA	By Age/Sex: 10-14 Male	1
TX_NEW_TA	By Age/Sex: 15-19 Male	5
TX_NEW_TA	By Age/Sex: 20-24 Male	22
TX_NEW_TA	By Age/Sex: 50+ Male	15
TX_NEW_TA	By Age/Sex: 10-14 Female	13
TX_NEW_TA	By Age/Sex: 15-19 Female	25
TX_NEW_TA	By Age/Sex: 20-24 Female	47
TX_NEW_TA	Sum of Age/Sex disaggregates	128
TX_NEW_TA	Pregnancy status	40
TX_NEW_TA	Breastfeeding status	40
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	90
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	40
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	25
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	25
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	27
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	37
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	16
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	34
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record	195,752



	and /or laboratory records in the past 12 months.	
TX_PVLS_DSD	Denominator: Indication: Routine	170,309
TX_PVLS_DSD	Denominator: Indication: Targeted	25,443
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	531
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	7,616
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	1,078
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	16,218
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	3,915
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	50,895
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	7,831
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	107,668
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	4,617
TX_PVLS_TA	Denominator: Indication: Routine	4,013
TX_PVLS_TA	Denominator: Indication: Targeted	604
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	183
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	24
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	92
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	11
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	2,538



TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	391
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	1,200
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	178
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	41,539
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	46,153
TX_RET_DSD	Numerator by Status: Pregnant	4,059
TX_RET_DSD	Numerator by Status: Breastfeeding	4,059
TX_RET_DSD	Denominator by Status: Pregnant	4,508
TX_RET_DSD	Denominator by Status: Breastfeeding	4,508
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	342
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	19,069
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	628
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	21,500
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	377
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total	21,191



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	697
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	23,888
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	930
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,033
TX_RET_TA	Numerator by Status: Pregnant	89
TX_RET_TA	Numerator by Status: Breastfeeding	89
TX_RET_TA	Denominator by Status: Pregnant	101
TX_RET_TA	Denominator by Status: Breastfeeding	101
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	427
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	14
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on	485



	treatment at 12 months after initiating ART)	
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	471
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	17
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	539
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	1,357
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	3,573
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	3,551
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	10,718
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	185
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	185
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	2,141



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	7,146
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	185
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	185
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	1,213
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	2,860
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	502
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	1,427
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	147
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	361
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	35,727
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	1,786
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted	5,354
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	361
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Unassisted	361
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	32,943
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly	38,754



	started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	2,327
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	1,550
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	23,641
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	11,236
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	1,977
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	1,319
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	20,091
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	9,556
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	33,711
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	3,875
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	1,009
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	159
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	28,653
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	3,294
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	860
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	136
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting	777

	period	
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	916
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	55
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	37
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	557
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	267
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	46
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	29
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	479
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	223
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	801
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	92
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	23
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	681
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	78
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	18
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	217,498
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	13,048
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	8,701



TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	132,670
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	63,079
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	8,701
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	434
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	1,745
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	6,522
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	189,215
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	5,658
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	21,749
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	876
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	5,132
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	307
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	206
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	3,130
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	1,489
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	206
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	6
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	40
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	160



TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	4,470
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	132
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	511
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	19

Implementing Mechanism Details

Mechanism ID: 17979	Mechanism Name: To support the centralized procurement; warehousing and distribution of HIV/AIDS related commodities for CDC funded programs in Uganda
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Medical Access Uganda Limited (MAUL)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 64,424,150	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 64,424,150	
Funding Source	Funding Amount
GHP-State	64,424,150

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	267,000
Water	457,441



Budget Code Information

Mechanism ID:	17979	
Mechanism Name:	To support the centralized procurement; warehousing and distribution of HIV/AIDS related commodities for CDC funded programs in Uganda	
Prime Partner Name:	Medical Access Uganda Limited (MAUL)	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	1,696,740
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	1,024,420
Strategic Area	Budget Code	Planned Amount
Care	PDCS	1,693,326
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	10,196,775
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	2,451,001
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	60,197
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	265,323
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	36,413,621
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	10,622,747
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18003	Mechanism Name: Technical assistance for strengthening national laboratory systems in Uganda under the President's Emergency Plan
----------------------------	--



	for AIDS Relief
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Global Healthcare Public Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,030,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,030,000	
Funding Source	Funding Amount
GHP-State	1,030,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18003	
Mechanism Name:	Technical assistance for strengthening national laboratory systems in Uganda under the President's Emergency Plan for	
Prime Partner Name:	AIDS Relief Global Healthcare Public Foundation	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount



Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	1,030,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0



Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18017	Mechanism Name: EGPAF: HQ Technical Assistance CoAg
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

Approved



(No data provided.)

Budget Code Information

Mechanism ID: 18017		
Mechanism Name: EGPAF: HQ Technical Assistance CoAg		
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details



Mechanism ID: 18032	Mechanism Name: Acceleration of Regional Comprehensive HIV & AIDS Service Delivery through HSS
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Rakai Health Sciences Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 15,680,468	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 1,500,000	
Total All Funding Sources and Applied Pipeline Amount: 17,180,468	
Funding Source	Funding Amount
GHP-State	15,680,468

Cross-Cutting Budget Attribution(s)

Gender: GBV	800,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Gender: Gender Equality	300,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Water	329,857
Renovation	236,942
Adolescent Girls and Young Women (AGYW)	3,216,571
Motor Vehicles: Purchased	349,313



Budget Code Information

Mechanism ID:	18032	
Mechanism Name:	Acceleration of Regional Comprehensive HIV & AIDS Service	
Prime Partner Name:	Delivery through HSS	
	Rakai Health Sciences Program	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	1,820,072
Strategic Area	Budget Code	Planned Amount
Care	HKID	1,404,198
Strategic Area	Budget Code	Planned Amount
Care	HVTB	497,855
Strategic Area	Budget Code	Planned Amount
Care	PDCS	780,127
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	150,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	1,069,943
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	1,002,683
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	3,206,705
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	782,470
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	4,687,570
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	278,845

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission	3,745



	(MTCT) during pregnancy	
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	38,604
PMTCT_ART_DSD	New on ART	1,076
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,669
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	4,818
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	46,870
PMTCT_ART_TA	New on ART	1,349
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	3,469
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	38,604
PMTCT_STAT_DSD	Number of new ANC and L&D clients	38,604
PMTCT_STAT_DSD	By Age (Denominator): <15-19	7,331
PMTCT_STAT_DSD	By Age (Denominator): 20-24	12,744
PMTCT_STAT_DSD	By Number of known positives: 15-19	16
PMTCT_STAT_DSD	By Number of known positives: 20-24	79
PMTCT_STAT_DSD	By Number of new positives: 15-19	228
PMTCT_STAT_DSD	By Number of new positives: 20-24	395
PMTCT_STAT_DSD	By Number of new negative: 15-19	7,087
PMTCT_STAT_DSD	By Number of new negative: 20-24	12,270
PMTCT_STAT_DSD	By Age (Numerator): 15-19	7,331
PMTCT_STAT_DSD	By Age (Numerator): 20-24	12,744
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	8,494
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	6,565
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	2,701
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	769
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult	1,212



	25-29, Female, Known at Entry Positive	
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	7,017
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	265
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	941
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	5,420
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	204
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	391
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	2,225
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	85
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	115
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	631
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	23
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	8,494
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	6,565
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	2,701
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	769
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	46,870
PMTCT_STAT_TA	Number of new ANC and L&D clients	46,870
PMTCT_STAT_TA	By Age (Denominator): 15-19	8,909
PMTCT_STAT_TA	By Age (Denominator): 20-24	15,465
PMTCT_STAT_TA	By known positives: 15-19	15



PMTCT_STAT_TA	By known positives: 20-24	107
PMTCT_STAT_TA	By new positives: 15-19	281
PMTCT_STAT_TA	By new positives: 20-24	489
PMTCT_STAT_TA	By new negatives: 15-19	8,613
PMTCT_STAT_TA	By new negatives: 20-24	14,869
PMTCT_STAT_TA	By Age (Numerator): : 15-19	8,909
PMTCT_STAT_TA	By Age (Numerator): 20-24	15,465
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 25-29, Female	10,310
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 30-34, Female	7,966
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 35-39, Female	3,280
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 40-49, Female	940
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	1,586
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	8,400
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	324
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	1,222
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	6,492
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	252
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	507
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	2,669
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	104
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	146
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	765



PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	29
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 25-29, Female	10,310
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 30-34, Female	7,966
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 35-39, Female	3,280
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 40-49, Female	940
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	63,402
VMMC_CIRC_DSD	By Age: 10-14	3,169
VMMC_CIRC_DSD	By Age: 15-19	15,854
VMMC_CIRC_DSD	By Age: 20-24	15,854
VMMC_CIRC_DSD	By Age: 25-29	19,021
VMMC_CIRC_DSD	By Age: 50+	1,896
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	36,773
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	55,794
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	63,052
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	350
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	2,536
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	2,536
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	2,536
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	528
PrEP_NEW_DSD	Male 15-19	5
PrEP_NEW_DSD	Male 20-24	37
PrEP_NEW_DSD	Male 50+	11
PrEP_NEW_DSD	Female 15-19	32
PrEP_NEW_DSD	Female 20-24	122
PrEP_NEW_DSD	Female 50+	5
PrEP_NEW_DSD	FSW	371
PrEP_NEW_DSD	MSM	21



PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	53
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	26
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	53
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	26
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	53
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	26
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	53
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	26
PrEP_NEW_DSD	PrEP_NEW_N_DSD_KeyPopAbr Other Key Populations	3
PrEP_NEW_TA	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	851
PrEP_NEW_TA	Male 15-19	9
PrEP_NEW_TA	Male 20-24	60
PrEP_NEW_TA	Male 50+	17
PrEP_NEW_TA	Female 15-19	51
PrEP_NEW_TA	Female 20-24	193
PrEP_NEW_TA	Female 50+	9
PrEP_NEW_TA	FSW	596
PrEP_NEW_TA	MSM	34
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 25-29, Female	85
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 25-29, Male	43
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 30-34, Female	85
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 30-34, Male	43
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 35-39, Female	85
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 35-39, Male	43
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 40-49, Female	85
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 40-49, Male	43
PrEP_NEW_TA	PrEP_NEW_N_TA_KeyPopAbr Other Key Populations	5
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the	34,054



	minimum components during the reporting period.	
PP_PREV_DSD	Age/sex: 15-19 Male	1,125
PP_PREV_DSD	Age/sex: 20-24 Male	2,162
PP_PREV_DSD	Age/sex: 50+ Male	794
PP_PREV_DSD	Age/sex: 15-19 Female	4,029
PP_PREV_DSD	Age/sex: 20-24 Female	2,973
PP_PREV_DSD	Age/sex: 50+ Female	452
PP_PREV_DSD	Sum of Age/Sex disaggregates	11,535
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	2,303
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	4,108
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	2,298
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	4,103
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	1,443
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	2,587
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	2,038
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	3,639
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	13,024
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	8,148
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,876
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	245,403
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14,	3,206



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	98
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	682
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	1,048
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	57
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	341
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	1,945
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	102
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	872
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	48
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	22
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	658
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	2,926
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	98
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	1,074
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	43



	15-19, Female, Positive	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	538
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	23
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	716
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	29
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	1,992
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	82
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	15
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	2,257
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	94
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	3,568
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	74
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	751
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	3,701
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	117
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	1,845
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	62



	Male, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	5,556
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	172
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	5,965
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	184
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	69
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	2,563
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	83
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	3,265
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	74
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	5,061
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	107
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	29
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	92
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	55



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	142
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	82
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	157
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	94
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	69
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	44
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	92
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	55
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	69
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	1,936
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	9,680
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	79
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	9,680
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	79
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	1,162
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	9



HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	466
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	26
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	103
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	197
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	100
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	330
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	63
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	366
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	68
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	284
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	56
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	425
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	24
HTC_TST_DSD	By Key Population: FSW, Negative	1,946
HTC_TST_DSD	By Key Population: FSW, Positive	998



HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	5,965
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	1,289
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	999
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	52
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	213
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	254
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	43
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	127
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	23
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	170
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	29
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	469
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	82
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	533
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	94



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	916
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	48
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	6,714
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	234
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	11,662
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	404
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	1,031
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	181
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	839
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	149
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	244
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	49
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	644
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	117
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	459
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	85
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	769
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	138
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	358



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	68
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	970
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	172
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	2,426
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	127
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	1,600
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	85
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	1,049
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	57
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	1,062
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	57
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	1,088
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	58
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	1,437
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	77
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	734
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	39



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	1,336
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	71
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	5,564
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	232
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	4,563
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	190
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	1,326
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	56
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	3,521
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	147
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	2,501
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	105
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	4,183
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	173
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	2,294
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	97
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	5,293

HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	219
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	619
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	1,314
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	232
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	1,077
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	190
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	314
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	56
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	832
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	147
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	591
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	105
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	987
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	173
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	542
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	97



HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	1,260
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	219
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	9,043
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	280
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	9,314
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	287
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	3,237
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	101
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	5,969
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	184
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	3,571
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	113
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	6,753
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	210
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	2,901
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	92
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	5,474

HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	171
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	7,761
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	263
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	3,357
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	206
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	3,490
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	89
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	2,351
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	260
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	88
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	484
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	216
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	20



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	607
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	52
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	399
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	260
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	265
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	270
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	356
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	182
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	332
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	12



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	160
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	69
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	44
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	81
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	46
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	55
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	99
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	60
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	157
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	94
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	69
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	69



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	11,614
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	93
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	1,549
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	1,549
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	1,549
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	13
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	146,082
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	1,060
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	33
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	224
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	221
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	12
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male,	72



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	410
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	21
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	182
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	9
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	6
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	137
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	968
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Positive	32
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	4,143
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	75
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	876
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	14
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	2,522
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	77
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19,	1,263



	Male, Negative	
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	34
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	3,794
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	117
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	4,072
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	127
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	41
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	1,749
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	49
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Negative	3,794
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Positive	75
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	5,870
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	115
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Negative	22
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Positive	13
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Negative	9
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female,	86



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Positive	54
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	123
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Positive	80
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	151
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	91
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	59
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	39
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	34
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	20
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	86
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	54
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Negative	59
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Positive	39
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 10-14, Negative	1,208
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 10-14, Positive	11
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Negative	6,041
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Positive	50
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Negative	6,041
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Positive	50
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Negative	725



HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	527
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Positive	25
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Negative	109
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	136
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	20
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	67
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	224
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	34
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	251
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	41
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	195
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	31
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	486
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Positive	23
HTC_TST_TA	By Key Population: FSW, Negative	852



HTC_TST_TA	By Key Population: FSW, Positive	438
HTC_TST_TA	By Key Population: People in prisons and other enclosed settings, Negative	3,404
HTC_TST_TA	By Key Population: People in prisons and other enclosed settings, Positive	707
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	7,813
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	275
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	13,574
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	480
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Negative	708
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Positive	125
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative	577
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Positive	100
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Negative	168
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Positive	25
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Negative	446
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Positive	77
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Negative	316
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Positive	50
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative	529
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Positive	91
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49,	242



	Female, Negative	
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Positive	39
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Negative	670
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Positive	117
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Negative	511
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Positive	27
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Negative	338
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Positive	17
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Negative	221
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Positive	12
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Negative	225
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Positive	12
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Negative	231
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Positive	13
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Negative	302
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Positive	15
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Negative	157
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Positive	7



	Female, Positive	
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Negative	282
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Positive	14
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Negative	720
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Positive	29
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Negative	6,183
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Positive	193
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Negative	6,359
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Positive	198
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Negative	2,214
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Positive	67
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Negative	4,075
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Positive	127
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Negative	2,446
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Positive	74
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Negative	4,616
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Positive	143
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49,	1,982



	Female, Negative	
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Positive	58
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Negative	3,739
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Positive	116
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Negative	9,038
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Positive	317
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Negative	3,912
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Positive	244
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Negative	4,057
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Positive	105
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Negative	2,732
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Positive	35
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Negative	178
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Positive	7
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Negative	54
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Negative	326
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female,	22



	Positive	
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Negative	148
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Positive	6
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Negative	416
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Positive	25
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Negative	268
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Positive	16
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Negative	178
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Positive	7
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Negative	179
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Positive	7
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Negative	186
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Positive	8
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Negative	242
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Positive	13
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Negative	126
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Positive	6
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male,	225



	Negative	
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Positive	12
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Female, Negative	3
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Negative	109
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Positive	4
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Negative	59
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Positive	39
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	34
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Positive	20
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Negative	72
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Positive	47
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	49
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Positive	30
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Negative	93
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Positive	57
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	151
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Positive	91
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49,	59

	Female, Negative	
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Positive	39
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative	59
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Positive	39
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 25-29, Male, Negative	7,251
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 25-29, Male, Positive	62
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 30-34, Male, Negative	968
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 30-34, Male, Positive	7
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 35-39, Male, Negative	968
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 35-39, Male, Positive	7
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 40-49, Male, Negative	968
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 40-49, Male, Positive	7
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	200
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	530
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	531
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	1,588
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	27
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male,	27



	Unassisted	
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	318
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	1,059
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	27
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	27
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	179
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	423
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	75
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	212
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	21
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	52
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Sex Partner	5,292
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest FSW, Directly-Assisted	264
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest FSW, Unassisted	794
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest MSM, Directly-Assisted	52
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest MSM, Unassisted	52
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	3,164
TB_STAT_DSD	Total number of registered new and relapsed TB cases,	3,164



	during the reporting period.	
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	174
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,897
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	158
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	935
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	174
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,897
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	158
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	935
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,000
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	2,000
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	101
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	107



TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	598
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,194
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	107
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,194
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	101
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	598
GEND_GBV_DSD	Number of people receiving post-GBV care	5,350
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	3,934
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,416
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	425
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	51
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	30
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	31
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	139
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	91
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	50
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	4
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	1,185
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	826



GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	120
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	31
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	584
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	246
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	292
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	106
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	154
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	10
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	96
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	4
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	217
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	17
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	151
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	5
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	217
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	17
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	151
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	5
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	217
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	17
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	151
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3	5



	35-39, Male, Sexual Violence (Post-Rape Care)	
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	73
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	5
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	50
GEND_GBV_TA	Number of people receiving post-GBV care	370
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	292
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	78
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	23
GEND_GBV_TA	<10, Female, Physical and/or Emotional Violence	3
GEND_GBV_TA	<10, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_TA	<10, Male, Physical and/or Emotional Violence	1
GEND_GBV_TA	10-14, Female, Physical and/or Emotional Violence	9
GEND_GBV_TA	10-14, Female, Sexual Violence (Post-Rape Care)	4
GEND_GBV_TA	10-14, Male, Physical and/or Emotional Violence	3
GEND_GBV_TA	15-19, Female, Physical and/or Emotional Violence	114
GEND_GBV_TA	15-19, Female, Sexual Violence (Post-Rape Care)	37
GEND_GBV_TA	15-19, Male, Physical and/or Emotional Violence	9
GEND_GBV_TA	15-19, Male, Sexual Violence (Post-Rape Care)	2
GEND_GBV_TA	20-24, Female, Physical and/or Emotional Violence	45
GEND_GBV_TA	20-24, Female, Sexual Violence (Post-Rape Care)	14
GEND_GBV_TA	20-24, Male, Physical and/or Emotional Violence	22
GEND_GBV_TA	20-24, Male, Sexual Violence (Post-Rape Care)	4
GEND_GBV_TA	50+, Female, Physical and/or Emotional Violence	10
GEND_GBV_TA	50+, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_TA	50+, Male, Physical and/or Emotional Violence	6
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	15
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29,	1



	Female, Sexual Violence (Post-Rape Care)	
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	10
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	15
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	10
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	15
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	10
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	4
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	3
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	22,861
OVC_SERV_DSD	Age/Sex: 10-14 Male	2,512
OVC_SERV_DSD	Age/Sex: 15-17 Male	2,055
OVC_SERV_DSD	By: Age/sex: Male 18-24	2,057
OVC_SERV_DSD	By: Age/sex: Male 25+	455
OVC_SERV_DSD	Age/Sex: 10-14 Female	2,742
OVC_SERV_DSD	Age/Sex: 15-17 Female	2,514
OVC_SERV_DSD	By: Age/sex: 18-24 Female	2,518
OVC_SERV_DSD	By: Age/sex: 25+ Female	687
OVC_SERV_DSD	Sum of Age/Sex disaggregates	9,823
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	2,363



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	589
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	2,052
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	518
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	1,418
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	356
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	1,236
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	312
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	463
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	72
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	425
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	58
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	322
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	643
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	2,246
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	256
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	514
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	1,799



OVC_SERV_DSD	Age/Sex: <1	919
OVC_SERV_DSD	Age/Sex: 1-9	6,402
OVC_SERV_DSD	Program Completion: Active	21,719
OVC_SERV_DSD	Program Completion: Graduation	1,142
OVC_SERV_DSD	OVC_SERV_N_DSD_Age_Sex_Service_v4 <1, Unknown Sex, Social Protection	157
OVC_SERV_DSD	OVC_SERV_N_DSD_Age_Sex_Service_v4 1-9, Unknown Sex, Social Protection	1,082
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	17,144
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	22,861
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,557
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	80
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	877
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	86
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	514
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART	1,051

	during TB treatment during the reporting period	
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	51
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	594
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	57
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	349
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	3,745
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	3,164
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	581
PMTCT_EID_DSD	Sum of Infant Age disaggregates	3,745
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	4,818
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	4,048
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	770
PMTCT_EID_TA	Sum of Infant Age disaggregates	4,818
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	67,604
TX_CURR_DSD	Age/Sex: 15-19 Male	233



TX_CURR_DSD	Age/Sex: 15-19 Female	1,366
TX_CURR_DSD	Sum of age/sex disaggregates	1,599
TX_CURR_DSD	Age/Sex: <1	272
TX_CURR_DSD	Age/Sex: <1-9	1,698
TX_CURR_DSD	Age/Sex: 10-14 Male	590
TX_CURR_DSD	Age/Sex: 10-14 Female	1,380
TX_CURR_DSD	Age/Sex: 20-24 Male	350
TX_CURR_DSD	Age/Sex: 50+ Male	4,846
TX_CURR_DSD	Age/Sex: 20-24 Female	4,046
TX_CURR_DSD	Age/Sex: 50+ Female	7,272
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	5,776
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,022
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	8,257
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	2,422
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	6,745
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	3,159
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	9,944
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	8,226
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	57,988
TX_CURR_TA	Age/Sex: 15-19 Male	198
TX_CURR_TA	Age/Sex: 15-19 Female	1,179
TX_CURR_TA	Sum of Age/Sex disaggregations	1,377
TX_CURR_TA	Age/Sex: <1	218
TX_CURR_TA	Age/Sex: 1-9	1,303



TX_CURR_TA	Age/Sex: 10-14 Male	455
TX_CURR_TA	Age/Sex: 10-14 Female	1,064
TX_CURR_TA	Age/Sex: 20-24 Male	302
TX_CURR_TA	Age/Sex: 50+ Male	4,183
TX_CURR_TA	Age/Sex: 20-24 Female	3,497
TX_CURR_TA	Age/Sex: 50+ Female	6,275
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	4,983
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	875
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	7,125
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	2,089
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	5,826
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	2,734
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	8,584
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	7,098
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	7,794
TX_NEW_DSD	By Age/Sex: <1	32
TX_NEW_DSD	By Age/Sex: 1-9	186
TX_NEW_DSD	By Age/Sex: 10-14 Male	45
TX_NEW_DSD	By Age/Sex: 15-19 Male	160
TX_NEW_DSD	By Age/Sex: 20-24 Male	408
TX_NEW_DSD	By Age/Sex: 50+ Male	302
TX_NEW_DSD	By Age/Sex: 10-14 Female	175
TX_NEW_DSD	By Age/Sex: 15-19 Female	494
TX_NEW_DSD	By Age/Sex: 20-24 Female	915



TX_NEW_DSD	By Age/Sex: 50+ Female	24
TX_NEW_DSD	Sum of Age/Sex disaggregates	2,523
TX_NEW_DSD	Pregnancy status	733
TX_NEW_DSD	Breastfeeding status	733
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	1,133
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	753
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	494
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	502
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	518
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	674
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	348
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	631
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	6,744
TX_NEW_TA	By Age/Sex: <1	39
TX_NEW_TA	By Age/Sex: 1-9	244
TX_NEW_TA	By Age/Sex: 10-14 Male	55
TX_NEW_TA	By Age/Sex: 15-19 Male	134
TX_NEW_TA	By Age/Sex: 20-24 Male	343
TX_NEW_TA	By Age/Sex: 50+ Male	251
TX_NEW_TA	By Age/Sex: 10-14 Female	226
TX_NEW_TA	By Age/Sex: 15-19 Female	415
TX_NEW_TA	By Age/Sex: 20-24 Female	770
TX_NEW_TA	By Age/Sex: 50+ Female	10
TX_NEW_TA	Sum of Age/Sex disaggregates	2,204



TX_NEW_TA	Pregnancy status	620
TX_NEW_TA	Breastfeeding status	620
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	971
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	636
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	415
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	420
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	427
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	569
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	290
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	529
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	60,841
TX_PVLS_DSD	Denominator: Indication: Routine	52,929
TX_PVLS_DSD	Denominator: Indication: Targeted	7,912
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	163
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	2,367
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	332
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	5,050
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,216
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+	15,818



	Male Routine	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2,435
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	33,460
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	52,192
TX_PVLS_TA	Denominator: Indication: Routine	45,409
TX_PVLS_TA	Denominator: Indication: Targeted	6,783
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2,086
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	288
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,046
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	141
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	28,704
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	4,325
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	13,573
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	2,029
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	13,471
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	14,966
TX_RET_DSD	Numerator by Status: Pregnant	1,333
TX_RET_DSD	Numerator by Status: Breastfeeding	1,333



TX_RET_DSD	Denominator by Status: Pregnant	1,481
TX_RET_DSD	Denominator by Status: Breastfeeding	1,481
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	54
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,262
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	95
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7,060
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	57
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,959
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	105
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,845
TX_RET_TA	Number of adults and children who are still alive and on	14,167



	treatment at 12 months after initiating ART	
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	15,742
TX_RET_TA	Numerator by Status: Pregnant	1,402
TX_RET_TA	Numerator by Status: Breastfeeding	1,402
TX_RET_TA	Denominator by Status: Pregnant	1,558
TX_RET_TA	Denominator by Status: Breastfeeding	1,558
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	49
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,590
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	93
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7,435
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	56
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,320
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	105



	stopped ART, and those lost to follow-up)	
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,261
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	376
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	990
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	991
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	2,971
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	48
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	48
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	594
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	1,981
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	48
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	48
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	338
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	793
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	139
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	396



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	40
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	100
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	9,905
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	496
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted	1,486
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	100
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Unassisted	100
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	10,240
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	12,048
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	722
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	480
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	7,353
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	3,493
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	616
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	409
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	6,243
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	2,972
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV	10,479



	Alternative TPT Regimen, Life-long ART, Already, Positive	
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	1,202
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	314
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	53
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	8,901
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	1,027
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	266
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	46
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	8,783
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	10,330
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	620
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	416
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	6,297
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	2,997
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	524
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	352



TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	5,362
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	2,545
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	8,993
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	1,034
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	268
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	35
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	7,647
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	876
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	229
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	31
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	67,604
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	4,057
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	2,704
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	41,236
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	19,607
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	2,704
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	135
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	543
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of	2,026



	Specimen Sent]: Gene Xpert MTB / R if Assay	
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	58,816
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	1,757
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	6,760
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	271
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	57,988
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	3,478
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	2,320
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	35,375
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	16,815
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	2,320
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	114
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	462
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	1,744
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	50,447
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	1,509
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	5,799
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	233

Implementing Mechanism Details



Mechanism ID: 18033	Mechanism Name: Acceleration of Regional Comprehensive HIV & AIDS Service Delivery through HSS
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Mildmay Uganda	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 12,807,245	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 12,807,245	
Funding Source	Funding Amount
GHP-State	12,807,245

Cross-Cutting Budget Attribution(s)

Gender: GBV	350,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Gender: Gender Equality	75,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Monitoring and Evaluation
Water	78,679
Adolescent Girls and Young Women (AGYW)	3,230,534

Budget Code Information



Mechanism ID:	18033	
Mechanism Name:	Acceleration of Regional Comprehensive HIV & AIDS Service	
Prime Partner Name:	Delivery through HSS Mildmay Uganda	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	1,331,116
Strategic Area	Budget Code	Planned Amount
Care	HKID	724,868
Strategic Area	Budget Code	Planned Amount
Care	HVTB	372,381
Strategic Area	Budget Code	Planned Amount
Care	PDCS	619,240
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	1,687,893
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	746,655
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	3,471,498
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	499,266
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	3,157,029
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	197,299

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	6,342
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	88,003



PMTCT_ART_DSD	New on ART	2,471
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	3,871
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	88,003
PMTCT_STAT_DSD	Number of new ANC and L&D clients	88,003
PMTCT_STAT_DSD	By Age (Denominator): <15-19	16,721
PMTCT_STAT_DSD	By Age (Denominator): 20-24	29,040
PMTCT_STAT_DSD	By Number of known positives: 15-19	20
PMTCT_STAT_DSD	By Number of known positives: 20-24	118
PMTCT_STAT_DSD	By Number of new positives: 15-19	502
PMTCT_STAT_DSD	By Number of new positives: 20-24	871
PMTCT_STAT_DSD	By Number of new negative: 15-19	16,199
PMTCT_STAT_DSD	By Number of new negative: 20-24	28,051
PMTCT_STAT_DSD	By Age (Numerator): 15-19	16,721
PMTCT_STAT_DSD	By Age (Numerator): 20-24	29,040
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	19,360
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	14,961
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	6,161
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	1,760
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	1,784
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	16,996
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	580
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	1,379
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	13,133
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	449
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult	570



	35-39, Female, Known at Entry Positive	
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	5,407
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	184
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	168
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	1,539
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	53
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	19,360
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	14,961
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	6,161
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	1,760
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	53,887
VMMC_CIRC_DSD	By Age: 10-14	2,694
VMMC_CIRC_DSD	By Age: 15-19	13,473
VMMC_CIRC_DSD	By Age: 20-24	13,473
VMMC_CIRC_DSD	By Age: 25-29	16,167
VMMC_CIRC_DSD	By Age: 50+	1,612
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	31,252
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	47,419
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	53,887
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	2,156
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	2,156
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	2,156
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	3,376
PP_PREV_DSD	Age/sex: 15-19 Male	149



PP_PREV_DSD	Age/sex: 20-24 Male	235
PP_PREV_DSD	Age/sex: 50+ Male	182
PP_PREV_DSD	Age/sex: 10-14 Female	97
PP_PREV_DSD	Age/sex: 15-19 Female	683
PP_PREV_DSD	Age/sex: 20-24 Female	392
PP_PREV_DSD	Age/sex: 50+ Female	102
PP_PREV_DSD	Sum of Age/Sex disaggregates	1,840
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	115
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	205
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	102
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	192
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	163
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	299
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	162
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	298
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	16,659
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	11,232
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	5,427
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	326,531
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	3,802



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	118
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	809
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	920
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	47
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	299
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	1,706
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	90
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	764
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	21
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	574
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	3,480
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	115
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	778



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	33
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	389
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	520
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	1,445
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	60
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	10
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	1,635
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	68
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	6,919
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	135
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	1,460
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	4,576
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	141
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	2,285



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	72
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	6,876
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	214
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	7,379
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	227
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	83
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	3,170
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	97
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	6,335
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	135
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	9,808
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	200
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	32
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	17
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	115



HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	57
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	168
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	86
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	197
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	97
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	82
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	41
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	49
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	115
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	57
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	82
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	41
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	2,687
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	13,433
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	13,433
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	1,612
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	5



HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	893
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	47
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	190
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	245
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	44
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	124
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	410
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	72
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	455
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	81
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	351
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	62
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	818
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	44
HTC_TST_DSD	By Key Population: FSW, Negative	2,949
HTC_TST_DSD	By Key Population: FSW, Positive	1,515



HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	9,086
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	1,965
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	893
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	47
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	190
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	183
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	33
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	91
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	124
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	341
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	60
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	387
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	68



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	818
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	44
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	15,452
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	502
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	26,830
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	871
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	1,269
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	224
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	1,040
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	183
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	303
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	53
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	803
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	141
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	569
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	100
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	953
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	169
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	441



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	78
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	1,207
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	214
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	2,128
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	111
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	1,406
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	74
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	922
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	47
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	933
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	48
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	957
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	1,259
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	65
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	646
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	36



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	1,172
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	4,032
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	169
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	3,307
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	137
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	961
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	2,552
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	106
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	1,811
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	76
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	3,032
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	127
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	1,661
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	70
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	3,834



HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	159
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	1,202
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	952
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	169
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	781
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	137
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	227
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	602
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	106
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	426
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	76
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	716
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	127
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	393
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	70



HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	903
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	159
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	11,197
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	346
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	11,517
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	357
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	4,008
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	125
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	7,386
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	228
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	4,423
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	136
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	8,361
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	259
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	3,590
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	111
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	6,776



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	210
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	17,868
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	571
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	7,732
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	444
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	8,028
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	190
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	5,409
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	65
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	323
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	105
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	598
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	267
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	21



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	728
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	56
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	490
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	323
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	327
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	333
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	440
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	35
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	225
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	410
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	11



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	197
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	82
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	49
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	99
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	49
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	66
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	125
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	60
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	197
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	97
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	82
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	41

HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	82
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	16,121
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	2,149
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	2,149
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	2,149
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	6
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	3,088
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	3,088
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	168
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,851
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	154
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number	915



	of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	168
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,851
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	154
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	915
GEND_GBV_DSD	Number of people receiving post-GBV care	6,836
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	4,893
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,943
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	584
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	64
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	38
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	35
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	3
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	173
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	121
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	62
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	9
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	1,495
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	1,113
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	152
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	42
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	727



GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	340
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	362
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	144
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	191
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	14
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	117
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	9
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	268
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	24
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	186
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	9
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	268
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	24
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	186
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	9
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	268
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	24
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	186
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	9
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	91
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3	9



	40-49, Female, Sexual Violence (Post-Rape Care)	
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	62
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	2
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	11,855
OVC_SERV_DSD	Age/Sex: 10-14 Male	1,306
OVC_SERV_DSD	Age/Sex: 15-17 Male	1,068
OVC_SERV_DSD	By: Age/sex: Male 18-24	1,070
OVC_SERV_DSD	By: Age/sex: Male 25+	237
OVC_SERV_DSD	Age/Sex: 10-14 Female	1,420
OVC_SERV_DSD	Age/Sex: 15-17 Female	1,302
OVC_SERV_DSD	By: Age/sex: 18-24 Female	1,306
OVC_SERV_DSD	By: Age/sex: 25+ Female	353
OVC_SERV_DSD	Sum of Age/Sex disaggregates	5,096
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	1,927
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	480
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	1,679
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	420
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	1,156
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	288
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	1,008
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	252



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	377
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	57
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	348
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	47
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	264
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	523
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	1,833
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	211
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	420
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	1,469
OVC_SERV_DSD	Age/Sex: <1	472
OVC_SERV_DSD	Age/Sex: 1-9	3,321
OVC_SERV_DSD	Program Completion: Active	11,264
OVC_SERV_DSD	Program Completion: Graduation	591
OVC_SERV_DSD	OVC_SERV_N_DSD_Age_Sex_Service_v4 <1, Unknown Sex, Social Protection	126
OVC_SERV_DSD	OVC_SERV_N_DSD_Age_Sex_Service_v4 1-9, Unknown Sex, Social Protection	880
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	8,889
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	11,855



TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,446
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	73
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	814
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	80
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	479
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	6,342
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	5,337
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,005
PMTCT_EID_DSD	Sum of Infant Age disaggregates	6,342
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	84,020
TX_CURR_DSD	Age/Sex: 15-19 Male	284
TX_CURR_DSD	Age/Sex: 15-19 Female	1,689
TX_CURR_DSD	Sum of age/sex disaggregates	1,973
TX_CURR_DSD	Age/Sex: <1	374
TX_CURR_DSD	Age/Sex: <1-9	2,295
TX_CURR_DSD	Age/Sex: 10-14 Male	799



TX_CURR_DSD	Age/Sex: 10-14 Female	1,869
TX_CURR_DSD	Age/Sex: 20-24 Male	432
TX_CURR_DSD	Age/Sex: 50+ Male	5,990
TX_CURR_DSD	Age/Sex: 20-24 Female	5,004
TX_CURR_DSD	Age/Sex: 50+ Female	8,987
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	7,139
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,257
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	10,204
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	2,994
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	8,340
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	3,910
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	12,289
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	10,164
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	1,323
TX_CURR_TA	Age/Sex: 15-19 Male	5
TX_CURR_TA	Age/Sex: 15-19 Female	26
TX_CURR_TA	Sum of Age/Sex disaggregations	31
TX_CURR_TA	Age/Sex: <1	6
TX_CURR_TA	Age/Sex: 1-9	38
TX_CURR_TA	Age/Sex: 10-14 Male	14
TX_CURR_TA	Age/Sex: 10-14 Female	30
TX_CURR_TA	Age/Sex: 20-24 Male	8
TX_CURR_TA	Age/Sex: 50+ Male	94
TX_CURR_TA	Age/Sex: 20-24 Female	78



TX_CURR_TA	Age/Sex: 50+ Female	141
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	111
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	21
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	160
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	46
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	130
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	61
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	194
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	160
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	10,823
TX_NEW_DSD	By Age/Sex: <1	60
TX_NEW_DSD	By Age/Sex: 1-9	379
TX_NEW_DSD	By Age/Sex: 10-14 Male	88
TX_NEW_DSD	By Age/Sex: 15-19 Male	217
TX_NEW_DSD	By Age/Sex: 20-24 Male	554
TX_NEW_DSD	By Age/Sex: 50+ Male	406
TX_NEW_DSD	By Age/Sex: 10-14 Female	350
TX_NEW_DSD	By Age/Sex: 15-19 Female	669
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,239
TX_NEW_DSD	By Age/Sex: 50+ Female	25
TX_NEW_DSD	Sum of Age/Sex disaggregates	3,548
TX_NEW_DSD	Pregnancy status	995
TX_NEW_DSD	Breastfeeding status	995
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29,	1,543



	Female, Positive	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,019
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	669
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	678
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	695
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	914
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	468
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	850
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	153
TX_NEW_TA	By Age/Sex: <1	2
TX_NEW_TA	By Age/Sex: 1-9	10
TX_NEW_TA	By Age/Sex: 10-14 Male	3
TX_NEW_TA	By Age/Sex: 15-19 Male	3
TX_NEW_TA	By Age/Sex: 20-24 Male	7
TX_NEW_TA	By Age/Sex: 50+ Male	5
TX_NEW_TA	By Age/Sex: 10-14 Female	10
TX_NEW_TA	By Age/Sex: 15-19 Female	8
TX_NEW_TA	By Age/Sex: 20-24 Female	16
TX_NEW_TA	Sum of Age/Sex disaggregates	52
TX_NEW_TA	Pregnancy status	13
TX_NEW_TA	Breastfeeding status	13
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	22
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	13



TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	8
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	8
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	8
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	12
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	6
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	12
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	75,619
TX_PVLS_DSD	Denominator: Indication: Routine	65,788
TX_PVLS_DSD	Denominator: Indication: Targeted	9,831
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	205
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	2,943
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	415
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	6,268
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,511
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	19,660
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	3,024
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	41,593
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral	1,190



	load result documented in the patient medical record and /or laboratory records in the past 12 months.	
TX_PVLS_TA	Denominator: Indication: Routine	1,036
TX_PVLS_TA	Denominator: Indication: Targeted	154
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	48
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	7
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	23
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	3
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	655
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	98
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	310
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	46
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	15,918
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	17,688
TX_RET_DSD	Numerator by Status: Pregnant	1,569
TX_RET_DSD	Numerator by Status: Breastfeeding	1,569
TX_RET_DSD	Denominator by Status: Pregnant	1,744
TX_RET_DSD	Denominator by Status: Breastfeeding	1,744
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	81
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of	7,374



	adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	151
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8,312
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	90
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,192
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	167
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9,239
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	173
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	191
TX_RET_TA	Numerator by Status: Pregnant	17



TX_RET_TA	Numerator by Status: Breastfeeding	17
TX_RET_TA	Denominator by Status: Pregnant	17
TX_RET_TA	Denominator by Status: Breastfeeding	17
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	77
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	89
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	86
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	96



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	229
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	604
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	602
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	1,812
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	31
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	31
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	363
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	1,208
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	31
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	31
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	205
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	483
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	84
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	241
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	24
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	60
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	6,039

HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	301
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted	905
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	60
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Unassisted	60
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	12,724
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	14,972
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	899
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	599
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	9,131
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	4,343
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	764
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	510
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	7,761
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	3,689
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	13,024
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	1,498
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	389



TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	61
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	11,067
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	1,273
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	331
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	53
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	202
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	235
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	14
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	9
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	144
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	68
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	12
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	8
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	123
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	59
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	206
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV	23



	Alternative TPT Regimen, Life-long ART, New, Positive	
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	6
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	177
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	20
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	5
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	84,020
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	5,041
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	3,362
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	51,250
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	24,367
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	3,362
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	169
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	672
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	2,521
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	73,098
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	2,185
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	8,402
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	335
TX_TB_TA	Number of ART patients who were screened for TB at	1,323



	least once during the reporting period	
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	80
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	52
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	807
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	384
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	52
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	2
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	12
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	38
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	1,152
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	34
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	132
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	5

Implementing Mechanism Details

Mechanism ID: 18034	Mechanism Name: Acceleration of Regional Comprehensive HIV & AIDS Service Delivery through HSS
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: The AIDS Support Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 5,322,557	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 5,322,557	
Funding Source	Funding Amount
GHP-State	5,322,557

Cross-Cutting Budget Attribution(s)

Gender: GBV	50,233
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Gender: Gender Equality	100,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Sub Area:	Collection and Use of Gender-related Strategic Information

Budget Code Information

Mechanism ID:	18034	
Mechanism Name:	Acceleration of Regional Comprehensive HIV & AIDS Service	
Prime Partner Name:	Delivery through HSS	
	The AIDS Support Organization	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	764,672
Strategic Area	Budget Code	Planned Amount



Care	HKID	279,718
Strategic Area	Budget Code	Planned Amount
Care	HVTB	212,698
Strategic Area	Budget Code	Planned Amount
Care	PDCS	412,877
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	547,868
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	283,492
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	70,986



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	320,344
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	2,197,188
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	232,714

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	2,373
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	66,308
PMTCT_ART_DSD	New on ART	448
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,925
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	66,308
PMTCT_STAT_DSD	Number of new ANC and L&D clients	66,308
PMTCT_STAT_DSD	By Age (Denominator): <15-19	12,599
PMTCT_STAT_DSD	By Age (Denominator): 20-24	21,882



PMTCT_STAT_DSD	By Number of known positives: 15-19	10
PMTCT_STAT_DSD	By Number of known positives: 20-24	58
PMTCT_STAT_DSD	By Number of new positives: 15-19	90
PMTCT_STAT_DSD	By Number of new positives: 20-24	157
PMTCT_STAT_DSD	By Number of new negative: 15-19	12,499
PMTCT_STAT_DSD	By Number of new negative: 20-24	21,667
PMTCT_STAT_DSD	By Age (Numerator): 15-19	12,599
PMTCT_STAT_DSD	By Age (Numerator): 20-24	21,882
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	14,587
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	11,272
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	4,642
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	1,326
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	892
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	13,589
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	106
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	691
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	10,500
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	81
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	287
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	4,322
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	33
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	84
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult	1,232

	40-49, Female, Newly Identified Negative	
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	10
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	14,587
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	11,272
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	4,642
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	1,326
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	23,413
VMMC_CIRC_DSD	By Age: 10-14	1,170
VMMC_CIRC_DSD	By Age: 15-19	5,853
VMMC_CIRC_DSD	By Age: 20-24	5,853
VMMC_CIRC_DSD	By Age: 25-29	7,024
VMMC_CIRC_DSD	By Age: 50+	702
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	13,578
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	20,602
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	23,413
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	937
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	937
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	937
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	1,131
PP_PREV_DSD	Age/sex: 15-19 Male	40
PP_PREV_DSD	Age/sex: 20-24 Male	71
PP_PREV_DSD	Age/sex: 50+ Male	84
PP_PREV_DSD	Age/sex: 15-19 Female	165
PP_PREV_DSD	Age/sex: 20-24 Female	106
PP_PREV_DSD	Age/sex: 50+ Female	47
PP_PREV_DSD	Sum of Age/Sex disaggregates	513
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	39



PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	74
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	38
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	68
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	70
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	131
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	69
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	129
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	4,320
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,614
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,706
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	157,905
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	1,042
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	224
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	365



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	119
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	678
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	37
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	304
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	228
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	957
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	31
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	287
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	144
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	192
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	8



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	534
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	23
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	5
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	606
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	1,895
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	36
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	400
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	1,837
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	57
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	919
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	29
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	2,764
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	86
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	2,963
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	92



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	32
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	1,273
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	1,736
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	36
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	2,691
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	54
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	22
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	76
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	123
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	130
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	53
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	4



HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	32
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	76
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	53
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	1,167
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	5,837
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	5,837
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	700
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	245
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	53
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	100
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	49



HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	165
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	185
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	142
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	225
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	12
HTC_TST_DSD	By Key Population: FSW, Negative	848
HTC_TST_DSD	By Key Population: FSW, Positive	436
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	3,272
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	682
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	245
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	53
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	75
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	14



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	37
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	50
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	139
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	25
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	158
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	27
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	225
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	12,125
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	90
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	21,054
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	157
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	506
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	92
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	423
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	74
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	124



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	324
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	58
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	230
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	387
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	68
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	180
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	490
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	88
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	846
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	558
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	365
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	19

HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	370
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	379
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	500
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	256
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	465
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	1,491
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	1,224
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	51
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	356
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	944



HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	670
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	1,121
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	46
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	614
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	1,415
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	58
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	330
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	389
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	68
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	318
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	56
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	94
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	17

HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	245
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	174
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	293
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	51
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	161
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	364
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	64
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	4,497
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	140
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	4,634
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	144
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	1,610
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	49
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	2,967



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	92
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	1,777
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	55
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	3,358
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	103
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	1,444
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	46
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	2,723
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	85
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	14,020
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	102
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	6,068
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	80
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	6,298
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	4,245
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	12



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	128
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	42
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	238
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	106
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	289
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	195
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	128
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	129
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	133



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	176
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	91
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	164
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	79
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	53
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	32
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	65
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	44



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	81
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	130
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	53
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	53
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	7,005
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	934
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	934
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	934
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	3



TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,657
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,657
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	90
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	991
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	85
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	491
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	90
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	991
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	85
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	491
GEND_GBV_DSD	Number of people receiving post-GBV care	1,280
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	962
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	318
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	95



GEND_GBVDSD	<10, Female, Physical and/or Emotional Violence	12
GEND_GBVDSD	<10, Female, Sexual Violence (Post-Rape Care)	7
GEND_GBVDSD	<10, Male, Physical and/or Emotional Violence	7
GEND_GBVDSD	10-14, Female, Physical and/or Emotional Violence	34
GEND_GBVDSD	10-14, Female, Sexual Violence (Post-Rape Care)	19
GEND_GBVDSD	10-14, Male, Physical and/or Emotional Violence	11
GEND_GBVDSD	15-19, Female, Physical and/or Emotional Violence	303
GEND_GBVDSD	15-19, Female, Sexual Violence (Post-Rape Care)	197
GEND_GBVDSD	15-19, Male, Physical and/or Emotional Violence	29
GEND_GBVDSD	15-19, Male, Sexual Violence (Post-Rape Care)	7
GEND_GBVDSD	20-24, Female, Physical and/or Emotional Violence	143
GEND_GBVDSD	20-24, Female, Sexual Violence (Post-Rape Care)	55
GEND_GBVDSD	20-24, Male, Physical and/or Emotional Violence	72
GEND_GBVDSD	20-24, Male, Sexual Violence (Post-Rape Care)	24
GEND_GBVDSD	50+, Female, Physical and/or Emotional Violence	37
GEND_GBVDSD	50+, Male, Physical and/or Emotional Violence	24
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	53
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	3
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	34
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	53
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	3
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	34
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	53
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	3
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3	34



	35-39, Male, Physical and/or Emotional Violence	
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	18
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	11
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	4,717
OVC_SERV_DSD	Age/Sex: 10-14 Male	519
OVC_SERV_DSD	Age/Sex: 15-17 Male	424
OVC_SERV_DSD	By: Age/sex: Male 18-24	425
OVC_SERV_DSD	By: Age/sex: Male 25+	92
OVC_SERV_DSD	Age/Sex: 10-14 Female	565
OVC_SERV_DSD	Age/Sex: 15-17 Female	518
OVC_SERV_DSD	By: Age/sex: 18-24 Female	522
OVC_SERV_DSD	By: Age/sex: 25+ Female	142
OVC_SERV_DSD	Sum of Age/Sex disaggregates	2,026
OVC_SERV_DSD	Age/Sex: <1	188
OVC_SERV_DSD	Age/Sex: 1-9	1,322
OVC_SERV_DSD	Program Completion: Active	4,482
OVC_SERV_DSD	Program Completion: Graduation	235
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	3,536
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	4,717
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	586
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	30



TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	330
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	34
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	192
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,373
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,997
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	376
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,373
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	43,430
TX_CURR_DSD	Age/Sex: 15-19 Male	140
TX_CURR_DSD	Age/Sex: 15-19 Female	825
TX_CURR_DSD	Sum of age/sex disaggregates	965
TX_CURR_DSD	Age/Sex: <1	345
TX_CURR_DSD	Age/Sex: <1-9	2,126
TX_CURR_DSD	Age/Sex: 10-14 Male	741
TX_CURR_DSD	Age/Sex: 10-14 Female	1,729
TX_CURR_DSD	Age/Sex: 20-24 Male	211
TX_CURR_DSD	Age/Sex: 50+ Male	2,928
TX_CURR_DSD	Age/Sex: 20-24 Female	2,448
TX_CURR_DSD	Age/Sex: 50+ Female	4,396
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	3,492



TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	615
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	4,991
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,465
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	4,080
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,913
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	6,012
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	4,973
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,524
TX_NEW_DSD	By Age/Sex: <1	17
TX_NEW_DSD	By Age/Sex: 1-9	106
TX_NEW_DSD	By Age/Sex: 10-14 Male	25
TX_NEW_DSD	By Age/Sex: 15-19 Male	70
TX_NEW_DSD	By Age/Sex: 20-24 Male	182
TX_NEW_DSD	By Age/Sex: 50+ Male	134
TX_NEW_DSD	By Age/Sex: 10-14 Female	100
TX_NEW_DSD	By Age/Sex: 15-19 Female	220
TX_NEW_DSD	By Age/Sex: 20-24 Female	406
TX_NEW_DSD	By Age/Sex: 50+ Female	9
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,146
TX_NEW_DSD	Pregnancy status	328
TX_NEW_DSD	Breastfeeding status	328
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	515
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	335



TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	220
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	221
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	229
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	302
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	153
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	280
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	39,087
TX_PVLS_DSD	Denominator: Indication: Routine	34,006
TX_PVLS_DSD	Denominator: Indication: Targeted	5,081
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	107
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	1,520
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	216
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	3,238
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	782
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	10,163
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,565
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	21,496
TX_RET_DSD	Number of adults and children who are still alive and on	8,299



	treatment at 12 months after initiating ART	
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	9,221
TX_RET_DSD	Numerator by Status: Pregnant	780
TX_RET_DSD	Numerator by Status: Breastfeeding	780
TX_RET_DSD	Denominator by Status: Pregnant	866
TX_RET_DSD	Denominator by Status: Breastfeeding	866
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	175
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,664
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	327
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,133
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	196
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,071
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	362

	stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,592
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	52
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	135
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	135
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	406
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	82
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	271
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	45
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	108
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	55



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	13
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	1,354
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	68
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted	203
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	13
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Unassisted	13
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	6,578
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	7,739
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	464
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	311
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	4,719
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	2,245
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	396
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	264
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	4,010
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	1,908
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV	6,732



	Alternative TPT Regimen, Life-long ART, Already, Positive	
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	774
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	201
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	32
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	5,722
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	659
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	170
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	27
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	43,430
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	2,607
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	1,738
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	26,491
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	12,594
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	1,738
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	87
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	347
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	1,304
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	37,781



TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	1,129
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	4,344
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	176

Implementing Mechanism Details

Mechanism ID: 18041	Mechanism Name: Technical Assistance to strengthen the Capacity of the MOH to execute its Public Health Functions for HIV & AIDS Epidemic control and respond to other disease outbreaks in the republic of Uganda under PEPFAR through HSS	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: African Field Epidemiology Network		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 3,070,093	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,070,093	
Funding Source	Funding Amount
GHP-State	3,070,093

Cross-Cutting Budget Attribution(s)

Gender: GBV	300,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Focus Area:	Post GBV Care



Water	7,503
-------	-------

Budget Code Information

Mechanism ID:	18041	
Mechanism Name:	Technical Assistance to strengthen the Capacity of the MOH to execute its Public Health Functions for HIV & AIDS Epidemic control and respond to other disease outbreaks in the republic of Uganda under PEPFAR through HSS	
Prime Partner Name:	African Field Epidemiology Network	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	202,000
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	202,000
Strategic Area	Budget Code	Planned Amount
Care	PDCS	303,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	270,093
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	100,000
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	180,000
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	500,000
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	202,000
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	707,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	404,000

Implementing Mechanism Indicator Information

Approved



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18042	Mechanism Name: Technical Assistance for Public Health Workforce Development
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Makerere University School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,230,005	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,230,005	
Funding Source	Funding Amount
GHP-State	1,230,005

Cross-Cutting Budget Attribution(s)

Adolescent Girls and Young Women (AGYW)	300,000
---	---------

Budget Code Information

Mechanism ID:	18042	
Mechanism Name:	Technical Assistance for Public Health Workforce Development	
Prime Partner Name:	Makerere University School of Public Health	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	50,005
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	1,180,000
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18273	Mechanism Name: Regional Health Integration to Enhance Services – North, Acholi (RHITES-N, Acholi)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 5,721,347	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 1,500,000	
Total All Funding Sources and Applied Pipeline Amount: 7,221,347	



Funding Source	Funding Amount
GHP-State	5,721,347

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	61,078
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	91,617
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Gender: GBV	350,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information



Focus Area:	Post GBV Care
Sub Area:	Capacity building
Gender: Gender Equality	109,610
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Capacity building
Food and Nutrition: Policy, Tools, and Service Delivery	183,235
Adolescent Girls and Young Women (AGYW)	840,879
Condom programming	244,313
Water	175,000

Budget Code Information

Mechanism ID:	18273	
Mechanism Name:	Regional Health Integration to Enhance Services – North, Acholi (RHITES-N, Acholi)	
Prime Partner Name:	University Research Corporation, LLC	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	944,373
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	246,347
Strategic Area	Budget Code	Planned Amount



Care	PDCS	345,371
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	55,700
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	428,814
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	305,606
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	840,879
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	259,115



Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	2,161,693
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	133,449

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	3,279
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	41,471
PMTCT_ART_DSD	New on ART	895
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,384
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	41,471
PMTCT_STAT_DSD	Number of new ANC and L&D clients	41,471
PMTCT_STAT_DSD	By Age (Denominator): <15-19	7,879
PMTCT_STAT_DSD	By Age (Denominator): 20-24	13,686
PMTCT_STAT_DSD	By Number of known positives: 15-19	12
PMTCT_STAT_DSD	By Number of known positives: 20-24	72
PMTCT_STAT_DSD	By Number of new positives: 15-19	190
PMTCT_STAT_DSD	By Number of new positives: 20-24	331
PMTCT_STAT_DSD	By Number of new negative: 15-19	7,677



PMTCT_STAT_DSD	By Number of new negative: 20-24	13,283
PMTCT_STAT_DSD	By Age (Numerator): 15-19	7,879
PMTCT_STAT_DSD	By Age (Numerator): 20-24	13,686
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	9,124
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	7,051
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	2,902
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	829
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	1,085
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	7,818
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	221
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	837
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	6,044
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	170
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	349
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	2,481
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	72
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	101
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	708
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	20
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	9,124
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	7,051

PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	2,902
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	829
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	30,005
VMMC_CIRC_DSD	By Age: 10-14	1,503
VMMC_CIRC_DSD	By Age: 15-19	7,504
VMMC_CIRC_DSD	By Age: 20-24	7,504
VMMC_CIRC_DSD	By Age: 25-29	9,002
VMMC_CIRC_DSD	By Age: 50+	892
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	17,403
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	26,405
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	30,005
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	1,200
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	1,200
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	1,200
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	4,852
PP_PREV_DSD	Age/sex: 15-19 Male	126
PP_PREV_DSD	Age/sex: 20-24 Male	366
PP_PREV_DSD	Age/sex: 50+ Male	301
PP_PREV_DSD	Age/sex: 10-14 Female	91
PP_PREV_DSD	Age/sex: 15-19 Female	631
PP_PREV_DSD	Age/sex: 20-24 Female	619
PP_PREV_DSD	Age/sex: 50+ Female	164
PP_PREV_DSD	Sum of Age/Sex disaggregates	2,298
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	190
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	334
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	187
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	320
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	269



PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	476
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	276
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	502
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	3,399
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	107
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	9
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,583
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,700
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	162,357
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	1,025
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male,	219



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	518
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	169
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	961
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	50
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	430
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	11
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	323
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	952
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	31
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	400
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	17
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	200
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	8



	15-19, Male, Positive	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	268
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	742
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	31
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	6
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	842
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	36
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	1,846
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	389
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	2,574
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	79
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	1,286
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	3,866
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	119



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	4,150
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	127
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	46
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	1,783
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	54
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	1,690
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	2,616
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	53
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	36
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	131
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	201
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	29
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female,	227



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	94
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	56
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	131
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	94
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	1,443
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	7,220
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	7,220
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	867
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	238
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	50



HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	139
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	69
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	232
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	41
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	259
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	45
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	200
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	218
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	11
HTC_TST_DSD	By Key Population: FSW, Negative	961
HTC_TST_DSD	By Key Population: FSW, Positive	425
HTC_TST_DSD	By Key Population: MSM, Negative	160
HTC_TST_DSD	By Key Population: MSM, Positive	72
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	3,519
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	636



HTC_TST_DSD	By Key Population: TG, Negative	58
HTC_TST_DSD	By Key Population: TG, Positive	10
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	241
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	51
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	106
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	53
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	71
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	197
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	35
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	225
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	40
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	220
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	11



HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	7,224
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	190
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	12,547
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	331
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	727
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	127
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	592
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	103
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	172
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	457
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	80
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	324
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	55
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	543
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	94
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	251
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	685



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	120
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	1,200
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	63
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	791
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	518
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	527
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	539
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	710
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	364
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	661
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	34

HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	2,074
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	86
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	1,701
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	70
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	494
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	1,312
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	55
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	932
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	1,558
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	66
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	856
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	1,973
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	83
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	321

HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	555
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	97
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	452
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	79
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	131
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	350
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	249
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	44
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	416
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	74
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	228
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	526
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	93



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	6,294
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	195
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	6,482
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	201
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	2,252
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	68
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	4,152
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	127
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	2,486
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	76
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	4,700
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	146
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	2,017
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	61
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	3,809
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	118
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	8,355



HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	215
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	3,615
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	168
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	3,753
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	72
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	2,528
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	178
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	57
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	331
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	148
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	413
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	30



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	273
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	179
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	183
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	186
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	245
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	125
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	227
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	8
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	110
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	9



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	94
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	56
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	112
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	75
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	140
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	227
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	94
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	94
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	8,667



HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	1,155
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	1,155
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	1,155
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	4
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,032
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	1



HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 10-14, Negative	50
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Negative	250
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Negative	250
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Negative	30
HTC_TST_TA	By Key Population: People in prisons and other enclosed settings, Negative	4
HTC_TST_TA	By Key Population: People in prisons and other enclosed settings, Positive	1
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Negative	3
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Negative	3
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Negative	1
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Negative	2
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Negative	1
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Negative	2
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Negative	1
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Negative	2
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39,	1



	Female, Negative	
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	1
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 25-29, Male, Negative	300
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 30-34, Male, Negative	40
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 35-39, Male, Negative	40
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 40-49, Male, Negative	40
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	3,268
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	3,268
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	178
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,957
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	164
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	969
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	178
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,957
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total	164

	number of registered new and relapsed TB cases, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	969
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	20
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	20
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	6
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	12
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	12
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	6
GEND_GBV_DSD	Number of people receiving post-GBV care	1,211
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence	1,040



	(Other Post-GBV Care)	
GEND_GBVDSD	By type of service: Sexual Violence (Post-Rape Care)	171
GEND_GBVDSD	By PEP service provision (related to sexual violence services provided)	52
GEND_GBVDSD	<10, Female, Physical and/or Emotional Violence	14
GEND_GBVDSD	<10, Female, Sexual Violence (Post-Rape Care)	4
GEND_GBVDSD	<10, Male, Physical and/or Emotional Violence	7
GEND_GBVDSD	10-14, Female, Physical and/or Emotional Violence	36
GEND_GBVDSD	10-14, Female, Sexual Violence (Post-Rape Care)	11
GEND_GBVDSD	10-14, Male, Physical and/or Emotional Violence	14
GEND_GBVDSD	15-19, Female, Physical and/or Emotional Violence	319
GEND_GBVDSD	15-19, Female, Sexual Violence (Post-Rape Care)	99
GEND_GBVDSD	15-19, Male, Physical and/or Emotional Violence	32
GEND_GBVDSD	15-19, Male, Sexual Violence (Post-Rape Care)	4
GEND_GBVDSD	20-24, Female, Physical and/or Emotional Violence	155
GEND_GBVDSD	20-24, Female, Sexual Violence (Post-Rape Care)	30
GEND_GBVDSD	20-24, Male, Physical and/or Emotional Violence	77
GEND_GBVDSD	20-24, Male, Sexual Violence (Post-Rape Care)	13
GEND_GBVDSD	50+, Female, Physical and/or Emotional Violence	41
GEND_GBVDSD	50+, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBVDSD	50+, Male, Physical and/or Emotional Violence	25
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	56
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	3
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	40
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	56
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	3
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	40



GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	56
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	3
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	40
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	18
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	14
GEND_GBV_TA	Number of people receiving post-GBV care	718
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	616
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	102
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	31
GEND_GBV_TA	<10, Female, Physical and/or Emotional Violence	8
GEND_GBV_TA	<10, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_TA	<10, Male, Physical and/or Emotional Violence	4
GEND_GBV_TA	10-14, Female, Physical and/or Emotional Violence	21
GEND_GBV_TA	10-14, Female, Sexual Violence (Post-Rape Care)	6
GEND_GBV_TA	10-14, Male, Physical and/or Emotional Violence	8
GEND_GBV_TA	15-19, Female, Physical and/or Emotional Violence	196
GEND_GBV_TA	15-19, Female, Sexual Violence (Post-Rape Care)	65
GEND_GBV_TA	15-19, Male, Physical and/or Emotional Violence	19
GEND_GBV_TA	15-19, Male, Sexual Violence (Post-Rape Care)	2
GEND_GBV_TA	20-24, Female, Physical and/or Emotional Violence	91
GEND_GBV_TA	20-24, Female, Sexual Violence (Post-Rape Care)	18
GEND_GBV_TA	20-24, Male, Physical and/or Emotional Violence	45
GEND_GBV_TA	20-24, Male, Sexual Violence (Post-Rape Care)	7
GEND_GBV_TA	50+, Female, Physical and/or Emotional Violence	22
GEND_GBV_TA	50+, Male, Physical and/or Emotional Violence	13
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29,	35

	Female, Physical and/or Emotional Violence	
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	24
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	34
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	23
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	33
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	22
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	12
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	8
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,382
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	70
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	777
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	76
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	459
TB_ART_TA	The number of registered new and relapse TB cases	9

	with documented HIV-positive status who are on ART during TB treatment during the reporting period	
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	3,279
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	2,765
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	514
PMTCT_EID_DSD	Sum of Infant Age disaggregates	3,279
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	64,285
TX_CURR_DSD	Age/Sex: 15-19 Male	222
TX_CURR_DSD	Age/Sex: 15-19 Female	1,303
TX_CURR_DSD	Sum of age/sex disaggregates	1,525
TX_CURR_DSD	Age/Sex: <1	252
TX_CURR_DSD	Age/Sex: <1-9	1,545
TX_CURR_DSD	Age/Sex: 10-14 Male	537
TX_CURR_DSD	Age/Sex: 10-14 Female	1,257
TX_CURR_DSD	Age/Sex: 20-24 Male	335
TX_CURR_DSD	Age/Sex: 50+ Male	4,619
TX_CURR_DSD	Age/Sex: 20-24 Female	3,860
TX_CURR_DSD	Age/Sex: 50+ Female	6,933
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	5,505
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	969

TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	7,872
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	2,309
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	6,434
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	3,019
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	9,474
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	7,840
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	57
TX_CURR_TA	Age/Sex: 15-19 Female	1
TX_CURR_TA	Sum of Age/Sex disaggregations	1
TX_CURR_TA	Age/Sex: 1-9	2
TX_CURR_TA	Age/Sex: 10-14 Male	1
TX_CURR_TA	Age/Sex: 10-14 Female	1
TX_CURR_TA	Age/Sex: 50+ Male	4
TX_CURR_TA	Age/Sex: 20-24 Female	4
TX_CURR_TA	Age/Sex: 50+ Female	6
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	5
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	1
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	7
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	2
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	6
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	2



TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	8
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	7
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	5,204
TX_NEW_DSD	By Age/Sex: <1	18
TX_NEW_DSD	By Age/Sex: 1-9	101
TX_NEW_DSD	By Age/Sex: 10-14 Male	23
TX_NEW_DSD	By Age/Sex: 15-19 Male	108
TX_NEW_DSD	By Age/Sex: 20-24 Male	277
TX_NEW_DSD	By Age/Sex: 50+ Male	205
TX_NEW_DSD	By Age/Sex: 10-14 Female	96
TX_NEW_DSD	By Age/Sex: 15-19 Female	334
TX_NEW_DSD	By Age/Sex: 20-24 Female	619
TX_NEW_DSD	By Age/Sex: 50+ Female	13
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,675
TX_NEW_DSD	Pregnancy status	498
TX_NEW_DSD	Breastfeeding status	498
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	767
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	510
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	334
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	337
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	346
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	456
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	235



TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	425
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	4
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	57,857
TX_PVLS_DSD	Denominator: Indication: Routine	50,335
TX_PVLS_DSD	Denominator: Indication: Targeted	7,522
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	158
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	2,250
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	318
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	4,796
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,156
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	15,043
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2,315
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	31,821
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	51
TX_PVLS_TA	Denominator: Indication: Routine	45
TX_PVLS_TA	Denominator: Indication: Targeted	6
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2

TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	29
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	4
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	13
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	2
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	17,432
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	19,369
TX_RET_DSD	Numerator by Status: Pregnant	1,704
TX_RET_DSD	Numerator by Status: Breastfeeding	1,704
TX_RET_DSD	Denominator by Status: Pregnant	1,891
TX_RET_DSD	Denominator by Status: Breastfeeding	1,891
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	141
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8,004
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	262
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9,025
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the	158



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,891
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	291
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	10,029
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	16
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	18
TX_RET_TA	Numerator by Status: Pregnant	1
TX_RET_TA	Numerator by Status: Breastfeeding	1
TX_RET_TA	Denominator by Status: Pregnant	2
TX_RET_TA	Denominator by Status: Breastfeeding	2
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total	9



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	64
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	166
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	169
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	498
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	100
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	332
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	57
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	133
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39,	23



	Female, Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	67
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	16
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	1,662
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	83
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted	249
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	16
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Unassisted	16
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	9,737
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	11,455
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	687
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	459
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	6,987
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	3,322
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	584
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	389



TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	5,939
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	2,825
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	9,966
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	1,146
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	298
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	45
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	8,471
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	974
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	254
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	38
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	9
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	10
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	1
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	6
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	3



TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	7
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	2
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	9
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	1
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	8
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	1
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	64,285
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	3,858
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	2,572
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	39,212
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	18,643
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	2,572
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	130
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	515
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	1,927
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	55,926
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	1,672
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	6,430
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV	257



	Life-long ART, New, TB Screen - Positive, Positive	
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	57
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	4
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	2
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	34
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	17
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	2
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	2
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	50
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	1
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	6

Implementing Mechanism Details

Mechanism ID: 18274	Mechanism Name: Regional Health Integration to Enhance Services – North, Lango (RHITES-N, Lango)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: John Snow Inc (JSI)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 10,373,301	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 1,676,030	
Total All Funding Sources and Applied Pipeline Amount: 12,049,331	
Funding Source	Funding Amount



GHP-State	10,373,301
-----------	------------

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	86,761
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	130,141
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Gender: GBV	180,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Gender: Gender Equality	155,700
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Water	180,000
Condom programming	347,043
Food and Nutrition: Policy, Tools, and Service Delivery	260,282
Adolescent Girls and Young Women (AGYW)	2,978,534



Budget Code Information

Mechanism ID:	18274	
Mechanism Name:	Regional Health Integration to Enhance Services – North, Lango	
Prime Partner Name:	(RHITES-N, Lango) John Snow Inc (JSI)	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	1,238,445
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	321,062
Strategic Area	Budget Code	Planned Amount
Care	PDCS	381,705
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	55,700
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	1,768,008
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	410,155
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	3,028,612
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	322,439
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	2,697,830
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	149,345

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	3,788
PMTCT_ART_DSD	Number of pregnant women with known HIV status	60,049



	(includes women who were tested for HIV and received their results)	
PMTCT_ART_DSD	New on ART	1,267
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,521
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	1
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	9
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	1
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	60,049
PMTCT_STAT_DSD	Number of new ANC and L&D clients	60,049
PMTCT_STAT_DSD	By Age (Denominator): <15-19	11,409
PMTCT_STAT_DSD	By Age (Denominator): 20-24	19,815
PMTCT_STAT_DSD	By Number of known positives: 15-19	13
PMTCT_STAT_DSD	By Number of known positives: 20-24	75
PMTCT_STAT_DSD	By Number of new positives: 15-19	271
PMTCT_STAT_DSD	By Number of new positives: 20-24	469
PMTCT_STAT_DSD	By Number of new negative: 15-19	11,125
PMTCT_STAT_DSD	By Number of new negative: 20-24	19,271
PMTCT_STAT_DSD	By Age (Numerator): 15-19	11,409
PMTCT_STAT_DSD	By Age (Numerator): 20-24	19,815
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	13,211
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	10,207
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	4,204
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	1,203
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	1,133
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	11,766



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	312
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	875
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	9,090
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	242
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	362
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	3,741
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	101
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	106
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	1,068
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	29
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	13,211
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	10,207
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	4,204
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	1,203
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	9
PMTCT_STAT_TA	Number of new ANC and L&D clients	9
PMTCT_STAT_TA	By Age (Denominator): 15-19	2
PMTCT_STAT_TA	By Age (Denominator): 20-24	2
PMTCT_STAT_TA	By new negatives: 15-19	2
PMTCT_STAT_TA	By new negatives: 20-24	2
PMTCT_STAT_TA	By Age (Numerator): : 15-19	2



PMTCT_STAT_TA	By Age (Numerator): 20-24	2
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 25-29, Female	2
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 30-34, Female	2
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 35-39, Female	1
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	2
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	2
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	1
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 25-29, Female	2
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 30-34, Female	2
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 35-39, Female	1
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	78,921
VMMC_CIRC_DSD	By Age: 10-14	3,946
VMMC_CIRC_DSD	By Age: 15-19	19,731
VMMC_CIRC_DSD	By Age: 20-24	19,731
VMMC_CIRC_DSD	By Age: 25-29	23,676
VMMC_CIRC_DSD	By Age: 50+	2,369
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	45,777
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	69,453
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	78,921
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	3,156
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	3,156
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	3,156
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	115
PrEP_NEW_DSD	Male 15-19	1
PrEP_NEW_DSD	Male 20-24	8
PrEP_NEW_DSD	Male 50+	2



PrEP_NEW_DSD	Female 15-19	7
PrEP_NEW_DSD	Female 20-24	24
PrEP_NEW_DSD	Female 50+	1
PrEP_NEW_DSD	FSW	80
PrEP_NEW_DSD	MSM	5
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	12
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	6
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	12
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	6
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	12
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	6
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	12
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	6
PrEP_NEW_DSD	PrEP_NEW_N_DSD_KeyPopAbr Other Key Populations	1
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	3,218
PP_PREV_DSD	Age/sex: 15-19 Male	84
PP_PREV_DSD	Age/sex: 20-24 Male	208
PP_PREV_DSD	Age/sex: 50+ Male	220
PP_PREV_DSD	Age/sex: 10-14 Female	73
PP_PREV_DSD	Age/sex: 15-19 Female	480
PP_PREV_DSD	Age/sex: 20-24 Female	376
PP_PREV_DSD	Age/sex: 50+ Female	119
PP_PREV_DSD	Sum of Age/Sex disaggregates	1,560
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	112
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	204
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	109
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	198
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	183
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	328



PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	188
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	336
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	2,561
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	308
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,253
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	158,717
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	761
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	163
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	426
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	139
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	7



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	790
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	42
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	354
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	265
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	698
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	22
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	466
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	232
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	310
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	864
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	36
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	5



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	979
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	1,107
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	234
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	1,774
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	55
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	887
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	2,667
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	83
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	2,861
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	90
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	32
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	1,230



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	1,009
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	1,563
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	30
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	17
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	103
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	164
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	175
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	43
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	73
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	45



HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	103
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	73
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	2,540
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	12,694
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	82
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	12,694
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	82
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	1,522
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	144
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	30
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	96
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	48
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	11



HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	158
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	174
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	138
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	132
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	8
HTC_TST_DSD	By Key Population: FSW, Negative	180
HTC_TST_DSD	By Key Population: FSW, Positive	93
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	2,756
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	507
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	320
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	17
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	67
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	109
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	19



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	55
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	74
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	204
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	36
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	231
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	40
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	291
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	6,171
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	151
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	10,713
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	263
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	489
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	86
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	403
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	71



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	116
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	313
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	55
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	222
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	371
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	64
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	170
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	467
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	84
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	986
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	52
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	650
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	427

HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	432
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	443
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	583
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	299
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	542
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	2,414
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	100
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	1,980
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	82
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	574
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	23



HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	1,527
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	64
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	1,084
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	1,815
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	75
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	995
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	2,301
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	96
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	191
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	570
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	100
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	467
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	82
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	135

HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	361
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	64
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	255
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	428
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	75
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	234
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	547
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	96
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	4,343
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	135
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	4,469
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	139
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	1,553
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	48



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	2,862
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	90
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	1,713
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	53
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	3,241
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	101
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	1,393
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	2,629
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	81
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	7,134
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	172
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	3,086
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	133
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	3,205
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	58
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	2,158



HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	126
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	41
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	233
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	103
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	292
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	188
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	126
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	128
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	11



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	130
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	170
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	87
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	158
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	78
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	73
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	45
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	89
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	24



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	60
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	111
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	175
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	73
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	73
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	15,232
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	98
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	2,030
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	2,030
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	2,030



HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	14
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	82,492
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	591
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	18
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	125
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	125
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	40
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	232
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	12
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	103
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	79
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	4



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	542
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Positive	18
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	1,359
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	27
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	286
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	964
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	29
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	481
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	14
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	1,449
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	45
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	1,557
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	47
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	17
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	668
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	21



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Negative	1,246
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Positive	27
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	1,929
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	38
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Negative	14
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Negative	4
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	46
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Positive	10
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	75
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Positive	16
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	83
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	20
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	33
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	20
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male,	46



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	10
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Negative	33
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 10-14, Negative	1,385
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 10-14, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Negative	6,923
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Positive	32
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Negative	6,923
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Positive	32
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Negative	831
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	176
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Negative	37
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	51
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	26
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	87



HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	14
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	97
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	17
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	73
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	11
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	159
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Positive	8
HTC_TST_TA	By Key Population: FSW, Negative	408
HTC_TST_TA	By Key Population: FSW, Positive	209
HTC_TST_TA	By Key Population: People in prisons and other enclosed settings, Negative	1,108
HTC_TST_TA	By Key Population: People in prisons and other enclosed settings, Positive	245
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	4,482
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	120
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	7,786
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	206
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Negative	269
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Positive	47
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative	220
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Positive	38
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Negative	64



HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Positive	10
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Negative	169
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Positive	29
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Negative	120
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Positive	21
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative	201
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Positive	36
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Negative	94
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Positive	15
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Negative	256
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Positive	45
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Negative	289
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Positive	15
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Negative	191
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Positive	11
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Negative	126
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Positive	7



HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Negative	126
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Positive	7
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Negative	129
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Positive	7
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Negative	172
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Positive	8
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Negative	88
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Positive	4
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Negative	159
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Positive	8
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Negative	236
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Positive	10
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Negative	2,359
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Positive	73
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Negative	2,427
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Positive	73
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Negative	845



HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Positive	26
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Negative	1,558
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Positive	47
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Negative	934
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Positive	29
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Negative	1,764
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Positive	54
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Negative	757
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Positive	23
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Negative	1,427
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Positive	44
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Negative	5,186
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Positive	135
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Negative	2,245
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Positive	107
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Negative	2,330
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Positive	45



HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Negative	1,570
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Positive	15
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Negative	67
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Positive	3
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Negative	23
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Negative	125
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Positive	8
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Negative	56
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Negative	159
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Positive	11
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Negative	105
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Positive	6
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Negative	67
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Negative	68



HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Positive	4
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Negative	68
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Positive	4
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Negative	93
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Positive	6
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Negative	47
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Negative	87
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Positive	6
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Female, Negative	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Negative	40
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Negative	33
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Positive	8
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	20
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Positive	3
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Negative	40



HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Positive	9
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	26
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Positive	4
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Negative	51
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Positive	10
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	83
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Positive	20
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Negative	33
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Positive	8
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative	33
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Positive	8
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 25-29, Male, Negative	8,306
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 25-29, Male, Positive	38
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 30-34, Male, Negative	1,109
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 30-34, Male, Positive	4
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 35-39, Male, Negative	1,109
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 35-39, Male, Positive	4



HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 40-49, Male, Negative	1,109
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 40-49, Male, Positive	4
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	22
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	57
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	58
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	173
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	3
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	3
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	35
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	116
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	3
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	3
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	20
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	46
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	8
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	23
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	2



HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	6
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Sex Partner	575
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest FSW, Directly-Assisted	29
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest FSW, Unassisted	86
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest MSM, Directly-Assisted	6
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest MSM, Unassisted	6
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	3,436
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	3,436
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	186
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,059
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	171
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,020
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	186
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,059



TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	171
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,020
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	334
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	334
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	17
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	18
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	98
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	201
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	18
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	201
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	17
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	98
GEND_GBV_DSD	Number of people receiving post-GBV care	1,314



GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1,005
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	309
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	92
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	13
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	6
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	7
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	36
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	20
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	13
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	308
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	180
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	32
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	6
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	150
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	53
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	74
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	23
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	38
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	24
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	55
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	4
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	38
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	1



GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	55
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	4
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	38
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	55
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	4
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	38
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	18
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	13
GEND_GBV_TA	Number of people receiving post-GBV care	2,886
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	2,000
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	886
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	267
GEND_GBV_TA	<10, Female, Physical and/or Emotional Violence	26
GEND_GBV_TA	<10, Female, Sexual Violence (Post-Rape Care)	20
GEND_GBV_TA	<10, Male, Physical and/or Emotional Violence	13
GEND_GBV_TA	<10, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_TA	10-14, Female, Physical and/or Emotional Violence	70
GEND_GBV_TA	10-14, Female, Sexual Violence (Post-Rape Care)	55



GEND_GBV_TA	10-14, Male, Physical and/or Emotional Violence	25
GEND_GBV_TA	10-14, Male, Sexual Violence (Post-Rape Care)	2
GEND_GBV_TA	15-19, Female, Physical and/or Emotional Violence	609
GEND_GBV_TA	15-19, Female, Sexual Violence (Post-Rape Care)	512
GEND_GBV_TA	15-19, Male, Physical and/or Emotional Violence	61
GEND_GBV_TA	15-19, Male, Sexual Violence (Post-Rape Care)	20
GEND_GBV_TA	20-24, Female, Physical and/or Emotional Violence	297
GEND_GBV_TA	20-24, Female, Sexual Violence (Post-Rape Care)	155
GEND_GBV_TA	20-24, Male, Physical and/or Emotional Violence	148
GEND_GBV_TA	20-24, Male, Sexual Violence (Post-Rape Care)	66
GEND_GBV_TA	50+, Female, Physical and/or Emotional Violence	78
GEND_GBV_TA	50+, Female, Sexual Violence (Post-Rape Care)	8
GEND_GBV_TA	50+, Male, Physical and/or Emotional Violence	49
GEND_GBV_TA	50+, Male, Sexual Violence (Post-Rape Care)	2
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	109
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	11
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	78
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	3
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	109
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	11
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	78
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	3
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	109
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	11



	Female, Sexual Violence (Post-Rape Care)	
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	78
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	3
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	37
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	3
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	26
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,450
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	72
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	817
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	82
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	479
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	171
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with	9



	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	96
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	9
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	57
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	3,788
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	3,191
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	597
PMTCT_EID_DSD	Sum of Infant Age disaggregates	3,788
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	1
PMTCT_EID_TA	Sum of Infant Age disaggregates	1
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	24,850
TX_CURR_DSD	Age/Sex: 15-19 Male	87
TX_CURR_DSD	Age/Sex: 15-19 Female	511
TX_CURR_DSD	Sum of age/sex disaggregates	598
TX_CURR_DSD	Age/Sex: <1	71
TX_CURR_DSD	Age/Sex: <1-9	438
TX_CURR_DSD	Age/Sex: 10-14 Male	152



TX_CURR_DSD	Age/Sex: 10-14 Female	356
TX_CURR_DSD	Age/Sex: 20-24 Male	132
TX_CURR_DSD	Age/Sex: 50+ Male	1,815
TX_CURR_DSD	Age/Sex: 20-24 Female	1,516
TX_CURR_DSD	Age/Sex: 50+ Female	2,723
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	2,164
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	383
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	3,091
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	908
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	2,526
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,185
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	3,713
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	3,079
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	62,428
TX_CURR_TA	Age/Sex: 15-19 Male	214
TX_CURR_TA	Age/Sex: 15-19 Female	1,266
TX_CURR_TA	Sum of Age/Sex disaggregations	1,480
TX_CURR_TA	Age/Sex: <1	244
TX_CURR_TA	Age/Sex: 1-9	1,492
TX_CURR_TA	Age/Sex: 10-14 Male	522
TX_CURR_TA	Age/Sex: 10-14 Female	1,214
TX_CURR_TA	Age/Sex: 20-24 Male	323
TX_CURR_TA	Age/Sex: 50+ Male	4,487
TX_CURR_TA	Age/Sex: 20-24 Female	3,748



TX_CURR_TA	Age/Sex: 50+ Female	6,734
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	5,347
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	942
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	7,646
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	2,241
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	6,248
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	2,930
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	9,212
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	7,618
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,879
TX_NEW_DSD	By Age/Sex: <1	4
TX_NEW_DSD	By Age/Sex: 1-9	23
TX_NEW_DSD	By Age/Sex: 10-14 Male	5
TX_NEW_DSD	By Age/Sex: 15-19 Male	40
TX_NEW_DSD	By Age/Sex: 20-24 Male	103
TX_NEW_DSD	By Age/Sex: 50+ Male	73
TX_NEW_DSD	By Age/Sex: 10-14 Female	23
TX_NEW_DSD	By Age/Sex: 15-19 Female	123
TX_NEW_DSD	By Age/Sex: 20-24 Female	227
TX_NEW_DSD	By Age/Sex: 50+ Female	5
TX_NEW_DSD	Sum of Age/Sex disaggregates	599
TX_NEW_DSD	Pregnancy status	183
TX_NEW_DSD	Breastfeeding status	183
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29,	277



	Female, Positive	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	189
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	123
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	125
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	129
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	169
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	85
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	156
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,660
TX_NEW_TA	By Age/Sex: <1	18
TX_NEW_TA	By Age/Sex: 1-9	116
TX_NEW_TA	By Age/Sex: 10-14 Male	28
TX_NEW_TA	By Age/Sex: 15-19 Male	96
TX_NEW_TA	By Age/Sex: 20-24 Male	244
TX_NEW_TA	By Age/Sex: 50+ Male	181
TX_NEW_TA	By Age/Sex: 10-14 Female	103
TX_NEW_TA	By Age/Sex: 15-19 Female	294
TX_NEW_TA	By Age/Sex: 20-24 Female	548
TX_NEW_TA	By Age/Sex: 50+ Female	10
TX_NEW_TA	Sum of Age/Sex disaggregates	1,504
TX_NEW_TA	Pregnancy status	438
TX_NEW_TA	Breastfeeding status	438
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	692
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male,	448



	Positive	
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	294
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	297
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	306
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	403
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	207
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	375
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	22,367
TX_PVLS_DSD	Denominator: Indication: Routine	19,460
TX_PVLS_DSD	Denominator: Indication: Targeted	2,907
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	60
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	869
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	124
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	1,854
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	446
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	5,814
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	895
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	12,305



TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	56,184
TX_PVLS_TA	Denominator: Indication: Routine	48,880
TX_PVLS_TA	Denominator: Indication: Targeted	7,304
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2,248
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	308
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,125
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	152
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	30,898
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	4,657
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	14,609
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	2,187
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	7,644
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	8,491
TX_RET_DSD	Numerator by Status: Pregnant	762
TX_RET_DSD	Numerator by Status: Breastfeeding	762
TX_RET_DSD	Denominator by Status: Pregnant	846
TX_RET_DSD	Denominator by Status: Breastfeeding	846
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11



TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,580
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	18
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,035
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	11
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,976
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	20
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,484
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	19,365
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	21,519



TX_RET_TA	Numerator by Status: Pregnant	1,914
TX_RET_TA	Numerator by Status: Breastfeeding	1,914
TX_RET_TA	Denominator by Status: Pregnant	2,127
TX_RET_TA	Denominator by Status: Breastfeeding	2,127
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	76
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9,000
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	140
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10,149
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	84
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	10,000
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	158
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	11,277



	stopped ART, and those lost to follow-up)	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	26
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	70
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	71
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	210
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	3
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	3
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	42
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	139
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	3
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	3
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	23
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	56
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	28
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	3
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted -	700



	Sex Partner	
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted	105
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Unassisted	7
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	3,764
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	4,428
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	266
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	177
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	2,701
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	1,284
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	225
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	150
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	2,297
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	1,092
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	3,851
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	442
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT,	116

	Life-long ART, Already, Positive	
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	19
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	3,274
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	377
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	97
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	16
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	9,455
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	11,124
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	667
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	445
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	6,786
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	3,226
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	568
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	380
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	5,766
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	2,741
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	9,678



TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	1,114
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	289
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	43
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	8,225
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	945
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	247
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	38
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	24,850
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	1,491
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	995
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	15,156
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	7,208
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	995
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	50
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	199
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	746
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	21,618
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	647



TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	2,485
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	100
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	62,428
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	3,745
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	2,496
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	38,083
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	18,104
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	2,496
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	125
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	498
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	1,873
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	54,315
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	1,621
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	6,242
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	250

Implementing Mechanism Details

Mechanism ID: 18276	Mechanism Name: PPL-LER Monitoring and Evaluation IDIQ
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: DevTech Systems Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18276	
Mechanism Name:	PPL-LER Monitoring and Evaluation IDIQ	
Prime Partner Name:	DevTech Systems Inc	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18361	Mechanism Name: 4Children - Coordinating Comprehensive Care for Children
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information



Mechanism ID: 18361		
Mechanism Name: 4Children - Coordinating Comprehensive Care for Children		
Prime Partner Name: Catholic Relief Services		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18369	Mechanism Name: Global Health Supply Chain – Procurement and Supply Management (GHSC-PSM) - HIV/AIDS Task Order
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 33,166,805	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 3,090,537	
Total All Funding Sources and Applied Pipeline Amount: 36,257,342	
Funding Source	Funding Amount
GHP-State	33,166,805

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18369	
Mechanism Name:	Global Health Supply Chain – Procurement and Supply	
Prime Partner Name:	Management (GHSC-PSM) - HIV/AIDS Task Order	
	Global Health Supply Chain Program	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	671,214
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	18,902
Strategic Area	Budget Code	Planned Amount
Care	PDCS	1,533,783



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	6,895,366
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	25,940
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXD	13,548,375
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	10,473,225
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18502	Mechanism Name: DREAMS Initiative and HIV/AIDS Prevention Support to the Ugandan Peoples Defense
Funding Agency: DOD	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 502,554	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 502,554	
Funding Source	Funding Amount
GHP-State	502,554

Cross-Cutting Budget Attribution(s)

Gender: GBV	20,000
Focus Area:	GBV Prevention



Sub Area:	Capacity building
Gender: Gender Equality	20,000
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Implementation
Adolescent Girls and Young Women (AGYW)	142,515
Condom procurement	20,000
Food and Nutrition: Commodities	10,000
Economic Strengthening	20,000

Budget Code Information

Mechanism ID:	18502
---------------	-------



Mechanism Name: DREAMS Initiative and HIV/AIDS Prevention Support to the Prime Partner Name: Ugandan Peoples Defense Population Services International		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	502,554
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	51,434
PP_PREV_DSD	Age/sex: 15-19 Male	1,430
PP_PREV_DSD	Age/sex: 20-24 Male	5,040
PP_PREV_DSD	Age/sex: 50+ Male	3,200
PP_PREV_DSD	Age/sex: 10-14 Female	330



PP_PREV_DSD	Age/sex: 15-19 Female	5,758
PP_PREV_DSD	Age/sex: 20-24 Female	7,376
PP_PREV_DSD	Age/sex: 50+ Female	1,800
PP_PREV_DSD	Sum of Age/Sex disaggregates	24,934
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	4,140
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	7,360
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	4,140
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	7,360
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	540
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	960
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	720
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	1,280
GEND_GBV_DSD	Number of people receiving post-GBV care	542
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	381
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	161
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	48
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	5
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	3
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	3
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	13
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	10
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	5
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	116
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	93
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	12
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	3
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	57
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	28
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	28



GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	12
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	15
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	9
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	21
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	14
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	21
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	14
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	21
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	14
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	7
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3	5



	40-49, Male, Physical and/or Emotional Violence	
--	---	--

Implementing Mechanism Details

Mechanism ID: 18553	Mechanism Name: Strengthening High Impact Interventions for an AIDS-free Generation (AIDSFree) Project
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: John Snow Inc (JSI)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,300,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,300,000	
Funding Source	Funding Amount
GHP-State	560,464
GHP-USAID	739,536

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18553	
Mechanism Name:	Strengthening High Impact Interventions for an AIDS-free Generation (AIDSFree) Project	
Prime Partner Name:	John Snow Inc (JSI)	
Strategic Area	Budget Code	Planned Amount



Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	1,300,000
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18554	Mechanism Name: EQUIP
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Right to Care	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 300,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	



Total All Funding Sources and Applied Pipeline Amount: 300,000	
Funding Source	Funding Amount
GHP-State	300,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18554		
Mechanism Name: EQUIP		
Prime Partner Name: Right to Care		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	45,000
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	30,000
Strategic Area	Budget Code	Planned Amount
Care	PDCS	45,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	30,000
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	105,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	45,000



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18557	Mechanism Name: Defeat TB
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Council	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 800,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 800,000	
Funding Source	Funding Amount
GHP-State	800,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	60,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Water	30,000
Human Resources for Health	30,000

Budget Code Information

Mechanism ID: 18557



Mechanism Name: Defeat TB		
Prime Partner Name: University Research Council		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	800,000
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18559	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18560	TBD: Yes
---------------------	----------



REDACTED

Implementing Mechanism Details

Mechanism ID: 18561	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18562	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18563	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18565	Mechanism Name: Provision of comprehensive, friendly services for key populations and CRANE follow on for enhanced surveillance
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Council	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 600,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 600,000	
Funding Source	Funding Amount



GHP-State	600,000
-----------	---------

Cross-Cutting Budget Attribution(s)

Gender: GBV	50,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information

Budget Code Information

Mechanism ID:	18565	
Mechanism Name:	Provision of comprehensive, friendly services for key populations and CRANE follow on for enhanced surveillance	
Prime Partner Name:	Population Council	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HVSI	150,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	300,000
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	150,000



Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18566	Mechanism Name: Production, distribution and monitoring implementation of Rapid HIV PT, facility and site certification, HIVDR sentinel surveys, validation of emerging lab assays and lab equipment	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Uganda Virus Research Institute		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	
Total All Funding Sources: 1,542,693		Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 1,542,693		
Funding Source	Funding Amount	
GHP-State	1,542,693	

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 18566 Mechanism Name: Production, distribution and monitoring implementation of Rapid HIV PT, facility and site certification, HIVDR sentinel surveys, validation of emerging lab assays and lab equipment Prime Partner Name: Uganda Virus Research Institute		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	806,693
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	200,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	536,000
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18567	Mechanism Name: Accelerating Epidemic Control in Fort Portal region in the Republic of Uganda under the President's Emergency Plan for AIDS Relief (PEPFAR)
----------------------------	--



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Baylor University, College of Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 12,034,765	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 1,700,000	
Total All Funding Sources and Applied Pipeline Amount: 13,734,765	
Funding Source	Funding Amount
GHP-State	12,034,765

Cross-Cutting Budget Attribution(s)

Gender: GBV	150,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Adolescent Girls and Young Women (AGYW)	754,749
Water	139,943

Budget Code Information

Mechanism ID:	18567	
Mechanism Name:	Accelerating Epidemic Control in Fort Portal region in the Republic of Uganda under the President's Emergency Plan for AIDS Relief (PEPFAR)	
Prime Partner Name:	Baylor University, College of Medicine	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	1,911,592



Strategic Area	Budget Code	Planned Amount
Care	HKID	2,250,257
Strategic Area	Budget Code	Planned Amount
Care	HVTB	501,768
Strategic Area	Budget Code	Planned Amount
Care	PDCS	620,169
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	42,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	463,943
Strategic Area	Budget Code	Planned Amount



Prevention	HVOP	133,603
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	569,805
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	5,300,162
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	241,466

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	3,197
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	56,183
PMTCT_ART_DSD	New on ART	945
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,252
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	2,742
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received	48,815



	their results)	
PMTCT_ART_TA	New on ART	843
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	1,899
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	56,183
PMTCT_STAT_DSD	Number of new ANC and L&D clients	56,183
PMTCT_STAT_DSD	By Age (Denominator): <15-19	10,674
PMTCT_STAT_DSD	By Age (Denominator): 20-24	18,544
PMTCT_STAT_DSD	By Number of known positives: 15-19	16
PMTCT_STAT_DSD	By Number of known positives: 20-24	72
PMTCT_STAT_DSD	By Number of new positives: 15-19	192
PMTCT_STAT_DSD	By Number of new positives: 20-24	333
PMTCT_STAT_DSD	By Number of new negative: 15-19	10,466
PMTCT_STAT_DSD	By Number of new negative: 20-24	18,139
PMTCT_STAT_DSD	By Age (Numerator): 15-19	10,674
PMTCT_STAT_DSD	By Age (Numerator): 20-24	18,544
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	12,363
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	9,547
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	3,931
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	1,124
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	1,038
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	11,104
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	221
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	807
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	8,569
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	171



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	335
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	3,522
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	74
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	101
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	997
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	26
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	12,363
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	9,547
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	3,931
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	1,124
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	48,815
PMTCT_STAT_TA	Number of new ANC and L&D clients	48,815
PMTCT_STAT_TA	By Age (Denominator): 15-19	9,277
PMTCT_STAT_TA	By Age (Denominator): 20-24	16,107
PMTCT_STAT_TA	By known positives: 15-19	9
PMTCT_STAT_TA	By known positives: 20-24	54
PMTCT_STAT_TA	By new positives: 15-19	168
PMTCT_STAT_TA	By new positives: 20-24	294
PMTCT_STAT_TA	By new negatives: 15-19	9,100
PMTCT_STAT_TA	By new negatives: 20-24	15,759
PMTCT_STAT_TA	By Age (Numerator): : 15-19	9,277
PMTCT_STAT_TA	By Age (Numerator): 20-24	16,107
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 25-29, Female	10,735
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 30-34, Female	8,302
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 35-39, Female	3,418



PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 40-49, Female	976
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	879
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	9,659
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	197
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	678
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	7,472
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	152
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	282
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	3,079
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	57
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	78
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	885
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	13
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 25-29, Female	10,735
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 30-34, Female	8,302
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 35-39, Female	3,418
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 40-49, Female	976
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	51,009
VMMC_CIRC_DSD	By Age: 10-14	2,552
VMMC_CIRC_DSD	By Age: 15-19	12,753



VMMC_CIRC_DSD	By Age: 20-24	12,753
VMMC_CIRC_DSD	By Age: 25-29	15,302
VMMC_CIRC_DSD	By Age: 50+	1,526
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	29,584
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	44,886
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	51,009
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	2,041
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	2,041
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	2,041
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	716
PrEP_NEW_DSD	Male 15-19	8
PrEP_NEW_DSD	Male 20-24	51
PrEP_NEW_DSD	Male 50+	13
PrEP_NEW_DSD	Female 15-19	42
PrEP_NEW_DSD	Female 20-24	170
PrEP_NEW_DSD	Female 50+	8
PrEP_NEW_DSD	FSW	502
PrEP_NEW_DSD	MSM	28
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	71
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	35
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	71
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	35
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	71
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	35
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	71
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	35
PrEP_NEW_DSD	PrEP_NEW_N_DSD_KeyPopAbr Other Key Populations	5
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the	3,178



	minimum components during the reporting period.	
PP_PREV_DSD	Age/sex: 15-19 Male	117
PP_PREV_DSD	Age/sex: 20-24 Male	185
PP_PREV_DSD	Age/sex: 50+ Male	196
PP_PREV_DSD	Age/sex: 10-14 Female	94
PP_PREV_DSD	Age/sex: 15-19 Female	602
PP_PREV_DSD	Age/sex: 20-24 Female	365
PP_PREV_DSD	Age/sex: 50+ Female	111
PP_PREV_DSD	Sum of Age/Sex disaggregates	1,670
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	97
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	184
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	90
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	189
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	168
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	311
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	164
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	305
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	5,321
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	87
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	113
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV	16



	preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,616
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,489
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	187,614
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	4,233
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	133
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	901
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	449
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	147
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	838
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	44



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	375
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	283
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	3,873
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	129
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	375
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	186
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	250
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	695
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	29
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	4
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	785



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	5,118
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	104
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	1,080
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	1,601
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	55
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	802
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	2,405
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	79
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	2,583
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	83
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	33
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	1,111
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	4,680



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	104
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	7,257
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	149
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	43
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	22
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	139
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	217
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	37
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	236
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	43
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	95
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	63
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	139



HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	95
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	1,973
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	9,860
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	9,860
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	1,183
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	669
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	37
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	143
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	92
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	48
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	146
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	28



HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	161
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	127
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	609
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	33
HTC_TST_DSD	By Key Population: FSW, Negative	1,541
HTC_TST_DSD	By Key Population: FSW, Positive	724
HTC_TST_DSD	By Key Population: MSM, Negative	156
HTC_TST_DSD	By Key Population: MSM, Positive	70
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	3,527
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	709
HTC_TST_DSD	By Key Population: TG, Negative	58
HTC_TST_DSD	By Key Population: TG, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	1,008
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	54
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	215
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	92
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	17
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	46



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	61
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	172
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	30
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	195
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	34
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	922
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	48
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	10,207
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	196
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	17,724
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	340
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	454
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	82
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	368
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	71
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	110
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	21



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	284
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	55
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	203
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	335
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	64
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	157
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	427
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	79
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	1,044
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	57
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	687
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	450
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	455



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	466
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	617
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	318
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	576
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	1,938
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	80
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	1,590
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	67
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	462
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	1,226
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	52



HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	871
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	1,457
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	60
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	800
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	1,849
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	76
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	885
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	479
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	84
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	394
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	70
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	114
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	302

HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	54
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	214
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	360
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	63
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	196
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	458
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	80
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	3,911
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	124
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	4,035
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	128
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	1,403
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	49
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	2,585
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	83



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	1,550
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	55
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	2,929
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	94
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	1,260
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	2,370
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	79
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	11,803
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	224
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	5,109
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	174
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	5,303
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	77
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	3,571
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	115



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	41
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	209
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	96
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	262
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	176
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	115
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	118
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	122
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	9



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	156
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	83
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	145
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	73
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	95
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	63
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	116
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	80
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	16



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	146
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	236
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	95
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	95
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	11,832
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	1,579
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	1,579
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	1,579
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12	79,378



	months	
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	56
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	12
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	8
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	12
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	4
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	4
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	51
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	2,121
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	38
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	447
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	592
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	13
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	293
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	6



	Male, Positive	
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	893
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	23
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	956
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	25
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	8
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	408
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	9
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Negative	1,946
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Positive	38
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	3,005
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	60
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Negative	5
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	30
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	45
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Positive	6



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	54
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	24
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	9
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	30
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Negative	24
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 10-14, Negative	575
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Negative	2,878
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Negative	2,878
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Negative	345
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	265
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Positive	13
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Negative	56
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Positive	1



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	27
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	10
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	50
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	57
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	42
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	246
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Positive	11
HTC_TST_TA	By Key Population: FSW, Negative	237
HTC_TST_TA	By Key Population: FSW, Positive	116
HTC_TST_TA	By Key Population: MSM, Negative	13
HTC_TST_TA	By Key Population: MSM, Positive	5
HTC_TST_TA	By Key Population: People in prisons and other enclosed settings, Negative	733
HTC_TST_TA	By Key Population: People in prisons and other enclosed settings, Positive	150
HTC_TST_TA	By Key Population: TG, Negative	4
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	8,557



HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	164
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	14,860
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	287
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Negative	163
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Positive	25
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative	133
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Positive	18
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Negative	35
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Positive	5
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Negative	103
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Positive	13
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Negative	71
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Positive	9
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative	123
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Positive	17
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Negative	56
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Positive	8
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Negative	155
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Positive	23



	Positive	
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Negative	15
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Negative	10
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Negative	8
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Negative	8
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Negative	8
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Negative	9
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Negative	4
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Negative	8
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Negative	372
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Positive	13
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Negative	1,457
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Positive	40
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Negative	1,494
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Positive	42
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Negative	519
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Positive	10
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Negative	956



	Male, Negative	
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Positive	25
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Negative	571
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Positive	12
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Negative	1,080
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Positive	31
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Negative	463
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Positive	10
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Negative	879
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Positive	22
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Negative	9,892
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Positive	187
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Negative	4,280
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Positive	146
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Negative	4,445
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Positive	58
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Negative	2,998
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Positive	16



	Female, Positive	
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Negative	37
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Negative	10
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Negative	78
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Positive	4
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Negative	31
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Negative	97
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Positive	5
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Negative	57
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Positive	4
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Negative	37
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Negative	37
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Negative	39
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Positive	2



	Positive	
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Negative	55
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Positive	4
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Negative	25
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Negative	50
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Positive	4
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Negative	21
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Negative	24
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Positive	4
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	9
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Negative	28
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Positive	4
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	17
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39,	33



	Female, Negative	
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Positive	4
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	54
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Positive	8
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Negative	24
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Positive	4
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative	24
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Positive	4
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 25-29, Male, Negative	3,451
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 30-34, Male, Negative	460
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 35-39, Male, Negative	460
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 40-49, Male, Negative	460
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	47
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	126
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	123
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	376
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male,	5



	Directly-Assisted	
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	5
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	75
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	252
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	5
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	5
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	43
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	101
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	18
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	50
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	5
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	13
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Sex Partner	1,256
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest FSW, Directly-Assisted	64
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest FSW, Unassisted	189
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest MSM, Directly-Assisted	13
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest MSM, Unassisted	13
TB_STAT_DSD	Number of registered new and relapsed TB cases with	2,989



	documented HIV status, during the reporting period.	
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	2,989
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	166
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,781
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	152
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	890
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	166
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,781
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	152
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	890
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	747
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	747
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	35
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total	37



	number of registered new and relapsed TB cases, during the reporting period)	
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	217
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	458
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	37
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	458
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	35
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	217
GEND_GBV_DSD	Number of people receiving post-GBV care	9,122
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	5,837
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	3,285
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	986
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	78
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	67
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	43
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	7
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	206
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	207
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	73
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	12



GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	1,787
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	1,887
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	182
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	70
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	867
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	573
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	432
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	243
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	226
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	24
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	141
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	12
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	320
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	40
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	221
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	15
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	320
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	40
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	221
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	15
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	320
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	40
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3	221



	35-39, Male, Physical and/or Emotional Violence	
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	15
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	106
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	13
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	73
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	5
OVC_SERVDSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	38,892
OVC_SERVDSD	Age/Sex: 10-14 Male	4,283
OVC_SERVDSD	Age/Sex: 15-17 Male	3,499
OVC_SERVDSD	By: Age/sex: Male 18-24	3,497
OVC_SERVDSD	By: Age/sex: Male 25+	779
OVC_SERVDSD	Age/Sex: 10-14 Female	4,663
OVC_SERVDSD	Age/Sex: 15-17 Female	4,278
OVC_SERVDSD	By: Age/sex: 18-24 Female	4,279
OVC_SERVDSD	By: Age/sex: 25+ Female	1,163
OVC_SERVDSD	Sum of Age/Sex disaggregates	16,723
OVC_SERVDSD	Age/Sex: <1	1,555
OVC_SERVDSD	Age/Sex: 1-9	10,896
OVC_SERVDSD	Program Completion: Active	36,949
OVC_SERVDSD	Program Completion: Graduation	1,943
OVC_HIVSTATDSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	29,174
OVC_HIVSTATDSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	38,892

TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,072
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	58
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	593
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	62
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	359
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	253
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	9
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	153
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	11
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The	80



	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	3,197
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	2,711
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	486
PMTCT_EID_DSD	Sum of Infant Age disaggregates	3,197
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,742
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	2,289
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	453
PMTCT_EID_TA	Sum of Infant Age disaggregates	2,742
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	66,066
TX_CURR_DSD	Age/Sex: 15-19 Male	225
TX_CURR_DSD	Age/Sex: 15-19 Female	1,327
TX_CURR_DSD	Sum of age/sex disaggregates	1,552
TX_CURR_DSD	Age/Sex: <1	293
TX_CURR_DSD	Age/Sex: <1-9	1,768
TX_CURR_DSD	Age/Sex: 10-14 Male	617
TX_CURR_DSD	Age/Sex: 10-14 Female	1,444
TX_CURR_DSD	Age/Sex: 20-24 Male	345
TX_CURR_DSD	Age/Sex: 50+ Male	4,720
TX_CURR_DSD	Age/Sex: 20-24 Female	3,937
TX_CURR_DSD	Age/Sex: 50+ Female	7,075
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	5,622
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male,	993



	Positive	
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	8,032
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	2,358
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	6,570
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	3,077
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	9,664
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	7,999
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	26,724
TX_CURR_TA	Age/Sex: 15-19 Male	90
TX_CURR_TA	Age/Sex: 15-19 Female	543
TX_CURR_TA	Sum of Age/Sex disaggregations	633
TX_CURR_TA	Age/Sex: <1	108
TX_CURR_TA	Age/Sex: 1-9	678
TX_CURR_TA	Age/Sex: 10-14 Male	235
TX_CURR_TA	Age/Sex: 10-14 Female	548
TX_CURR_TA	Age/Sex: 20-24 Male	134
TX_CURR_TA	Age/Sex: 50+ Male	1,911
TX_CURR_TA	Age/Sex: 20-24 Female	1,602
TX_CURR_TA	Age/Sex: 50+ Female	2,874
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	2,279
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	400
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	3,265
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	957



	Positive	
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	2,660
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	1,249
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	3,938
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	3,253
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,662
TX_NEW_DSD	By Age/Sex: <1	49
TX_NEW_DSD	By Age/Sex: 1-9	291
TX_NEW_DSD	By Age/Sex: 10-14 Male	72
TX_NEW_DSD	By Age/Sex: 15-19 Male	91
TX_NEW_DSD	By Age/Sex: 20-24 Male	223
TX_NEW_DSD	By Age/Sex: 50+ Male	166
TX_NEW_DSD	By Age/Sex: 10-14 Female	268
TX_NEW_DSD	By Age/Sex: 15-19 Female	269
TX_NEW_DSD	By Age/Sex: 20-24 Female	503
TX_NEW_DSD	By Age/Sex: 50+ Female	10
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,602
TX_NEW_DSD	Pregnancy status	403
TX_NEW_DSD	Breastfeeding status	403
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	574
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	413
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	270
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	274
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39,	281



	Female, Positive	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	371
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	192
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	345
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,886
TX_NEW_TA	By Age/Sex: <1	16
TX_NEW_TA	By Age/Sex: 1-9	115
TX_NEW_TA	By Age/Sex: 10-14 Male	23
TX_NEW_TA	By Age/Sex: 15-19 Male	31
TX_NEW_TA	By Age/Sex: 20-24 Male	88
TX_NEW_TA	By Age/Sex: 50+ Male	64
TX_NEW_TA	By Age/Sex: 10-14 Female	108
TX_NEW_TA	By Age/Sex: 15-19 Female	108
TX_NEW_TA	By Age/Sex: 20-24 Female	195
TX_NEW_TA	By Age/Sex: 50+ Female	3
TX_NEW_TA	Sum of Age/Sex disaggregates	620
TX_NEW_TA	Pregnancy status	158
TX_NEW_TA	Breastfeeding status	158
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	296
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	162
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	108
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	109
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	109
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	144



	Positive	
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	72
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	135
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	59,456
TX_PVLS_DSD	Denominator: Indication: Routine	51,727
TX_PVLS_DSD	Denominator: Indication: Targeted	7,729
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	161
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	2,311
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	333
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	4,924
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,189
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	15,459
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2,377
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	32,702
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	24,055
TX_PVLS_TA	Denominator: Indication: Routine	20,928
TX_PVLS_TA	Denominator: Indication: Targeted	3,127
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	964
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15	127



	Female Targeted	
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	482
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	64
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	13,227
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	1,999
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	6,255
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	937
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	13,782
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	15,312
TX_RET_DSD	Numerator by Status: Pregnant	1,335
TX_RET_DSD	Numerator by Status: Breastfeeding	1,335
TX_RET_DSD	Denominator by Status: Pregnant	1,486
TX_RET_DSD	Denominator by Status: Breastfeeding	1,486
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	154
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,273
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	280
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on	7,075



	treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	169
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,978
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	311
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,854
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	5,385
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	5,985
TX_RET_TA	Numerator by Status: Pregnant	525
TX_RET_TA	Numerator by Status: Breastfeeding	525
TX_RET_TA	Denominator by Status: Pregnant	583
TX_RET_TA	Denominator by Status: Breastfeeding	583
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	44
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of	2,471

	adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	89
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,781
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	51
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,738
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	98
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,098
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	213
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	556
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	549
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24,	1,669



	Female, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	29
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	29
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	334
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	1,110
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	29
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	29
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	190
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	444
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	77
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	224
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	23
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	55
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	5,552
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	276
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted	832
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	55
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM,	55



	Unassisted	
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	10,011
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	11,774
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	709
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	475
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	7,174
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	3,416
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	603
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	401
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	6,106
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	2,901
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	10,238
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	1,174
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	309
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	53
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	8,705
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	1,000

TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	261
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	45
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	4,044
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	4,760
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	283
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	187
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	2,911
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	1,379
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	239
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	162
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	2,468
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	1,175
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	4,147
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	479
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	121
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	13
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already,	3,525



	Positive	
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	405
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	103
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	11
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	66,066
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	3,964
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	2,649
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	40,293
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	19,160
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	2,649
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	136
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	534
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	1,979
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	57,476
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	1,714
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	6,608
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	268
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	26,724
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	1,604
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	1,064



TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	16,307
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	7,749
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	1,064
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	49
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	209
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	806
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	23,250
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	698
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	2,672
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	104

Implementing Mechanism Details

Mechanism ID: 18568	Mechanism Name: Project SOAR (Supporting Operational AIDS Research)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Council	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 275,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 275,000	
Funding Source	Funding Amount



GHP-State	275,000
-----------	---------

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18568		
Mechanism Name: Project SOAR (Supporting Operational AIDS Research)		
Prime Partner Name: Population Council		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	275,000
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18569	Mechanism Name: UNICEF MCH Umbrella Grant
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: UNICEF	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 300,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 300,000	
Funding Source	Funding Amount
GHP-State	300,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18569		
Mechanism Name: UNICEF MCH Umbrella Grant		
Prime Partner Name: UNICEF		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	300,000
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18583	Mechanism Name: STOP TB Partnership
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: STOP TB Partnership Trust Fund	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,485,124	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,485,124	
Funding Source	Funding Amount
GHP-State	1,485,124



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18583 Mechanism Name: STOP TB Partnership Prime Partner Name: STOP TB Partnership Trust Fund		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	1,485,124
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Approved



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18668	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18671	Mechanism Name: REFUGEE - Over five years this follow-on mechanism will utilize comprehensive facility and community approaches to build on existing interventions and scale up HIV prevention, care and treatment services in the mid-Western and West-Nile regions of Uganda
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Infectious Disease Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

18671 REFUGEE - Over five years this follow-on mechanism will utilize Mechanism ID: comprehensive facility and community approaches to build on Mechanism Name: existing interventions and scale up HIV prevention, care and Prime Partner Name: treatment services in the mid-Western and West-Nile regions of Uganda Infectious Disease Institute		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18672	TBD: Yes
----------------------------	-----------------



REDACTED

Implementing Mechanism Details

Mechanism ID: 70363	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70364	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70365	Mechanism Name: [Placeholder - 70365 Uganda DOD]
Funding Agency: DOD	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 70365 Mechanism Name: [Placeholder - 70365 Uganda DOD] Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70366	Mechanism Name: [Placeholder - 70366 Uganda DOD]
Funding Agency: DOD	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 70366		
Mechanism Name: [Placeholder - 70366 Uganda DOD]		
Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70367	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70368	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70369	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70370	Mechanism Name: [Placeholder - 70370 Uganda HHS/CDC]
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes



Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 70370		
Mechanism Name: [Placeholder - 70370 Uganda HHS/CDC]		
Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70371	Mechanism Name: [Placeholder - 70371 Uganda HHS/CDC]	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: [Placeholder]		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 70371



Mechanism Name: [Placeholder - 70371 Uganda HHS/CDC] Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70372	Mechanism Name: [Placeholder - 70372 Uganda HHS/CDC]
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 70372		
Mechanism Name: [Placeholder - 70372 Uganda HHS/CDC]		
Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0



Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70373	Mechanism Name: [Placeholder - 70373 Uganda HHS/CDC]
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	70373
Mechanism Name:	[Placeholder - 70373 Uganda HHS/CDC]
Prime Partner Name:	[Placeholder]



Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70374	Mechanism Name: [Placeholder - 70374 Uganda HHS/CDC]
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 70374		
Mechanism Name: [Placeholder - 70374 Uganda HHS/CDC]		
Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount



Treatment	PDTX	0
-----------	------	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70375	Mechanism Name: [Placeholder - 70375 Uganda HHS/CDC]
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 70375 Mechanism Name: [Placeholder - 70375 Uganda HHS/CDC] Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount



Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70376	Mechanism Name: [Placeholder - 70376 Uganda HHS/CDC]
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A



Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 70376		
Mechanism Name: [Placeholder - 70376 Uganda HHS/CDC]		
Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70377	Mechanism Name: [Placeholder - 70377 Uganda HHS/CDC]
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 70377		
Mechanism Name: [Placeholder - 70377 Uganda HHS/CDC]		
Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70378	Mechanism Name: [Placeholder - 70378 Uganda HHS/CDC]
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 70378 Mechanism Name: [Placeholder - 70378 Uganda HHS/CDC] Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70379	Mechanism Name: [Placeholder - 70379 Uganda HHS/HRSA]
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 70379		
Mechanism Name: [Placeholder - 70379 Uganda HHS/HRSA]		
Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0



Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount



Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70380	Mechanism Name: [Placeholder - 70380 Uganda HHS/HRSA]
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 70380		
Mechanism Name: [Placeholder - 70380 Uganda HHS/HRSA]		
Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details



Mechanism ID: 70381	Mechanism Name: [Placeholder - 70381 Uganda HHS/HRSA]
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 70381		
Mechanism Name: [Placeholder - 70381 Uganda HHS/HRSA]		
Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0



Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount



Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70382	Mechanism Name: [Placeholder - 70382 Uganda PC]
Funding Agency: PC	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 70382		
Mechanism Name: [Placeholder - 70382 Uganda PC]		
Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70383	Mechanism Name: [Placeholder - 70383 Uganda PC]
Funding Agency: PC	Procurement Type: Cooperative Agreement



Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 70383		
Mechanism Name: [Placeholder - 70383 Uganda PC]		
Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70384	Mechanism Name: Fiduciary Agent
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Price Waterhouse Coopers	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information



Mechanism ID: 70384 Mechanism Name: Fiduciary Agent Prime Partner Name: Price Waterhouse Coopers		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	600,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70385	TBD: Yes
REDACTED	

Implementing Mechanism Details



Mechanism ID: 70386	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70387	Mechanism Name: LARA
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Research Triangle International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 478,929	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 300,000	
Total All Funding Sources and Applied Pipeline Amount: 778,929	
Funding Source	Funding Amount
GHP-State	478,929

Cross-Cutting Budget Attribution(s)

Adolescent Girls and Young Women (AGYW)	478,929
---	---------

Budget Code Information

Mechanism ID:	70387	
Mechanism Name:	LARA	
Prime Partner Name:	Research Triangle International	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	478,929
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70388	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70389	Mechanism Name: VMMC Commodities BPA
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Beyond Logistics	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 70389		
Mechanism Name: VMMC Commodities BPA		
Prime Partner Name: Beyond Logistics		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount

Approved



Treatment	PDTX	0
-----------	------	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70390	Mechanism Name: PSM-RTK
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Remote Medical International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 70390		
Mechanism Name: PSM-RTK		
Prime Partner Name: Remote Medical International		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	2,353



Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	432,233
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	1,304,081
Strategic Area	Budget Code	Planned Amount



Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	131,561
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70391	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70392	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70393	Mechanism Name: [Placeholder - 70393 Uganda USAID]
----------------------------	---



Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 70393		
Mechanism Name: [Placeholder - 70393 Uganda USAID]		
Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount



Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70394	Mechanism Name: [Placeholder - 70394 Uganda USAID]
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 70394 Mechanism Name: [Placeholder - 70394 Uganda USAID] Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70395	Mechanism Name: [Placeholder - 70395 Uganda USAID]
Funding Agency: USAID	Procurement Type: Cooperative Agreement



Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 70395		
Mechanism Name: [Placeholder - 70395 Uganda USAID]		
Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70396	Mechanism Name: [Placeholder - 70396 Uganda USAID]
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 70396		
Mechanism Name: [Placeholder - 70396 Uganda USAID]		
Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70397	Mechanism Name: [Placeholder - 70397 Uganda USAID]
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 70397		
Mechanism Name: [Placeholder - 70397 Uganda USAID]		
Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0

Approved



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70518	TBD: Yes
REDACTED	



Agency Information - Costs of Doing Business
U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services			261,250	261,250	288,522	549,772
ICASS			1,158,054	1,158,054	1,278,946	2,437,000
Institutional Contractors		0	1,458,378	1,458,378	1,610,622	3,069,000
Management Meetings/Professional Development			158,478	158,478	175,022	333,500
Non-ICASS Administrative Costs			450,581	450,581	497,619	948,200
Staff Program Travel			466,168	466,168	514,832	981,000
USG Staff Salaries and Benefits - Internationally Recruited			1,380,715	1,380,715	1,524,852	2,905,567
USG Staff Salaries and Benefits - Locally Recruited			1,209,340	1,209,340	1,335,585	2,544,925



Total	0	0	6,542,964	6,542,964	7,226,000	13,768,964
--------------	----------	----------	------------------	------------------	------------------	-------------------

U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
ICASS		0		0	108,522	108,522
Management Meetings/Professional Development		0		0	56,217	56,217
Non-ICASS Administrative Costs		0		0	166,684	166,684
Staff Program Travel		0		0	80,133	80,133
USG Staff Salaries and Benefits - Internationally Recruited		0		0	180,800	180,800
USG Staff Salaries and Benefits - Locally Recruited		135,226		135,226	107	135,333
Total	0	135,226	0	135,226	592,463	727,689



U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Capital Security Cost Sharing		2,280,778		2,280,778	0	2,280,778
Computers/IT Services		862,058		862,058	0	862,058
ICASS		1,836,000		1,836,000	0	1,836,000
Management Meetings/Professional Development	260,724	600,534		861,258	0	861,258
Non-ICASS Administrative Costs		1,207,653		1,207,653	0	1,207,653
Non-ICASS Motor Vehicles		353,980		353,980	0	353,980
Staff Program Travel	300,000	1,087,739		1,387,739	0	1,387,739
USG Staff Salaries and Benefits - Internationally Recruited	2,651,776	170,680		2,822,456	0	2,822,456
USG Staff Salaries and Benefits - Locally Recruited		4,175,421		4,175,421	0	4,175,421
Total	3,212,500	12,574,843	0	15,787,343	0	15,787,343



U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		0		0	5,000	5,000
ICASS		0		0	150,000	150,000
Indirect Costs		0		0	55,000	55,000
Management Meetings/Professional Development		0		0	235,449	235,449
Non-ICASS Administrative Costs		0		0	37,608	37,608
Staff Program Travel				0	225,000	225,000
USG Staff Salaries and Benefits - Internationally Recruited				0	609,570	609,570
USG Staff Salaries and Benefits - Locally Recruited				0	240,000	240,000
Total	0	0	0	0	1,557,627	1,557,627



U.S. Peace Corps

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Non-ICASS Administrative Costs		196,600		196,600	0	196,600
Peace Corps Volunteer Costs		1,369,896		1,369,896	276,562	1,646,458
Staff Program Travel		49,800		49,800	0	49,800
USG Staff Salaries and Benefits - Locally Recruited		224,594		224,594	0	224,594
Total	0	1,840,890	0	1,840,890	276,562	2,117,452